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Abstract 
Through their use as mimics of post-translational modifications (PTMs) and in 
bioorthogonal chemical reporting strategies, unnatural amino acids (UAAs) are vital tools 
for studying biological systems. 
Unnatural Amino Acids as Phosphohistidine Mimics 
-Phosphotriazolylalanine I can act as a non-hydrolysable analogue of phosphohistidine and 
is compatible with the Fmoc-strategy for peptide synthesis. Peptides containing either I or 
an alternative phosphoamino acid were synthesised and used to demonstrate the selectivity 
of the SH2 domain of the growth factor receptor-bound 2 protein (a phosphotyrosine 
binding protein) towards -phosphohistidine. In addition, peptides containing I were 
ineffectively used to study the binding interaction between a histidine-phosphorylated 
protein, phosphoenolpyruvate synthase and its cognate regulatory protein, YdiA. It was 
concluded that mimicking the primary structure of one protein through peptide generation 
was not sufficient to study this protein-protein interaction. As a result, third generation 
-phosphotriazolylalanine II was synthesised, which has the potential to be genetically 
incorporated into proteins using amber suppression.  
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Unnatural Amino Acids as Bioorthogonal Probes 
Bioorthogonal reactions can be used to selectively derivatise probes onto biomolecules. 
Although there are a number of chemical reactions that have been used for this purpose, 
many are limited in terms of biocompatibility and synthetic accessibility of bioorthogonal 
reagents. Therefore, a novel bioorthogonal reaction was developed based on the 
cycloaddition of 1,2,4-triazines to strained dienophiles. An accessible and robust synthesis 
of novel 1,2,4-triazin-3-yl-linked amino acid III was devised and its reactivity towards a 
range of strained dienophiles was investigated. It was determined that III reacted readily 
with bicyclononyne at 37 °C with a second order rate constant between 
0.3 - 0.5 ×10
-3
 M
-1
 s
-1
, depending on solvent mix. The utility of III towards late stage 
functionalisation of probe molecules was also demonstrated through generation of a 
fluorescent probe containing III. This triazine probe was used to demonstrate the 
cycloaddition of triazine to a strained dienophile in vitro. 
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Chapter 1  Introduction 
 
1.1 Unnatural Amino Acids as Molecular Mimics 
Post-translational modifications (PTMs) of proteins are involved in the regulation of almost 
all aspects of cell biology. Protein PTMs expand the functional diversity of the proteome 
through covalent addition of functional groups; proteolysis of regulatory domains and 
protein degradation.
1
 It has been found that approximately 5% of the genome is devoted to 
enzymes that catalyse protein PTMs in higher eukaryotes. The major types of modifications 
include phosphorylation, acetylation, methylation, ubiquitination, nitrosylation, 
glycosylation, lipidation and proteolysis; of these, protein phosphorylation is the most 
prevalent. 
A major challenge in this area is to understand how post-translational modifications alter 
protein structure, function, activity and regulation.
2
 In order to study them in vitro, a 
homogenous protein or a relevant peptide sequence needs to be altered on a specific residue 
to contain the covalent modification that is being investigated.
3
 This can often be difficult as 
the enzyme that catalyses the modification in vivo may not be known or it cannot be used in 
vitro. Chemically synthesised unnatural amino acids (UAAs) can be designed to mimic 
amino acids that have been post-translationally modified and incorporated into proteins and 
peptides. As such, UAAs are increasingly becoming indispensable research tools as 
molecular probes for the study of PTMs of proteins in biological systems. 
1.1.1 Protein Phosphorylation 
Protein phosphorylation is essential to the roles of proteins in signal transduction and 
cellular regulation in prokaryotes and is becoming increasingly observed in eukaryotes. It is 
estimated that at any one time, approximately 30% of proteins are phosphorylated in the 
- 2 - 
cell.
4
 Phosphorylation of proteins is a reversible process and as such involves two distinct 
classes of enzymes: kinases (for phosphorylation) and phosphatases (for 
dephosphorylation). Nearly all heteroatomic amino acids can be phosphorylated; the most 
well characterised of these are the phosphate esters phosphothreonine 1,
5
 phosphotyrosine 2
6
 
and phosphoserine 3,
5
 and this is due to their stability under the acidic conditions routinely 
used to study them (Figure 1.1).
7
 The phosphoroamidates derived from lysine 4,
8
 arginine 5
9
 
and the two regioisomers of histidine (6 and 7)
10
 have also been detected in proteins as well 
as phosphocysteine 8
11
 and the phosphoanhydrides derived from glutamate 9
12
 and aspartate 
10.
13
 
 
Figure 1.1: Phosphorylated amino acids that have been detected in proteins 
1.1.2 Phosphohistidine 
Protein histidine phosphorylation plays a crucial role in signalling processes in prokaryotes 
and is being increasingly observed in eukaryotes.
10
 Phosphohistidine (pHis) is unusual 
compared to other phosphoamino acids in that phosphorylation can occur on either of the 
imidazole nitrogens to give two chemically distinct regioisomers: π(pros)-phosphohistidine 
6 and (tele)-phosphohistidine 7.i Phosphohistidine contains a high-energy P-N 
phosphoroamidate bond that is readily hydrolysed under acidic conditions. Hultquist
14
 
assessed the hydrolytic stability of chemically phosphorylated π-pHis 6 and -pHis 7 under 
a range of acidic conditions and found that in 1M HCl aq at 49 °C, π-pHis 6 was hydrolysed 
                                                     
i There is some ambiguity in the nomenclature of the phosphohistidine isomers. Throughout this text 
the isomers will be referred to as π-(pros - near) 6 and τ-(tele - far) 7.  
- 3 - 
faster than -pHis 7 (Figure 1.2). Under mildly acidic conditions (pH 5, 49 °C) the 
difference in hydrolytic stability is more pronounced with π-pHis 6 being dephosphorylated 
10 times faster then -pHis 7. Moreover, under mildly basic conditions, when facile 
dephosphorylation does not occur, slow conversion of 6 to 7 is observed; although it should 
be noted that -pHis 7 is stable in these conditions. These results correspond with the 
intrinsic kinetics of histidine phosphorylation as the kinetic product, π-pHis 6, is more prone 
to hydrolysis and hence less thermodynamically stable than -pHis 7.    
 
Figure 1.2: Relative stabilities of phosphohistidine regioisomers 6 and 7 in acidic conditions 
1.1.3 Analysis of Phosphohistidine-containing Systems 
Phosphohistidine has a higher ΔG of hydrolysis (-12 to -13 kcal mol-1) in comparison to 
phosphohydroxyamino acids,
15
 making it an excellent facilitator for the downstream transfer 
of phosphoryl groups to target molecules. However, the transient nature of 
phosphohistidines P-N bond is also why this modification has proven to be so difficult to 
detect and study.  
1.1.3.1 Detection of Protein Histidine Phosphorylation 
Historically, acidic conditions have been employed in protein phosphorylation analysis 
which fail to preserve the phosphohistidine modification.
16
 Adaptations of such 
methodologies using milder conditions have now been reported. However, histidine 
phosphorylation can easily be unnoticed if it is not being specifically looked for as the 
detection strategy being used to identify other phosphoamino acids could result in the loss 
of phosphohistidines phosphoryl group modification.
15
 Conventionally, a combination of 
phosphoamino acid analysis, radiolabelling, reverse-phase thin layer chromatography 
(TLC), reverse-phase electrophoresis, high performance liquid chromatography (HPLC), 
31
P NMR spectroscopy and mass spectrometry (MS) is used to detect and localise the site of 
protein histidine phosphorylation. However, phosphoproteins are low in abundance and as 
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such, need to be enriched before analysis. This has traditionally been achieved through 
immunoaffinity chromatography or immobilized metal affinity chromatography (IMAC). 
There are no examples of IMAC enrichment on histidine-phosphorylated proteins, although 
Napper et al.
17
 have successfully utilised Cu(II) to enrich phosphohistidine-containing 
peptides digested from an in vitro enzymatic phosphorylated HPr protein from E. coli. 
1.1.3.2 Studying Protein Histidine Phosphorylation 
In addition to detecting protein histidine phosphorylation, methods are needed to generate 
phosphohistidine containing proteins or peptides in order to study the modification. For 
histidine-containing proteins that autophosphorylate it is possible to use the substrate to 
selectively phosphorylate a defined histidine.
18
 However, in many instances the kinase 
needed for, or the route towards, protein histidine phosphorylation is not known and as a 
result the use of enzymatic phosphorylation for this purpose is limited.
15
 Histidines in 
proteins and peptides can also be selectively chemically phosphorylated using potassium 
phosphoroamidate.
19
 Indeed, synthetic phosphopeptide generation has significantly 
facilitated investigation into serine, threonine and tyrosine phosphorylation in proteins.
20,21
 
However histidine rephosphorylation does not prevent hydrolysis and as a result, a basic pH 
must be maintained; restricting subsequent experiment type required for analysis.  
1.1.3.3 Analogues of Phosphohistidine 
Due to the difficulties in detecting and studying protein histidine phosphorylation, a number 
of unnatural amino acids acting as non-hydrolysable mimics of phosphohistidine have been 
generated. Arguably, the most important class of phosphohistidine analogues to date are 
phosphonotriazoles (pTz) 11 and 12, which were designed to mimic τ-pHis 7 and π-pHis 6 
respectively (Figure 1.3). These compounds maintain the 5-membered ring scaffold of the 
imidazole in phosphohistidine to ensure correct orientation of functional groups through 
replacement with a triazole moiety and incorporate the hydrogen bond accepting nitrogen 
present in phosphohistidine, whilst the hydrolytic P-N bond is replaced with a P-C bond. 
Their syntheses were independently described by the groups of Muir,
22
 Webb
23
 and 
Piggott
24
. Both the Muir and Piggott groups reported the generation of τ- and 
π-phosphotriazoles 13 and 16; with Muir and co-workers demonstrating the compatibility of 
both regioisomers with the Boc-strategy for SPPS through their incorporation into peptides 
based on the sequence surrounding His18
 
of histone H4. McAllister et al.
23
 synthesised 
Fmoc-protected τ-phosphotriazolylalanine derivative 14 and demonstrated its incorporation 
into a range of peptides using Fmoc-based SPPS and a two-step deprotection strategy using 
TMS-bromide for ethyl ester removal. Synthesis of Fmoc-protected pTz 14 obviates the 
need for a hydrogen fluoride facility, and more importantly, the use of this corrosive and 
dangerous gas, which was required for Boc deprotection when generating peptides 
- 5 - 
incorporating triazolylalanines 13 and 16. McAllister et al.
25
 went on to synthesise τ-pHis 
analogue 15 that included a dibenzyl-protected phosphonate, and demonstrated its full 
compatibility with the Fmoc-strategy for peptide synthesis with phosphoryl group 
deprotection being achieved under standard peptide cleavage conditions.  
 
Figure 1.3: Stable analogues of τ- and π- phosphohistidine 7 and 6 based on a triazole scaffold.  
Very recently, Hunter and co-workers
26
 incorporated τ-pTz 11 and π-Tz 12 into degenerate 
peptide libraries and used these to develop monoclonal antibodies that specifically recognise 
either τ-pHis or π-pHis in a sequence independent manner. The development of such 
antibodies could enable the detection of histidine phosphorylation on a wide variety of 
phosphohistidine substrates. They could also be used to enrich samples containing 
phosphohistidine for further analysis. The successful generation of antibodies using 
τ-pTz 15 and π-Tz 16 as haptens also demonstrates the utility of these compounds as mimics 
of phosphohistidine for studying the modification. 
1.1.4 Phosphohistidine Prevalence in Biology 
While protein histidine phosphorylation is known to be vital for the survival of prokaryotes, 
observed occurrence in eukaryotes is relatively low.
27
 It is possible that the reason for this is 
that higher organisms use different PTMs to relay biochemical information; but is most 
likely that the previous lack of biochemical tools available to study phosphohistidine is the 
cause. The latter proposition is reinforced when considered alongside the case of the slime 
mould Physarum polycephalum; where phosphohistidine was found to account for 6% of all 
phosphoamino acids in its basic nuclear proteins.
28
 This prevalence is extremely high when 
compared with prevalence of phosphotyrosine in eukaryotic cellular phosphoproteins, which 
- 6 - 
is under 1%.
29
 Therefore, it is possible that protein histidine phosphorylation is significantly 
more prevalent in eukaryotes and higher mammals than currently thought.  
1.1.4.1 Prokaryotes 
In bacteria, the lability of phosphohistidines phosphoroamidate bond is exploited in a 
number of ubiquitous systems including bacterial two-component signalling
30
 and sugar 
phosphotransferase systems.
31
 Furthermore, phosphohistidine is utilised as an intermediate 
in phosphoglycerate mutase (PGM) to alter the phosphorylation pattern of glycerate 
molecules
27
 (PGM is an enzyme that is involved in gluconeogenesis and glycolysis).
32
 In 
general, these systems have been extensively studied, and as such are well understood. 
1.1.4.2 Eukaryotes 
In eukaryotes, a small number of proteins have been identified to contain phosphohistidine. 
These include Histone H4, which is part of a family of histones that condense DNA into 
nucleosomes within cell nuclei.
33
 In Histone H4, phosphorylation of both His18 and His75 
has been observed, although the purposes of these phosphorylation events are unknown. The 
β-subunit of heterotrimeric G-proteins34 have also been identified to contain a 
phosphohistidine residue as well as nucleoside phosphate kinases (NDPKs).
35
 
Heterotrimeric G-proteins transmit chemical signals across cell membranes and NDPKs 
sustain cellular levels of nucleoside triphosphates (NTPs). A crystal structure of 
succinyl-CoA synthetase, which catalyses the formation of succinyl-CoA for use in ketone 
body metabolism, was also found to contain a τ-phosphohistidine residue.36 In addition, 
studies suggest that protein histidine phosphorylation may play a role in mammalian cell 
signalling with phosphorylated histidine residues being identified on both the cytoplasmic 
tail of P-selectin (a leukocyte adhesion molecule)
37
 and Annexin I (a phospholipid-binding 
protein).
38
 Protein histidine phosphorylation has also been shown to play an important role 
in C4 carbon fixation of plants. 
1.1.4.2.1 C4 Carbon Fixation 
C4 photosynthesis is the means in which plants including maize, sorghum and sugar cane, 
obtain energy from the sun.
39
 C4 plants represent under 4% of all flowering plants; which 
could be thought insignificant if not considered alongside the fact that they dominate some 
of the most productive ecosystems on earth. In C4 carbon fixation, carbon dioxide is 
captured in mesophyll cells through its conversion to hydrogen carbonate and reacted with 
phosphoenol pyruvate (PEP) to form oxaloacetate (Figure 1.4). Oxaloacetate is then 
converted to C4 acids, which are shuttled to the bundle sheath cell. Here, the organic acids 
are decarboxylated to form pyruvate, enabling the release of carbon dioxide to enter the 
Calvin cycle where it is used to make sugars via C3 photosynthesis. Pyruvate is transported 
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back to the mesophyll cells where it is rephosphorylated by pyruvate, phosphate dikinase 
(PPDK) to regenerate PEP; a reaction that requires ATP and inorganic phosphate and 
produces AMP and diphosphate. 
 
Figure 1.4: The mechanism of C4 carbon fixation as used by a number of flowering plants. Carbon 
dioxide is fixed via reaction with PEP to form oxaloacetate, which is in turn converted to C4 
acids. The C4 acids are transported to the bundle sheath and broken down into carbon dioxide 
and pyruvate by decarboxylases. β-phosphate is then transferred from ATP to Pyruvate to 
regenerate PEP; a reaction that is catalysed by PPDK. 
PPDK consists of an ATP binding domain, a phosphohistidine binding domain and a 
pyruvate/PEP binding domain (Figure 1.5a).
40
 The phosphohistidine binding domain 
swivels between the ATP domain where histidine becomes phosphorylated, and the 
pyruvate/PEP domain where the phosphoryl group is transferred to pyruvate to form PEP. 
C4 carbon fixation is regulated by changes in PPDK activity which is achieved by the PPDK 
regulatory protein, PDRP.
41
 PDRP binds to PPDK in its histidine phosphorylated form and 
phosphorylates a proximal threonine residue using ADP. This renders PPDK inactive by 
preventing phosphoryl group transfer to pyruvate to form PEP. After phosphorolytic 
cleavage of phosphohistidine, PDRP catalyses the dephosphorylation of phosphothreonine, 
a process that is inhibited by ADP, and PPDK is reactivated (Figure 1.5b). In the dark, 
stromal levels of ADP increase which serve to inhibit dephosphorylation of 
- 8 - 
phosphothreonine and PPDK is inactivated. In the light, stromal levels of ADP decrease, 
and hence dephosphorylation of phosphothreonine is favoured and PPDK is reactivated.
42
 
 
Figure 1.5: a) Crystal structure of PPDK with N-terminal ATP binding domain shown in blue, the 
phosphohistidine binding domain shown in yellow, and the C-terminal pyruvate/PEP binding 
domain shown in green. The two polypeptide segments that connect the pHis binding domain 
to the other two domains are shown in grey; b) Mechanism by which PPDP is regulated by 
PDRP: PDRP binds to the pHis binding domain (yellow in a)) of PPDK, when it contains a 
τ-phosphohistidine residue and uses ADP to phosphorylate a proximal threonine residue, 
rendering PPDK inactive. PPDK is reactivated by dephosphorylation of phosphothreonine, a 
process that is inhibited by ADP. PDB file: 1DIK 
PDRP is an unusual enzyme in that it acts as both an ADP-dependent kinase and a 
phosphatase. Although the structure of PPDK is well characterised and has been extensively 
studied, not a lot is known about its regulatory protein PDRP and how this bifunctional 
enzyme regulates PPDK activity. In addition, it has not been elucidated how 
- 9 - 
phosphorylation of a threonine residue proximal to the catalytic histidine entirely eclipses 
PPDK activity. It is possible that this could be through electrostatic repulsion of negatively 
charged substrates (pyruvate, ATP and Pi) by the dianionic phosphoryl group of threonine.
40
 
Equally, steric interference of the proximal phosphothreonine residue could prevent 
association of the catalytic phosphohistidine domain to the pyruvate/PEP domain.
41
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1.2 Unnatural Amino Acids as Bioorthogonal Probes 
In addition to their use as molecular mimics, unnatural amino acids bearing reactive 
moieties can be incorporated into biomolecules and used to introduce biophysical probes 
and labels to study the function and dynamics of proteins.
43
 A UAA that has unique 
chemical functionality is incorporated into a biomolecule through genetic or chemical 
methods or via hijacking a metabolic pathway. An external chemical probe is introduced 
which selectively and specifically reacts with the incorporated functionality, resulting in the 
covalent labelling of the biomolecule with the probe. For this to be possible, the associated 
chemical reaction must be bioorthogonal.  
1.2.1 Bioorthogonal Reactions 
A bioorthogonal reaction is a chemical reaction that can take place selectively inside a living 
system without interfering with any endogenous functional groups that are found in 
biomolecules.
44
 The reactants, side-products, and products must not be toxic to the cell; be 
thermodynamically, kinetically and metabolically stable; and the resultant product must be 
covalently linked. Bioorthogonal reactions tend to be governed by second order reaction 
kinetics, and as such, their reaction rates depend upon the effective concentration of both of 
the reactive components. Because of this, the rate of reaction must be fast enough to obviate 
the need for a large excess of one reagent. This is to prevent solubility issues or off-target 
reactions of the excess reagent with abundant endogenous functional groups, the latter being 
possible when a reactive component is not infinitely chemoselective (which is unfortunately 
often the case). A number of chemical reactions have been successfully used both in vitro 
and in vivo as bioorthogonal chemical reporters, although many of these reactions have 
intrinsic limitations that put their biocompatibility into question. 
1.2.1.1 Ketone/Aldehyde Condensations with Amine Nucleophiles 
The reaction of aldehydes (17, R = H) or ketones (17, R = alkyl) with alkoxyamines (19, 
X = O) or hydrazides (19, X = N) was among the first reactions to be used as a 
bioorthogonal chemical reporter (Scheme 1.1a).
44
 In acidic conditions (pH 4-6), the ketone 
or aldehyde 17 that has been previously incorporated into the biomolecule becomes 
protonated and reacts with amine nucleophile 19 to form Schiff base 20.
45
 Due to the acidic 
conditions needed, this reaction is only appropriate for in vitro systems.
46,47
 It should also be 
noted that the reaction has slow reaction kinetics (k2 = 10
-4 
- 10
-3 
M
-1
 s
-1
).
48
 However, these 
undesirable reaction kinetics and acidic conditions can be overcome by using aniline as a 
nucleophilic catalyst (Scheme 1.1b).
49,50
 Unfortunately, the incorporated carbonyl 
functionality faces competition from carbonyl bearing metabolites such pyruvate, 
oxaloacetate and sugars.  
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Scheme 1.1: Condensation of ketones or aldehydes with alkoxyamines (19, X = O) or hydrazides (19, 
X = N) to fluorescently label a biomolecule under a) acid catalysis or b) aniline catalysis. 
1.2.1.2 The Staudinger Ligation 
First reported by Saxon and Bertozzi
51
 in 2000, the Staudinger ligation, which involves the 
reaction of azide 22 to triarylphosphine reagent 23, has been applied both in vitro and in 
vivo to covalently link biomolecules to phosphine derived probes (Scheme 1.2a).
52,53
 This 
reaction has relatively slow reaction kinetics (k2 = 10
-3 
M
-1
 s
-1
),
54
 and as a result of this and 
the intrinsic oxidation sensitivity of phosphine; high concentrations of the phosphine reagent 
are required. Other limitations include reduction of the incorporated azide functionality 22 
by endogenous thiols or other reductants before reaction with 23 and cross-reactivity of the 
phosphine functionality with disulfides. There is also a traceless version of the Staudinger 
ligation in which the final amide-linked product 26 is released from the phosphine oxide 
moiety 27 (Scheme 1.2b).
55
 
 
Scheme 1.2: a) The Staudinger ligation between azides 22 and triarylphosphines 23 via an aza-ylide 
intermediate as a chemoselective labelling strategy and b) a traceless version of the Staudinger 
ligation in which the fluorescently labelled product 26 is freed from the phosphine moiety 27. 
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1.2.1.3 Reactions of Azides with Alkynes 
The use of azides as 1,3-dipoles in (3 + 2) cycloadditions with terminal alkynes to generate 
stable triazoles was discovered by Rolf Huisgen in the 1950s,
56
 with the addition of Cu(I) 
salts to accelerate reaction rate being independently demonstrated by the Sharpless and 
Meldal groups in 2002 (Scheme 1.3a).
57,58
 The copper-catalysed azide-alkyne cycloaddition 
(CuAAC) reaction is approximately seven orders of magnitude faster than its analogous 
uncatalysed counterpart. Unfortunately, Cu(I) is toxic to living systems and this reaction is 
therefore not suitable for in vivo studies.
59
  
Bertozzi’s strain-promoted azide-alkyne cycloaddition (SPAAC) exploits the intrinsic 
reactivity of strained cyclooctynes towards azides, and thus circumvents the need for a metal 
catalyst (Scheme 1.3b).
60
 Cycloadditions between a highly strained cyclooctyne such as 30 
and azides have marginally improved reaction kinetics in comparison to CuAAC with 
reported second order rate constants between 0.1
 
- 1
 
M
-1
 s
-1
.
61,62
 Dubbed ‘copper-free Click 
chemistry’, this reaction has been successfully used in the imaging of live cells63 and 
zebrafish embryos.
64
 Despite this, cyclooctyne derivatives such as 30 often require complex, 
multistep synthesis and some have poor water solubility (although many are now 
commercially available).
61
 
 
Scheme 1.3: Chemoselective labelling using azide-alkyne cycloaddition reactions with a) copper (I) 
catalysis, and b) a strained alkyne 30, to promote reaction rate. 
1.2.1.4 PhotoClick Reactions 
The photoinduced dipolar cycloaddition of alkenes to nitrile imines (generated via in situ 
photoactivation of the corresponding tetrazole) to yield pyrazoline products such as 35 has 
relatively fast reaction kinetics (k2 < 6
 
M
-1
 s
-1
) (Scheme 1.4). Known as a PhotoClick 
reaction, its utility as a bioorthogonal probe has been demonstrated both in vitro and in 
living systems.
65,66
 This chemistry is particularly useful as a bioorthogonal labelling strategy 
as the pyrazoline products are fluorescent, whilst the starting reagents are not. In addition, 
the requirement of UV light for reaction initiation allows for spatiotemporal photoactivation 
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of the reaction. There is some debate as to whether the nitrile imine may cross-react with 
endogenous alkenes; although the decreased reactivity of cis-alkenes (which are the most 
abundant form found in biomolecules) in comparison to terminal alkenes suggests that this 
may not be an issue.
44
 Development of tetrazoles that can be activated with light at 
wavelengths not harmful for living cells will make the PhotoClick reaction highly attractive 
for use in the chemoselective labelling of biomolecules.    
 
Scheme 1.4: Photoclick reaction to label a biomolecule; in situ photoactivation of tetrazole 32 
generates nitile imine intermediate 33 which undergoes a (3 + 2) dipolar cycloaddition to 
alkene 34 and fluorescent pyrazoline product 35 is generated. 
1.2.1.5 1,2-Aminothiol Condensations 
The condensation of 1,2-aminothiol 36 with 2-cyanobenzothiazole (CBT) 37 takes place 
under physiological conditions with a reported second order rate constant of ~9 
 
M
-1
 s
-1
, and 
its utility as a bioorthogonal probe has been demonstrated in vitro (Scheme 1.5).
67
 
Moreover, 1,2-aminothiol derivatives can now be genetically encoded into proteins using 
amber suppression and CBT 37 displays no cross-reactivity with any endogenous functional 
groups.
68
 The 1,2-aminothiol condensation is yet to be demonstrated in living systems. 
 
Scheme 1.5: Condensation of fluorescently tagged CBT 37 with 2-aminothiol 36 to label a 
biomolecule. 
1.2.1.6 Other Bioorthogonal Reactions 
Other chemistries that have been used in bioorthogonal chemical reporting strategies include 
the cycloaddition of azides to strained alkenes such as norbornadiene 39 (Scheme 1.6a).
69
 
This reaction has sluggish reaction rates (k2 = 10
-3 
M
-1
 s
-1
) and, due to the addition of cellular 
nucleophiles to 39 to form addition products, the reaction is not strictly chemoselective.
70
 
Nitrones such as 41 can also be used as 1,3-dipoles and added to cyclooctynes in a strain-
promoted azide-nitrone cycloaddition (SPANC) reaction to yield N-alkylated isoxazolines 
like 43 (Scheme 1.6b).
71
 This reaction was demonstrated in vivo through the cellular 
imaging of epidermal growth factor receptors.
72
 Unfortunately, the hydrolytic instability of 
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nitrones limits its applicability as a bioorthogonal probe.
44
 Other cycloadditions that have 
been used for protein labelling include the (2 + 2 + 2)  cycloaddition of highly strained 
quadricyclane 44 to π-systems73 and the (4 + 1) cycloaddition between isonitriles such as 47 
and aromatic tetrazines (Scheme 1.6c and d respectively).
74
 In the former case, the 
cycloaddition can only be applied in vitro due to instabilities of both 44 and 45 in living 
systems. The latter cycloaddition has successfully been used to label cell surface glycans 
through the metabolic incorporation of isonitrile-modified monosaccharides and subsequent 
addition of fluorescently tagged tetrazine derivative 48 (Scheme 1.6d).
75
 In addition, a 
number of carbon-carbon bond forming reactions have shown utility as bioorthogonal 
probes. These include the cross metathesis of alkenes (Scheme 1.6e)
76
 and a number of 
palladium-catalysed cross-coupling reactions (Scheme 1.6f).
44
 Investigations into the 
stability and solubility of the catalysts required for these reactions will demonstrate whether 
they have broad compatibility with biological systems. 
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Scheme 1.6: Other reactions that have been used to label biomolecules; a) (3 + 2) cycloaddition of 
azide 22 and norbornadiene 39 to form stable triazole 40; b) (3 + 2) cycloaddition of nitrone 41 
and dibenzocyclooctyne 42; c) (2 + 2 + 2) cycloaddition of quadricyclane 44 to nickel 
bis(dithiolene) 45 with stabilising adducts; d) (4 + 1) cycloaddition of isonitile 47 to aromatic 
tetrazine 48; e) olefin cross-metathesis of alkenes 34 and 50 using a Hoveyda-Grubbs second-
generation ruthenium catalyst and f) Suzuki-type cross-coupling reaction of aryl halide 52 and 
boronic acid 53 to generate 54. 
A reaction that has not yet been mentioned but has widespread use in the chemoselective 
labelling of biomolecules both in vitro and in vivo, is the inverse electron-demand 
Diels-Alder (IEDDA) cycloaddition between tetrazines and strained dienophiles. 
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1.2.2 The Inverse Electron-demand Diels-Alder Cycloaddition 
The IEDDA cycloaddition between aromatic N-heterocycles and dienophiles was first 
described by Carboni and Lindsey
77
 in 1952 and since then has been used to facilitate the 
synthesis of pyridazine and pyridine derivatives of varying complexity.
78–81
 It was not until 
2008 that two groups simultaneously recognised that the strain-promoted inverse electron-
demand Diels-Alder cycloaddition (SPIEDAC) between 1,2,4,5-tetrazine and strained 
dienophiles had application as a bioorthogonal probe.
82,83
 While many nitrogen heterocycles 
can undergo cycloaddition reactions, tetrazine is the most reactive towards dienophiles. As a 
result, efforts have focused on the development of tetrazine derivatives and dienophiles with 
increased reactivity towards one another and not on cycloaddition reactions concerning 
other, less reactive nitrogen-containing aromatic compounds. 
1.2.2.1 The 1,2,4,5-Tetrazine Cycloaddition to Strained Dienophiles 
Tetrazines conjugate to strained dienophiles through an inverse electron-demand hetero-
Diels-Alder retro-Diels-Alder type cascade to form pyridazine products (Scheme 1.7).
84
 The 
highly strained bicyclic adduct 57, formed from (4 + 2) cycloaddition with inverse electron-
demand of tetrazine 55 and strained dienophile 56, undergoes a rapid cycloreversion to give 
the corresponding 4,5-dihydropyridazine 59 (for olefin dienophiles (Path A, Scheme 1.7a)) 
or pyridazine 58 (for alkyne dienophiles (Path B, Scheme 1.7a) with the liberation of 
dinitrogen. When the dienophile is an olefin, 1,3-prototropic isomerisation normally gives 
the corresponding 1,4-dihydropyridazine 60,ii which, dependent upon alkene type, may or 
may not be oxidised to the fully conjugated pyridazine 61. Strained dienophiles reported to 
react with tetrazine derivatives included norbornene 62,
85
 cyclopropene 63,
86
 bicyclononyne 
64
87
 and trans-cyclooctenes 65 and 66 (Scheme 1.7b).
87
 
The tetrazine cycloaddition to strained dienophiles proceeds without a catalyst, is high 
yielding, produces no toxic by-products and has rate constants ranging from 
1 - 10
5
 M
-1
 s
-1
.
85–87
 The possible biological applications of this cycloaddition are extensive 
and it has now been applied in many: including intracellular imaging;
88
 in vivo imaging;
64,89
 
live labelling of cell-surface antigens
90
 as well as the modification of cells with 
nanomaterials for clinical diagnostics.
91
 
 
                                                     
ii If an appropriately good leaving group is present at this point, it will eliminate to give the fully 
aromatised tetrazine 61. 
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Scheme 1.7: a) SPIEDAC of tetrazine 55 to a cycloalkene (Path A) or cycloalkyne (Path B). Rate 
determining (4 + 2) cycloaddition between 55 and 56 leads to a highly strained bicyclic adduct 
57 which undergoes a cycloreversion yielding pyridazine derivative 58 (Path B) or 59 (Path A) 
and releasing dinitrogen; b) examples of strained dienophiles that react with tetrazine. 
1.2.2.2 Limitations of the Tetrazine-SPIEDAC 
Although tetrazine-SPEIDAC reactions are rapid and efficient, production of functionalised 
tetrazine scaffolds needed for derivatisation onto probes remains synthetically challenging.
92
 
Furthermore, some tetrazines are prone to either hydrolysis
93
 or decomposition into the 
corresponding pyrazoles or thiazoles when exposed to endogenous cellular nucleophiles.
94
  
Historically, substituted aromatic tetrazines have been accessed inefficiently via the Pinner 
synthesis.
95
 The Pinner synthesis involves the dimerisation of aromatic nitriles (or their 
analogues such as nitrile imines or aldehydes) and hydrazine to form dihydrotetrazine 
derivatives such as 68, using acid or sulphur as co-catalysts (Scheme 1.8ai).
95,96
 Oxidation of 
68 affords the corresponding disubstituted tetrazine 69 together with 1,2,4-triazoles or 
thiadiazoles (when sulphur is used as a co-catalyst) as side-products. Use of formamidine 
acetate in place of one equivalent of hydrazine will lead to the generation of mono-
substituted tetrazines (Scheme 1.8b).
93
 Yields for the generation of tetrazine derivatives 
using this methodology vary considerably.
93,97
 For some time, this route was limited to the 
generation of aromatic substituted tetrazines and if used to synthesise aliphatic substituted 
tetrazines, would not work, or would work but in low yields.
92
 This was until Yang et al.
98
 
found that if a Lewis acid was used to activate alkyl nitrile 67 (R = alkyl), alkyl substituted 
tetrazines could be generated in good yields (Scheme 1.8aii). It should be noted that in this 
synthesis anhydrous hydrazine is required, which is volatile and has limited commercial 
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availability. An alternative strategy to generate functionalised tetrazines is the base-
promoted dimerization of ethyl diazoacetate 72 to form dimethyl tetrazine-3,6-dicarboxylate 
74, after oxidation of dihydrotetrazine 73 (Scheme 1.8c).
99
 However, 74 is prone to acid 
promoted rearrangement and slowly decomposes on warming.  
 
Scheme 1.8: Reported syntheses of functionalised 1,2,4,5-tetrazines; a) generation of 
3,6-disubstituted (i) aromatic-
95,97
 or (ii) alkyl-
98
 tetrazines via the Pinner synthesis; b) 
generation of mono-substituted tetrazine 71 using formamidine acetate and c) synthesis of 
dimethyl tetrazine-3,6-dicarboxylate 74 through base-catalysed dimerization of 
ethyldiazoacetate 72.
99
  
Tetrazines can also be functionalised through the nucleophilic aromatic substitution (SNAr) 
of dimethylthio-,
100
 dipyrazolyl-,
101
 and dichloro-
102,103
 tetrazines 75-77 with nucleophiles 
(Scheme 1.9a). In order to perform SNAr on the tetrazine ring, tetrazines 75-77 must first be 
synthesised. This is relatively straightforward when dimethylthiotetrazine 75 (Scheme 
1.9b)
104
 or dipyrazolyltetrazine 76 (Scheme 1.9c)
101
 is required; but increases in number of 
synthetic steps in the case of dichlorotetrazine 77 (Scheme 1.9c).
92
 Furthermore, 
dihydrazinotetrazine 85, an intermediate in the synthetic route to 77, is explosive.
103
 
Dichlorotetrazine 77 is the most electrophilic, and hence most reactive towards nucleophilic 
aromatic substitution, of the three cores. The added synthetic complexity required to access 
this derivative may be discouraging to synthetic chemists. Substitution reactions of 75-77 
have been reported with nucleophiles such as alcohols,
105
 thiols,
106
 and amines/amides.
100,103
 
However the tetrazine cores of 75-77 are readily decomposed by reductive metals and are 
therefore not compatible in substitution reactions involving organometallic species.
92
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Scheme 1.9: a) General approach for the nucleophilic substitution of methylthio-, dipyrazolyl- or 
dichloro- tetrazines 75-77; b) & c) Reported generation of 3,6-disubsituted 1,2,4,5-tetrazines 
75-77 for use in SNAr reactions; a) Synthesis of 3,6-dimethylthio-1,2,4,5-tetrazine 75 through 
base catalysed dimerization of thiocarbohydrazide and trithiocarbodiglycolic acid 79;
104
 b) 
Generation of 3,6-pyrazolyl-1,2,4,5-tetrazine 76
101
 through the condensation of 
triaminoguanidine hydrochloride 83 with pentenedione and subsequent generation of 
3,6-dichloro-1,2,4,5-tetrazine 77 via nucleophllic aromatic substitution of dipyrazolyl-tetrazine 
76.
92
  
1.2.2.3 The 1,2,4-Triazine Cycloaddition 
An effective alternative to the use of 1,2,4,5-tetrazine in chemoselective labelling strategies 
might be 1,2,4-triazine. Cross-linking reactions have been reported to occur between 
1,2,4-triazines and acyclic dienophiles to form dihydropyridine and pyridine derivatives.
107–
109
 The earliest example of a 1,2,4-triazine cycloaddition dates back to 1969 when 
Neunhoeffer et al
110
 conjugated a range of 3-substituted-1,2,4-triazines to simple alkenes 
and alkynes. Poor regiocontrol combined with modest yields led to limited interest in this 
transformation for some time. It was not until 1981 that Boger and Panek
111
 discovered that 
the cycloaddition of pyrrolidine or morpholine enamines 87 to 1,2,4-triazine 86 generated 
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pyridine products with the expected regioselectively in moderate to good yields (Scheme 
1.10). This, and the establishment of robust synthetic routes
112,113
 to access 1,2,4-triazine 
derivatives has led to the reaction being exploited to access a range of polycyclic and fused 
heterocycles through tethered triazine -alkyne/-alkene scaffolds.
108,112,114
 Although this 
cycloaddition is now commonly used as a participant in elegant synthetic routes to provide 
complex pyridyl-containing structures, the need for elevated temperatures (mostly 
exceeding 100 °C), and extended reaction times means that it has never been considered for 
cellular applications. To date, nearly all examples of 1,2,4-triazine cycloaddition reactions 
involve open-chain and unstrained cyclic dienophiles. There are just two reports concerning 
1,2,4-triazine-SPIEDAC reactions between a range of tri-substituted triazines
115
 or tethered 
triazines
116
 and a strained dienophile, norbornadiene.  
 
Scheme 1.10:
111
 The 1,2,4-triazine-IEDDA to pyrrolidine or morpholine enamines 87 to yield 
pyridine derivative 89. 
1.2.2.4 Kinetics of Tetrazine and Triazine Cycloadditions 
The concerted (4 + 2) cycloaddition is the rate determining step (rds) in both 1,2,4,5-
tetrazine and 1,2,4-triazine LUMOdiene - HOMOdienophile controlled conjugations.
117
 The rate 
of conjugation is controlled by an interplay of steric and electronic effects of both the diene 
and dienophile. Electron-donating dienophiles raise the energy of the dienophile HOMO, 
resulting in a smaller energy difference between the frontier molecular orbitals and an 
increase in reaction rate. Dienophiles with a high degree of ring strain also reduce the 
activation energy of the rds by raising the energy of the dienophile HOMO, and decreasing 
the distortion energy needed to reach the cycloaddition transition state.
117,118
 Conversely, 
dienophile hydrogen exchange for a sterically demanding electron-donating substituents can 
have an impeding steric effect and raise the distortion energy needed to reach the transition 
state;
119
 this effect is prevalent in alkynes and alkenes bearing large methylthio-, methoxy- 
and ethoxy- substituents.
117
 Therefore, exchange of hydrogen for an electron-donating 
substituent can lead to an increase or decrease in dienophile reactivity depending upon the 
electron-donating power and steric bulk of the substituents, and the inherent strain of the 
dienophile.  
Similarly, addition of electron deficient substituents onto the triazine and tetrazine rings 
lowers the energy of the diene LUMO and increases reaction rate.
107
 Wang et al.
120
 assessed 
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the rate of cycloaddition of a range of 3,6-disubstituted tetrazines to bicyclononyne 64 and 
found significant variations in the bimolecular rate constant dependent upon the electron-
withdrawing nature of the tetrazine substituents. For instance, 3,6-dipyridinyl-tetrazine was 
found to cross-link to bicyclononyne 32 times faster than 3,6-diphenyl-tetrazine. Tetrazine 
is more electron deficient than triazine due to an additional nitrogen in the tetrazine core; 
this means that the diene LUMO of tetrazine is lower than that of triazine. Cycloaddition 
reactions involving tetrazines and a specific dienophile will therefore be intrinsically faster 
than the corresponding triazine-dienophile cycloaddition.  
1.3 Incorporation of Unnatural Amino Acids into Proteins 
1.3.1 Incorporation via Chemical or Enzymatic Methods 
In order to use any of the aforementioned chemoselective reactions to label proteins, one of 
the reagents needs to be incorporated into the protein. This can be achieved chemically 
through bioconjugation reactions of an appropriately functionalised reagent with either the 
side chains of residues in the protein, or the N-terminal of the protein.
43
 However, 
modification of a protein on a single residue is difficult to achieve unless there is a single 
reactive residue on the surface of a protein. In addition, N-terminal modification of proteins 
tends to rely on the presence of a specific residue at the N-terminal and is therefore limited 
in application. It is also possible to synthetically generate moderately sized proteins with an 
UAA bearing the desired reagent through the transthioesterification of two synthetic 
polypeptides containing an N-terminal cysteine and a C-terminal thioester respectively- a 
technique known as native chemical ligation (NCL).
121
 This methodology is 
time-consuming and limited to proteins containing a cysteine residue at an optimal position 
for ligation.iii  
It is also possible to incorporate some bioorthogonal reagents into proteins enzymatically. 
This is achieved through engineering ligases to recognise unnatural modifications instead of 
their natural small-molecule substrates. This was elegantly demonstrated by Ting and co-
workers through the site-specific ligation of a trans-cyclooctene derivative
94
 and an alkyl 
azide
122
 onto both cell surface and intracellular proteins using engineered lipoic acid ligases. 
Site-specific incorporation of probe molecules using this technology is growing in 
popularity. However, for each new substrate to be incorporated, a lipoic acid ligase with an 
altered active site needs to be engineered; a process which is costly and time-consuming.
44
 
                                                     
iii It is possible to use a thiol containing  removable auxillary or NCL followed by desulfurisation of 
the cysteine residue to alanine in order to generate a protein without a cysteine residue; although 
this adds to the complexity of an already complicated process.
176
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1.3.2 Incorporation via Genetic Methods: Amber Suppression 
UAAs can also be incorporated into specific sites into proteins by exploitation of the 
protein’s natural translational machinery using amber suppression.123 Currently, over 30 
UAAs have been genetically incorporated using this methodology.
44
 Amber suppression 
uses the amber stop codon UAG, a codon that normally directs the termination of protein 
synthesis, to encode an unnatural amino acid loaded onto a complimentary tRNA. Due to 
the tolerance of the ribosome for UAAs, the unnatural amino acid can be incorporated into 
proteins during normal protein synthesis.
43
 
To do this, employment of an orthogonal tRNACUA and an aminoacyl-tRNA synthetase (RS) 
that will explicitly recognise the amber stop codon and the UAA respectively are needed. 
The amber suppression technique is depicted in Figure 1.6: initially the codon (XXX) for 
the specific gene is mutated to the amber codon (TAG) by PCR facilitated site directed 
mutagenesis. The RS then loads the orthogonal tRNACUA-unnatural amino acid pair, and on 
recognition of the amber codon (UAG) by the ribosome, a 21
st
 amino acid will be 
incorporated at a specific site into the developing peptide. In order to do this, substrate 
recognition properties of a natural aminoacyl-tRNA synthetase must be altered so that the 
synthetase will selectively acylate its cognate tRNACUA with the desired unnatural amino 
acid.
124
 This can be achieved through a variety of methodologies, all involving repetitive 
rounds of positive and negative selections in order to amplify synthetase variants selective 
towards the UAA, and eliminate the variants selective towards endogenous amino acids or 
both the UAA and natural amino acids. The use of this strategy to generate unnatural RSs to 
genetically encode distinct unnatural amino acids has been tremendously successful; 
however, practises for evolving an unnatural RS are costly and time-consuming. 
Revolutionary work by Mehl and co-workers
125
 has shown that some amino acyl tRNA 
synthetases have broad specificity for families of structurally (and electronically) similar 
unnatural amino acids; these synthetases are termed permissive. It is thus possible to use 
these evolved RSs to genetically encode similar UAAs in addition to the UAA the unnatural 
amino acyl tRNA synthetase was originally evolved to incorporate. Successful screening of 
existing tRNA synthetases that have been evolved to incorporate similar UAAs for 
incorporation of the desired UAA has saved the time and cost that is associated with the 
generation of novel mutant RSs, or for that matter, the generation of engineered ligases for 
enzyme mediated incorporation of probes into proteins. 
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Figure 1.6: The amber suppression technique for incorporation of an UAA. The codon (XXX) for a 
gene is mutated to the amber stop codon TAG. After loading of the UAA and tRNA by an 
orthogonal tRNA synthetase and recognition of TAG by the ribosome, the UAA will be 
genetically incorporated at a specific site in the developing protein.  
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1.4 Aims and Objectives 
1.4.1 Phosphotriazolylalanine as a Phosphohistidine Mimic 
 
Figure 1.7: Outline of the method to achieve first set of research objectives. It was proposed that 
τ-pTz 15 would be incorporated into peptides and used to investigate and identify 
phosphohistidine mediated interactions of proteins. A 3
rd
 generation pTz analogue, pTz-3, 
would also be synthesised and screened as a substrate for existing tRNA synthetases for 
incorporation into proteins or a new amber suppression system would be evolved to 
incorporate it. 
Following the successful generation of non-hydrolysable τ-phosphohistidine mimic 15 in 
the group,
25
 the aim of this project was to use 15 as a probe to identify phosphohistidine 
binding proteins and to study known phosphohistidine-mediated interactions that are 
dependent upon binding of phosphohistidine but not on hydrolysis. It was proposed that this 
would be achieved through incorporation of τ-pTz 15 into peptides that mimic the binding 
site of the protein in question and the subsequent use of biophysical techniques to determine 
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binding parameters of interactions between peptides containing τ-pTz 15 with relevant 
proteins. In addition, it was envisaged that a third generation phosphohistidine mimic, 
pTz-3 would be synthesised with alternative phosphoryl group protection to τ-pTz 15 
suitable for incorporation into proteins using amber suppression. The ability to incorporate a 
phosphohistidine mimic into proteins as well as peptides will further advance studies into 
protein histidine phosphorylation. These objectives are outlined in Figure 1.7.  
1.4.2 The Triazine Cycloaddition to Strained Dienophiles as a Novel 
Bioorthogonal Probe 
Based on the knowledge that strained dienophiles increase the rate of cycloaddition towards 
N-heterocycles, the aim of this project was to generate a novel bioorthogonal probe using 
the cycloaddition of triazine to a strained dienophile. It was proposed that this cross-linking 
reaction would proceed without the need for elevated temperatures, and could thus offer an 
alternative to the 1,2,4,5-tetrazine-SPIEDAC for use in the chemoselective labelling of 
biomolecules. Although inherently slower than its tetrazine counterpart, the triazine 
cycloaddition to strained dienophiles would prevent the use of toxic and volatile precursors 
and offer improved synthetic accessibility to functionalised triazine scaffolds. In addition, 
reduced reactivity of triazine in comparison to tetrazine may offer enhanced stability in vivo. 
To achieve this, it was envisaged that the reactivity of 1,2,4-triazines would be evaluated 
against a range of strained dienophiles at physiological temperatures to decide upon a 
suitable reaction partner. Following this, either a triazine- or strained dienophile- containing 
UAA would be synthesised, screened for genetic incorporation against existing tRNA 
synthetases and co-translationally incorporated into a model protein. The resultant mutant 
protein would then be incubated with the other reactive partner, which would have been 
derivatised onto a fluorescent tag, to yield a covalently labelled fluorescent protein. These 
objectives are summarised in Figure 1.8. 
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Figure 1.8: Outline of method to achieve second set of research objectives. An unnatural amino acid 
containing either a triazine (left) or strained dienophile (right) would be genetically 
incorporated into a model protein and incubated with a fluorescent probe containing the other 
reactive entity to generate a fluorescently labelled protein. If successful, this would 
demonstrate the utility of the triazine-SPIEDAC as a bioorthogonal labelling strategy. 
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Chapter 2 Use of τ-phosphotriazolylalanine as a Molecular Probe 
2.1 Introduction 
Following the generation of non-hydrolysable τ-phosphohistidine analogue, pTz 15 in the 
group, a natural progression was to incorporate 15 into peptides and use these peptides in a 
biophysical context to study proteins that have affinity for τ-phosphohistidine and 
protein-protein interactions that are contingent upon binding of τ-phosphohistidine. 
2.2 Investigations into the Promiscuity of a Phosphotyrosine-
Binding Protein 
Previous work in the group using ITC had demonstrated that the Src Homology 2 (SH2) 
domain of the Growth Factor Receptor-bound 2 (Grb2) protein (a phosphotyrosine binding 
protein) binds to a peptide containing τ-pTz with micromolar affinity.126 Following these 
preliminary results, an independent biophysical assay was required to determine whether the 
τ-phosphotriazole peptide bound to the phosphotyrosine-binding site of Grb2-SH2; and if it 
did, whether the protein simply binds phosphorylated amino acids or has selectivity towards 
τ-pTz (and phosphotyrosine). The role of Grb2-SH2 is typical to that of most 
phosphotyrosine binding modules. Selective binding of Grb2-SH2 to the τ-phosphotriazole 
peptide and not to analogous peptides containing other phosphoamino acids (apart from 
phosphotyrosine), would indicate that τ-phosphohistidine may recognise these domains in 
vivo. In this sense, Grb2-SH2 is being used as a prototype to study the interaction of 
τ-phosphohistidine to SH2 protein modules.
2.2.1 Growth Factor Receptor-Bound 2 
Grb2 is a homodimeric adaptor protein that consists of one SH2 domain flanked by two SH3 
domains and is known to play a crucial role in signal transduction through the linking of 
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receptor and cytoplasmic protein tyrosine kinases to the Ras signalling pathway (Figure 
2.1).
127
  
  
Figure 2.1: Crystal structure of Grb2 consisting of one SH2 domain (shown in blue) flanked by two 
SH3 domains (shown in green); b) Grb2 as its homodimer with the same colouring as a) for 
one monomer and the other monomer shown in yellow. PDB file: a) & b) -1GR1. 
Grb2 links tyrosine kinases to the Ras signalling pathway through a translocation 
mechanism of activation.
128
 As shown in Figure 2.2a, each SH3 domain of Grb2 binds to a 
short proline-rich sequence on the guanine nucleotide releasing factor for the Ras protein 
(Sos (Son of Sevenless)) in the cytoplasm. The resultant Grb2/Sos complex is then recruited 
to the cytoplasmic membrane where the Ras protein is located. The SH2-domain binds to a 
phosphotyrosine residue in the epidermal growth factor receptor (EGR) that has been 
autophosphorylated via activation by an epidermal growth factor (EGF). Increase in the 
effective concentration of the Grb2-Sos complex at the plasma membrane results in 
interaction of Sos with the Ras protein. The Ras protein becomes activated through an 
exchange of GDP to GTP, initiating a downstream kinase cascade; relaying signals to both 
the cytoplasm to control metabolic processes, and the nucleus to control gene expression. 
Grb2-SH2 can also directly and indirectly interact with other receptor and non-receptor 
kinases to stimulate the Ras signalling pathway.
127
 For instance, association of the SH2 
domain of Grb2 with the SH2-domain containing oncogenic protein Shc (which has been 
phosphorylated on a tyrosine residue by the oncogenic kinase ν-Src) is also believed to 
activate Sos-mediated guanine nucleotide exchange on Ras (Figure 2.2b).
6
 The use of SH2 
domains to localise the proteins they are contained in through binding to short 
phosphotyrosine sequences is typical to many adaptor proteins, although many are less well 
characterised than Grb2-SH2. 
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Figure 2.2: The role of Grb2 in signal transduction a) The SH2 domain binds a tyrosine residue on 
the EGF receptor that has been autophosphorylated through activation by an EGF. In doing so, 
Sos, which is bound to Grb2 through interaction with its SH3 domain, is recruited to the 
plasma membrane. Association of Sos and Ras stimulates the exchange of GDP to GTP, which 
in turns initiates a downstream signalling cascade ending in protein transcription; b) indirect 
interaction of the SH2 domain of Grb2 with non-receptor kinase Src (through a phosphorylated 
Shc intermediate) can also activate the Ras signalling pathway. 
2.2.1.1 Binding of  Grb2-SH2 to Phosphotyrosine-containing Peptides 
The SH2 domain of Grb2 binds with high affinity to target proteins through short 
phosphotyrosine-containing sequences of the type pY(I/V)NX; with a hydrophobic residue 
at the +1 position and asparagine at the +2 position in the C-terminal direction from 
phosphotyrosine.
129
 Weber and co-workers
130
 have shown that an Shc-derived 
phosphotyrosine-containing synthetic peptide of the sequence Ac-SpYVNVQ-NH2 binds to 
Grb2-SH2 with a Kd of ca. 200 nM. The crucial residues involved in the binding interaction 
of Grb2-SH2 and phosphotyrosine-containing proteins have been elucidated by Ogura et 
al.
131
 through NMR experiments, and are highlighted in Figure 2.3. As well as the cluster of 
positively charged residues that constitute the phosphate binding pocket of phosphotyrosine; 
the asparagine residue at the +2 position C-terminal to phosphotyrosine forms hydrogen 
bonds to Lys109 and Leu120 and is essential for specific binding to the SH2 domain of 
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Grb2. Moreover, the bulky side chain of Trp121 interacts with asparagine at the +2 position, 
causing the binding peptide to turn and preventing it from forming an extended structure. 
The strong recognition of asparagine (pTyr +2) as well as phosphotyrosine by Grb2-SH2 
demonstrates that the protein recognises target phosphotyrosine-containing peptides in a 
sequence specific manner. 
 
Figure 2.3: Structure of the SH2 domain (blue), with residues identified as being involved in binding 
depicted as yellow sticks.
131
 The critical peptide sequence needed for binding (pTyr-Val-Arg) 
is shown in green, for simplicity, the rest of the peptide sequence has been omitted. PDB file 
1QG1. 
2.2.2 Previous Work in the Group 
Work carried out by Dr Tom McAllister using ITC demonstrated that 
-phosphotriazolylalanine peptide  91 (Figure 2.4b) binds to the SH2 domain of Grb2 with 
~2000 fold lower affinity then the analogous phosphotyrosine-containing peptide 90 (Figure 
2.4a).
126
 pTyr and pTz peptides 90 and 91 of consensus sequence Ac-SpXVNVQ-NH2 were 
synthesised using standard Fmoc SPPS and their binding to an N-terminally His-tagged SH2 
domain of Grb2 (subcloned into a pET28a vector from a full-length Grb2-GST fusion 
protein)i was measured using ITC. Control pY peptide 90 was titrated into His6–Grb2-SH2 
to yield a sigmoidal binding curve that corresponded to 1:1 binding with Kd = 385 ± 41 nM 
(Figure 2.4a). Titration of pTz-containing peptide 91 into the protein gave a binding curve 
                                                     
i The Grb2-GST fusion protein aggregated at concentrations needed to measure binding of pTza 
peptide 91 by ITC. 
- 31 - 
with an affinity of 719 ± 28 μM (Figure 2.4b). To determine whether the reduced binding 
affinity of pTz peptide 91 to Grb2-SH2 was due to differing protonation states of the 
phosphoryl groups of 90 and 91, the pKa of both peptides were determined via NMR 
titrations. These experiments revealed a pKa of 5.8 for pY peptide 90 and 5.95 for pTz 
peptide 91 (data not shown); hence both phosphoryl groups will be dianionic under the 
conditions of the ITC experiments (pH 7.4). It is therefore unlikely that the change in 
binding affinity is due to different protonation states. 
The discovery that Grb2-SH2 binds to pTz peptide 91 was serendipitously made whilst 
investigating whether a peptide containing an analogue of phosphotriazole, 
phosphohomotriazole (phTz) peptide 92 could act as a mimic of phosphotyrosine and hence 
have affinity for the SH2 domain of Grb2 (Figure 2.4c). The extension of the linkage 
between the backbone of the peptide and the triazole by one carbon in comparison to parent 
pTz peptide 91 was expected to present the phosphoryl group in a similar orientation to that 
of phosphotyrosine. Moreover, Hofmann et al.
132
 had previously demonstrated that a 
synthetic peptide containing phosphoarginine 5 binds to the SH2 domain of Src with a 
reduced affinity of ~4000 fold less than the analogous pY peptide. Phosphohomotriazole is 
similar in structure to phosphoarginine 5 and therefore it was highly possible that phTz 
peptide 92 would show affinity towards SH2 domains. Surprisingly, titration of 92 (of the 
same consensus sequence of 90 and 91) into His6–Grb2-SH2 using ITC showed no binding 
(Figure 2.4c). 
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Figure 2.4: ITC experiments titrating a) pY peptide 90, b) pTz peptide 91 and c) phTz peptide 92 into His6–Grb2-SH2 gave equilibrium binding constants of (385 ± 41) nM for 
90 and (719 ± 28) μM for 91. Binding of 92 to His6–Grb2-SH2 was not observed.
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2.2.3 Further Investigations into the Phosphotyrosine-Binding site of 
Grb2-SH2  
Following the discovery that pTz peptide 91 had affinity towards Grb2-SH2, the next step 
was to use an alternative biophysical technique to confirm that pTz peptide 91 was binding 
to the same site on Grb2-SH2 as phosphotyrosine peptide 90, and to investigate the 
promiscuity of the protein to other phosphoamino acids. To this end, it was decided to 
conduct a series of fluorescence anisotropy competition experiments. For these assays, a 
phosphotyrosine-containing fluorescent probe of sequence FITC-GaSpXVNVQ-NH2 and a 
series of phosphoamino acid containing peptides of consensus sequence Ac-SpXVNVQ-
NH2 (pX = phosphoamino acid) were required. 
2.2.3.1 Synthesis of a Fluorescent Probe 
Phosphotyrosine-containing peptide with N-terminal FITC 95 was synthesised using 
standard Fmoc-based SPPS and reaction with FITC overnight in the dark on Rink amide 
resin (Scheme 2.1). The peptide was cleaved from the resin using a standard cleavage 
cocktail (TFA/H2O/TIS 95:2.5:2.5). Interestingly, use of mono-benzyl phosphotyrosine 93 
resulted in a mixture of unassignable peptide products; believed to be the result of reaction 
of the free phosphonate hydroxyl group and the highly electrophilic isothiocyanate carbon 
(Scheme 2.1a). A globally protected phosphotyrosine was therefore needed. 
bis(dimethylamino)phosphotyrosine 94 is commercially available and accordingly was used 
in place of monobenzyl phosphotyrosine 93. The dimethylamino- protection for the 
phosphonate of 94 has reduced lability in acidic conditions and will not be removed when 
swelling in a standard cleavage cocktail for two hours. Accordingly, a two-step deprotection 
strategy was employed in which the peptide was cleaved from the resin using a standard 
cleavage cocktail for two hours, 10% (v/v) more H2O was added and the mixture swelled 
overnight. After purification using anion-exchange chromatography, pY probe 95 was 
afforded in 57% yield. 
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Scheme 2.1: Synthesis of pY probe 95 by Fmoc SPPS; a) Incorporation of monobenzyl 
phosphotyrosine 93 resulted in a mixture of unassignable peptide products; b) Use of 
bis(dimethylamino) phosphotyrosine 94 gave the desired fluorescent peptide 95 in a yield of 
57%. 
2.2.3.2 Synthesis of Phosphotriazoles Compatible with the Fmoc-Strategy for 
SPPSi  
In order to generate pTz peptide 91, the synthesis of Fmoc-protected pTz 15 was required. It 
seemed prudent to also use competitive fluorescence polarisation to conclusively confirm 
that phTz peptide 92 did not bind to the SH2 domain of Grb2 (as previously determined by 
ITC (Figure 2.4c)); thus Fmoc-protected phTz 103 was also synthesised. 
Following the route of McAllister et al.,
25
 triazoles 15 and 103 were synthesised in 6 steps. 
TIPS acetylene 96 was converted to reactive intermediate 97 using isopropylmagnesium 
chloride in THF at 0 °C; addition of bis(diethylamino)chlorophosphine to the reaction 
mixture and warming to room temperature afforded intermediate 98. Protected alkyne 96 
was used to prevent side reactions involving the terminal alkyne.ii Following a solvent 
switch to acetonitrile the diethylamino- groups of intermediate 98 were displaced using 
benzyl alcohol together with the dropwise addition of 1H-tetrazole at 0 °C. The reaction was 
allowed to warm to room temperature and stirred overnight. 1H-tetrazole was required for 
phosphoroamidate activation (through formation of the tetrazolide). Oxidation of the 
corresponding benzyl phosphite by washing the organics with 10% hydrogen peroxide gave 
benzyl phosphonate 99 in a yield of 44%. The TIPS group was removed using TBAF in 
                                                     
i Synthesis of phTz 103 was carried out by Dr. Tom McAllister 
ii McAllister et al.
25
 described the concurrent formation of Michael addition-type products when 
using the unprotected version of 96 with nucleophiles such as benzyl alcohol. 
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THF at -78 °C to yield phosphoalkyne 100 in 83% yield. Using copper(II) sulfate 
pentahydrate and sodium ascorbate in 1:1 THF/H2O, triazoles 15 and 103 were generated 
through a cycloaddition reaction between phosphoalkyne 100 and azidoalanines 101 or 102 
in yields of 84% and 75% respectively. 
 
Scheme 2: Synthesis of pTz 15 and phTz 103 through the (3 + 2) cycloaddition of dibenzyl 
phosphoalkyne 100 to azidoalanine 101 or 102 respectively. Phosphoalkyne 100 was 
generated in 5 synthetic steps from commercially available TIPS-acetylene 96. 
2.2.3.3 Synthesis of Phosphoamino Acid-containing Peptidesiii 
To investigate whether Grb2-SH2 selectively binds to -phosphohistidine sequences or to 
phosphorylated amino acids in general, the affinity of pS peptide 104 and pT peptide 105 
towards Grb2-SH2 would also be determined using competitive fluorescence anisotropy. 
The affinity of pArg- and pK- containing peptides towards the SH2 domain of Grb2 was not 
investigated due to previous work (Figure 2.4c) indicating that the structurally similar phTza 
peptide 92 did not bind (to Grb2-SH2).  
Peptides of sequence AcSXVNVQ-NH2 (where X is either pTz 91, phTz- 92, pSer- 104, 
pThr- 105, pTyr- 90, His 106 or Tyr 107) were synthesised using a standard Fmoc SPPS 
protocol (5 eq. of the commercially available amino acids, 5 eq. HCTU and 10 eq. DIPEA 
and 3/3/6 for pTza 15 and phTz 103); cleaved from the resin using a standard cleavage 
cocktail (TFA:H2O:TIS 95:2.5:2) and purified using anion-exchange chromatography. pTyr 
                                                     
iii Peptides 92 and 104-107 were synthesised by Dr Tom McAllister. 
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peptide 90 and His and Tyr peptides 106 and 107 were to be used as positive and negative 
control(s) respectively.  
 
Scheme 2.2: Peptides synthesised by Fmoc SPPS to be used in fluorescence anisotropy competition 
assays. pTz 15 and phTz 103 were incorporated into peptides 91 and 92. All other amino acids 
were commercially available. 
2.2.3.4 Lysis and Purification of His6–Grb2-SH2 
Following overexpression from pET28a-Grb2-SH2 in E. coli C41(DE3) cells, the cells were 
lysed and the inclusion bodies that were collected with the cellular debris solubilised in 8M 
urea overnight. The solubilised protein was applied to a nickel affinity column, refolded 
through washing with Phosphate Buffer 1, and purified using a standard Ni-NTA protocol. 
Fractions containing His6–Grb2-SH2 were determined by measuring UV absorbance at 
280 nm and those containing protein were combined, concentrated and purified further 
using size exclusion chromatography (SEC) (Figure 2.5a). The SEC trace showed two peaks 
eluting at 175 ml and 220 ml; the former peak corresponded to a domain-swapped dimer 
and the latter was the correctly folded His6–SH2Grb2 as previously shown by Benfield et 
al.
133,iv Thus, fractions corresponding to the later peak were concentrated. Analysis by SDS-
                                                     
iv Dr Tom McAllister had previously ran ITC experiments with protein corresponding to both of 
these peaks shown on the SEC trace to obtain Kd values for their binding to pY peptide 90. He 
found that the peak eluting at 220 ml had a Kd corresponding to correctly folded His6–Grb2-
SH2. 
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PAGE (Figure 2.5b) and mass spectrometry (Figure 2.5c) revealed a protein corresponding 
to a mass of 12999.6 consistent with the mass of His6–Grb2-SH2 after cleavage of the N-
terminal methionine (expected mass 13000.6 Da).  
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Figure 2.5: a) SEC trace of fractions containing His6–SH2-Grb2. Peak 1 corresponds to a domain 
swapped dimer, peak 2 is monomeric His6–Grb2-SH2; b) 12% SDS-PAGE gel of His6–SH2-
Grb2 after purification by SEC; ci) HRMS trace and cii) deconvoluted HRMS trace for His6–
SH2-Grb2 gave a measured mass 12999.6 Da, consistent with the mass of His6–SH2-Grb2 
after cleavage of the N-terminal methionine (expected mass 13000.6 Da). PDB file: 2H46 
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2.2.3.5 Development of a Fluorescence Anisotropy Competition Assay 
2.2.3.5.1 An Introduction to Fluorescence Anisotropy  
Fluorescence anisotropy determines the extent of decorrelation of plane polarised light of a 
sample and can be used to obtain information about protein binding interactions.
134
 It is 
particularly appropriate for the studying of protein-protein or protein-peptide interactions 
due to its sub-nanomolar sensitivity and its applicability at low concentrations; providing a 
suitable fluorophore is used for the system in question.  
If a sample of fluorescent molecules is illuminated with plane polarised light, only the 
subset of molecules that have absorption dipoles aligned to the plane of polarisation are 
raised to an excited electronic state.
135
 The excited state will exist normally for a few to tens 
of nanoseconds, and after emission of a photon, the molecules will return to their ground 
electronic state. The probability of excitation (Pex) that a fluorescent molecule will absorb a 
photon is proportional to the angle between the polarisation of exciting light and the 
excitation transition dipole (φ). 
Pex∝ cos
2φ                                                     (1) 
The probability of excitation is maximal if both the plane of polarisation and the transition 
dipole moment of excitation are aligned (φ = 0). If both the plane of polarisation and the 
transition dipole moment of excitation are perpendicular (φ = 90°), Pex will be zero. This is 
known as selective photoexcitation and can be used to look at the relative anisotropies of 
associated and dissociated protein complexes through the differences in their plane polarised 
orientated subpopulations. If during the excited state lifetime, there is no rotation of the 
probe molecule and excitation and emission dipoles are aligned; the emitted fluorescence 
will be polarised in the same direction. Conversely, if the fluorescent molecule rotates 
during the excited state lifetime, the plane of polarisation of emitted fluorescence will rotate 
and be depolarised relative to the excitation light.  
The rotation of a molecule on a characteristic fluorescent timescale can be theoretically 
calculated.
134
 Assuming a protein is globular and rigid, the rotational correlation time (ϴ) 
can be approximately linked to its molecular weight (MW) by the following equation: 
θ =  
ηMW
RT
 (ν +  h)                                            (2)  
Where η = solvent viscosity (P), R = 8.31 x 107 erg Mol-1 K-1, T = absolute temperature (K), 
ν = partial specific volume and h = the degree of hydration. If a spherical rigid protein 
monomer of 30 kDa at 298 K had typical values of ν = 0.74 ml/g and h = 0.2 gwater/gprotein and 
was in a solvent of η = 0.01 P, its rotational correlation time would be ~11 ns. Similarly, in 
these conditions a 1 kDa substrate would have ϴ = ~0.4 ns. Fluorescein has an excited state 
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lifetime of 4 ns; shorter than the rotational correlation time for the 30 kDa protein but longer 
than that for the 1 kDa substrate. Hence, excitation of a fluorophore attached to a small 
peptide or protein with plane polarised light will result in rotation of the molecule a number 
of times throughout the excited state lifetime as its rotational correlation time is below that 
of the fluorescence timescale. Consequently a low level of light relative to the excitation 
plane of polarisation will be emitted (Figure 2.6a). The corresponding peptide-protein 
complex, which is significantly larger, will have a slower rotation than the excited state 
lifetime and a higher level of plane polarised light will be emitted (Figure 2.6b). Therefore, 
an increase in anisotropy signal will show an increase in ligand-protein association. Exciting 
a sample with polarised light both parallel and perpendicular to the plane of excitation will 
mean that the extent of a molecules rotation can be assessed and anisotropy values can be 
calculated. Observing a system over a range of concentrations of one of the binding 
partners, or a competitive binder, will enable the generation of binding curves required to 
attain parameters such as the Kd and IC50. 
 
Figure 2.6: Fluorescence anisotropy: Excitation with plane polarised light of a) a fluorescent peptide 
and b) a fluorescent peptide-protein complex. Fast rotation of the free peptide on the 
fluorescent timescale will result in depolarised emission. Slow rotation of the protein-peptide 
complex will lead to plane polarised emission. 
2.2.3.5.2 Fluorescence Anisotropy Experiments 
2.2.3.5.2.1 Determination of the Binding Affinity of FITC-pY Peptide 95 to Grb2-SH2 
To determine the binding constant (Kd) of fluorescent pY probe 95 to the SH2 domain of 
Grb2, a 2–fold dilution series of purified His6–Grb2-SH2 in ITC buffer containing 100 nM 
95 was prepared and the fluorescence intensity was measured in both parallel and 
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perpendicular channels. The total intensity IT and anisotropy r were calculated for each data 
point through application of equations (3) and (4): where I parallel is the intensity of light 
emitted with parallel polarisation to the laboratory source, I perpendicular is the intensity of light 
emitted with perpendicular polarisation, and G is the instrumental grating factor which 
allows for the variation in responsivity of an instrument to light polarised in the 
perpendicular direction. G was approximated under the assumption that the free peptide 95 
had anisotropy r = 0. A logistic model was then used to fit data points and their standard 
deviation (averaged from each triplicate measurement after subtraction from a blank 
average) to give maximum and minimum limiting values for IT and r (Figure 2.7a and b 
respectively). 
𝐼T = 𝐼 parallel  + 2GI perpendicular                                                 (3)   
𝑟 =
𝐼 parallel  − GI perpendicular
𝐼T
                                (4) 
Under the assumption that plane polarised light is exciting an ensemble of randomly 
orientated dipoles, the anisotropy must be averaged over all possible orientations and 
weighted by the probability of a dipole being excited at that orientation. Therefore the 
maximal fluorescence anisotropy value for one photon should be equal to 0.4.
134
 Binding of 
fluorescent pY peptide 95 to His6–SH2-Grb2 resulted in a maximum anisotropy value of 
0.08 (Figure 2.7b), a significant deviation from the theoretical maximum value. Hence, 
considerable fluorescence quenching is occurring upon complex formation. Anisotropy 
values were therefore converted to the fraction bound (F) by application of equation (5) 
where λ = I bound / I free using maximal and minimal anisotropy values (r max and r min), before 
being fit with a hyperbolic binding model to give a Kd of 283 ± 18 nM (Figure 2.7c). This 
result is consistent with the binding constant measured previously in ITC experiments 
(Figure 2.4). 
𝐹 =
r − r min
λ (r max − r − r min)
 where 𝜆 =
𝐼 bound
𝐼 free
    (5) 
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Figure 2.7: Fluorescence anisotropy analysis of the binding of fluorescent peptide 95 to His6–Grb2-
SH2: a) Total fluorescence as a function of [Grb2-SH2] with 100 nM 95; data were fit using a 
logistic model to give limiting values of I bound 10.34 abu and I free 5.63 abu; b) Dependence of 
anisotropy upon [Grb2-SH2] revealing r min 0.0021 abu and r max 0.083 abu; c) Fraction bound 
95 as a function of [Grb2-SH2] gave a binding constant of 283 ± 18 nM. 
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2.2.3.5.2.1.1 Competition Assays 
For the fluorescence anisotropy competition experiments, peptides pTz  91, phTza 92, 
pSer 104, pThr 105, pTyr 90, His 106 and Tyr 107 were dissolved in ITC buffer and a 2.5–
fold or 3–fold dilution series of each peptide was prepared in triplicate containing 200 nM 
of peptide probe 95 and 175 nM of His6–Grb2-SH2. A binding response (displacement of 
peptide probe 95) was observed only for pTz peptide 91 and pY peptide 90. Accordingly the 
anisotropy for each data point was converted to the fraction bound via application of 
equation (5) using the maximum and minimum values for fluorescence intensity and 
anisotropy determined for binding of fluorescent pY probe 95 to Grb2-SH2. Data were 
globally fit using a logistic binding model to yield half maximal inhibitory concentrations of 
363 ± 25 μM and 442 ± 66 nM for pTz peptide 91 and pY peptide 90 respectively (Figure 
2.8a). The IC50 value calculated for pTz peptide 91 was slightly lower than anticipated when 
compared to the binding constant of 700 μM calculated from ITC experiments (Figure 2.4); 
indicating that initial ITC analysis might have underestimated the affinity of pTz peptide 91 
for Grb2-SH2. 
As can be seen in Figure 2.8b, no displacement of fluorescent peptide 95 was observed for 
peptides pS 104, pT 105, phTz 92, Tyr 106 or His 107. These results indicate that the SH2 
domain of Grb2 does not simply have affinity for phosphoryl groups orientated at the 
appropriate position in a peptide sequence and that Grb2-SH2 does not just bind to an 
aromatic ring. It is noteworthy that phTz peptide 92 does not have affinity to Grb2-SH2; 
especially when considered alongside reports from Hoffman et al.,
132
 who demonstrated that 
the structurally similar pArg 5 binds to the SH2 domain of Src kinase. Moreover, it is 
interesting that extension of the linkage between the triazole and peptide backbone by just 
one carbon atom results in total elimination of binding.  
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Figure 2.8: Fluorescence anisotropy competition experiments. All peptides serially diluted and mixed 
with 175 nM His6–Grb2-SH2 and 200 nM pY probe 95. a) Competition of pTz and pY 
peptides 91 and 90 for binding of Grb2-SH2 over pY probe 95 reveal half maximal inhibitory 
concentrations of 363 ± 25 μM and 442 ± 66 nM respectively; b) No competition is evident for 
peptides 92 and 104-107.  
Results of the fluorescence anisotropy competition experiments confirm that a known 
τ-phosphohistidine mimic binds to a canonical phosphotyrosine binding domain with ~1000 
fold weaker affinity then the analogous phosphotyrosine-containing sequence. The 
mechanism by which Grb2-SH2 links receptor tyrosine kinases to the Ras signalling 
pathway is well established and it is therefore unlikely that the SH2 domain of Grb2 
interacts with τ-phosphohistidine in vivo. However, it is a possible that a subset of other 
SH2 domains that have less well-defined targets may bind τ-phosphohistidine-containing 
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sequences. The prevalence of phosphotyrosine binding modules in human signalling 
proteins is relatively high, and the binding affinity of phosphotyrosine peptide sequences to 
these target protein modules can vary from high micromolar to low nanomolar.
136
 Hence, 
the micromolar affinity of pTz peptide 91 to the SH2 domain of Grb2 does not mean that it 
is an insignificant interaction. Binding of τ-pHis-containing sequences could therefore be a 
characteristic feature of many phosphotyrosine binding modules. Further investigations to 
establish the incidence of this are needed. 
This result contrasts studies by Senderowicz et al.
137
 who demonstrated that a peptide 
derived from FGFR1 containing a τ-phosphohistidine residue did not bind to the SH2 
domain of phospholipase C-γ1 (FGFR1 is known to bind to the SH2 domain of PLC-γ1 
when its tyrosine residue is phosphorylated). However, it should be noted that in this study, 
the conditions used prevented observation of low affinity binding. 
2.2.4 Conclusions 
It has been unequivocally demonstrated that peptide 91 containing a known 
τ-phosphohistidine analogue, interacts with the SH2 domain of Grb2 using two distinct 
biophysical techniques. Conversely, it has been shown that with the exception of 
phosphotyrosine peptide 90, a number of other phosphoamino acid-containing peptides do 
not bind to Grb2-SH2. This includes phosphohomotriazole peptide 92, an analogue 
conjectured to mimic phosphotyrosine (a known, high affinity substrate of Grb2-SH2). 
From a functional perspective, the fact that τ-pTz peptide 91 binds selectively to Grb2-SH2 
suggests that τ-phosphohistidine-containing sequences may be recognised by a subset of 
SH2 binding modules in vivo. 
 
Figure 2.9: Summary of binding interactions of Grb2-SH2 to phosphoamino acid-containing peptides.
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2.3 Examining the Interaction between PPDK and its Regulatory 
Protein, PDRP 
τ-Phosphotriazole can also be used as a probe molecule to study known 
τ-phosphohistidine-meditated protein-protein interactions. As described in Section 1.1.4.2.1, 
interaction of pyruvate, orthophosphate dikinase (PPDK) and PDRP (PPDKs regulatory 
protein) is dependent upon phosphorylation of a catalytic histidine residue.
41
 Work carried 
out by Dr. Zhenlian Ling demonstrated that PDRP is unstable and prone to precipitation and 
is therefore unsuitable for use in experiments to study binding interactions of this protein. 
Fortunately, an analogous phosphohistidine-mediated regulatory system exists in E. coli in 
which the protein equivalent to PPDK is known as phosphoenolpyruvate synthase (PPS), 
and its regulatory protein, analogous to PDRP, is YdiA.
138
 PPS is known to catalyse the 
formation of phosphoenolpyruvate (PEP) from pyruvate in a similar mechanism to that of 
PPDK. Furthermore, there is a high level of sequence homology around the active sites in 
PPDK and PPS.
139
 The following section focuses on the use of biophysical techniques to 
study the PPS-YdiA regulatory system in an attempt to further understanding of the binding 
interaction between these two proteins and the analogous PPDK/PDRP system. 
2.3.1 Studying the Binding Interaction between YdiA and PPS 
2.3.1.1 Previous Work in the Groupi 
Preliminary investigations into the binding interaction between PPS and YdiA had 
previously been carried out by Dr Tom McAllister and Dr Jeff Hollins in which they used 
ITC to determine the binding parameters between YdiA and two related peptides that were 
designed to mimic the binding site of PPS.
126,140
 τ-pTz peptide 108 (Ac-RGGRTSpTzAA-
NH2), which contains τ-phosphohistidine analogue pTz, was synthesised to study the 
binding interaction of catalytic histidine-phosphorylated PPS and YdiA (Figure 2.10a). pT 
peptide 109 (Ac-RGGRpTSHAA-NH2), which contains a phosphothreonine residue, was 
synthesised to investigate binding of regulatory threonine-phosphorylated PPS to YdiA 
(Figure 2.10b). ITC experiments were conducted in which PPS peptides 108 and 109 were 
titrated into purified YdiA (expressed as a fusion protein with MBP) to yield binding 
constants of 11.4 ± 6.9 μM for pTz peptide 108 (Figure 2.10a) and 39.8 ± 5.5 μM for pT 
peptide 109 (Figure 2.10b). 
                                                     
i Synthesis of peptides for ITC and subsequent ITC experiments were carried out by Dr Tom 
McAllister and Dr Jeff Hollins respectively. Dr Jeff Hollins generated MBP–YdiA. 
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Figure 2.10: ITC experiments were carried out titrating PPS-derived a) pTz peptide 108 or b) pT 
peptide 109 into MBP–YdiA to give dissociation constants of 11.4 ± 6.9 μM and 
39.8 ± 5.5 μM respectively. 
2.3.1.2 Fluorescence Polarisation Experimentsii 
Following the successful use of competitive fluorescence polarisation to study the 
interaction between Grb2-SH2 and phosphoamino acid-containing sequences (Section 
2.2.3.5.2), it was decided to use an analogous assay to further elucidate the binding 
interaction between YdiA and a variety of PPS-derived peptides. For these assays, 
fluorescent τ-pTz peptide 110 comprising an N-terminal FITC and an analogous peptide 
sequence to τ-pTz peptide 108 (that had been used in preceding ITC experiments) would be 
used as the competitive probe (Figure 2.11a). After using fluorescence polarisation to obtain 
                                                     
ii Fluorescence anisotropy experiments and purification of MBP–YdiA were performed by Ieva 
Drulyte (Wellcome Trust rotation student) under the supervision of KAH. Fluorescence 
polarisation analysis was performed by KAH. 
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the binding affinity of 110 to YdiA, pTz probe 110 would be used in a series of competition 
experiments against a range of PPS derived peptides of differing lengths containing either 
phosphothreonine 1 and/or τ-phosphotriazolylalanine 11. Variation of the length of peptide 
sequence surrounding the PPS-binding site would provide insight into the crucial residues 
and length of sequence needed for binding to YdiA. It would also be interesting to see 
whether a PPS-derived peptide containing both phosphothreonine 1 and τ-phosphohistidine 
analogue 11 had affinity for the protein 
pTz peptide probe 110 was synthesised using Fmoc SPPS with reaction of the peptide 
N-terminal with fluorescein isothiocyanate (Figure 2.11a). To investigate binding of pTz 
probe 110 to YdiA, a 3–fold dilution series of MBP–YdiA in SEC Buffer containing 45 nM 
of 110 was prepared in triplicate. Fluorescence intensity was measured in both parallel and 
perpendicular channels and the resultant data points were converted to anisotropy r through 
application of equations (3) and (4) (Section 2.2.3.5.2.1). Surprisingly, this revealed a 
pattern inconsistent with a binding event (Figure 2.11b).  
 
Figure 2.11: a) Synthesis of PPS-derived pTz- probe 110 via Fmoc SPPS; b) Fluorescence 
polarisation analysis of the binding 110 to serially diluted MBP-YdiA (140 μM – 2.4 nM) 
shows no binding interaction. 
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2.3.2 Discussion and Conclusions 
Clearly, there is contradiction in the data obtained from ITC and fluorescence anisotropy 
experiments. It is possible that the presence of a relatively bulky fluorophore in pTz probe 
110 could decrease binding affinity towards YdiA. However, this is unlikely since no low 
affinity binding was observed in the polarisation assays, even at protein concentrations as 
high as 140 μM. It is also doubtful that MBP-YdiA had unfolded before use in the 
fluorescence anisotropy assay as circular dichroism (CD) experiments conducted by Ieva 
Drulyte demonstrated that MBP-YdiA retains its secondary structure over time, even after 
being stored for 30 days (data not shown). It is possible that ITC data indicative of a binding 
event between pTz peptide 108 and MBP-YdiA (Figure 2.10) was due to peptide 
disaggregation and not a protein-peptide interaction. It is probable that the peptide 
sequences generated to mimic the binding site of PPS are not extended to the crucial length 
of residues needed for interaction with YdiA.  
From the disappointing results of these experiments, it is evident that use of a peptide chain 
to mimic the primary structure of one protein counterpart to study a binding interaction is 
often not sufficient. This is because protein-protein interactions can be the result of 
association of residues over a considerable surface area of a protein. It may be possible to 
study binding of PPS to YdiA if the whole PPS protein could be generated with a 
τ-phosphohistidine mimic (or phosphothreonine) incorporated at the desired position. In 
fact, the ability to site-specifically incorporate a τ-pHis analogue into any protein would be 
of considerable use in studying a wide array of τ-phosphohistidine-mediated systems. The 
following section describes current progress towards this goal. 
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2.4 A Third Generation τ-phosphohistidine Analogue 
As described in Section 1.3.2, unnatural amino acids can be incorporated into specific sites 
in proteins by exploitation of the protein’s natural machinery using amber suppression.123 
Previous attempts to incorporate UAAs bearing phosphate groups have been unsuccessful as 
the highly charged nature of the phosphoryl moiety has prevented transportation across the 
cell membrane.
124,126
 τ-phosphotriazolylalanine (pTz-3) 111, that has allyl-protected 
phosphoryl groups, should have reduced polarity sufficient to penetrate cellular membranes 
(Figure 2.12).  
It should be possible to synthesise 111 using the established synthetic procedure previously 
used to generate pTz 15 and phTz 103 (Section 2.2.3.2). Once synthesised, pTz-3 111 will 
be sent to Jason Chin’s laboratory at the University of Cambridge and screened as a 
substrate for a vast library of pyrrolysyl- and tyrosyl-tRNA synthetases. If a compatible 
synthetase is not found, a novel amber suppression system will be evolved to genetically 
encode pTz-3 111 into proteins. On discovery or evolution of a system such as this, it will 
be possible to site-specifically incorporate 111 into a range of proteins including PPS. It 
should be possible to remove the allyl protection of 111 after incorporation into proteins 
using palladium(0). 
 
Figure 2.12: Genetic incorporation of a third generation τ-phosphohistidine mimic 111. After 
incorporation, the phosphoryl groups can be removed using Pd(0). 
2.4.1 Synthesis of Second Generation τ-Phosphotriazole 
2.4.1.1 Phosphoalkyne Synthesis 
Protected phosphoalkyne 113 was generated in 4 steps from TIPS-acetylene 96 in a good 
overall yield of 59% (Scheme 2.3).
25
  Phosphine 112 was found to be volatile and therefore 
prior to oxidation with hydrogen peroxide to yield phosphate 113, concentration of 112 in 
vacuo was performed at 50 mbar and 40 °C; this served to minimise loss of intermediate 
112. Deprotection of 113 using freshly opened TBAF in THF at -78 °C gave phosphoalkyne 
114 in 89% yield. Repetition of this step with TBAF that had been stored in the fridge for 
ca. 1 month reduced the yield of the final step to 50%. Generation of novel allyl protected 
alkynylphosphonate 113 demonstrates the robustness of the synthetic route devised by 
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McAllister et al.,
25
 who synthesised analogous tBu- and Bn- versions of 113. The ability to 
incorporate a variety of phosphoryl protecting groups via reaction of the corresponding 
alcohol with intermediate 98 makes this route adaptable to the synthesis of a range of 
different phosphonates (and phosphonites).   
 
Scheme 2.3: Synthesis of target phosphoalkyne 114 in an overall yield of 52% via alkynylphosphine 
intermediate 98. Use of intermediate 98 allows for any organic alcohol to be used to form the 
corresponding ethynylphosphonite 112. After oxidation of 112 to form phosphonate 113, 
simple removal of the TIPS protecting group using TBAF gave the free phosphoalkyne 114. 
2.4.1.2 Triazole Synthesis 
2.4.1.2.1 Synthesis through a Boc-protected Intermediate 
Boc-protected triazole 116 was synthesised through a Cu(I) catalysed cycloaddition reaction 
between phosphoalkyne 114 and Boc-protected azidoalanine 115 (Scheme 2.4).
25
 
Azidoalanine 115 was purchased as the dicyclohexylammonium (DCA) salt. Cu(I) was 
generated in situ from the reduction of copper (II) sulfate pentahydrate by sodium ascorbate 
in a 1:1 mixture of H2O and tBuOH. Work-up of the crude mixture resulted in the product 
being distributed between the aqueous and organic layers; acidification to pH 1 and 
subsequent extraction with ether did not lead to total extraction of 116 into the ethereal 
layer. A monoallylated version of triazole 116 was also observed in the aqueous layers 
through LCMS analysis. The reaction was carried out a second time and crude 116 was 
applied directly to a column after concentration without work up. Purification by column 
chromatography gave diallyl-phosphotriazole 116 together with a number of contaminants 
that were revealed to be the DCA salt from azidoalanine 115, and both monoallyl- and fully 
deprotected- versions of triazole 116. Purification of crude 116 by anion-exchange 
chromatography, eluting the Q-sepharose resin with increasing concentrations of 
ammonium bicarbonate (10-500 mM), did serve to remove the DCA salt but lead to 
increased formation of the monoallylated version of 116. Purification by mass-directed 
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HPLC gave phosphotriazole 116 in a poor yield of 12%; NMR analysis showed that 116 
still had low levels of contamination by impurities.  
Nevertheless, Boc-protected phosphotriazole 116 was used in a trial deprotection reaction to 
generate third generation phosphotriazole 111 by stirring in 2M HCl in dioxane overnight. 
Analysis of the crude reaction mixture revealed the presence of the desired product 111 
together with the corresponding monoallylated derivative. Purification by mass-directed 
HPLC yielded pTz-3 111 in a moderate yield of 34%.  
 
Scheme 2.4: Synthesis of third generation phosphotriazole 111 via Boc-protected triazole 116, 
adapted from a route described by McAllister et al.
25
 Protected triazole 116 was synthesised 
via the (2+3) cycloaddition of alkyne 114 and azidoalanine 115 to yield 116 in 12% yield. The 
poor yield can be attributed to in situ allyl-group deprotection of 116 and purification by 
MD-HPLC. Acid-catalysed Boc-deprotection of 116 yielded desired product 111 together with 
the corresponding monoallylated derivative.  
Use of ammonium bicarbonate in anion-exchange chromatography in attempted purification 
of protected triazole 116 and use of 2M HCl to form triazole 111 both lead to removal of 
one or both of the allyl protecting groups. Commercially available azidoalanine 115 is 
purchased as the dicyclohexylammonium salt and this has been proven difficult to remove 
via manual column chromatographic methods. Although purification by mass-directed 
HPLC served to remove the DCA-salt, it may have also served to reduce the yield of 
protected triazole 116. To circumvent these problems, azidoalanine with alternative 
amino-group protection was required. 
2.4.1.2.2 Synthesis through an Fmoc-protected Intermediate 
Fmoc-protected triazole 117 was initially generated from the cycloaddition of commercially 
available Fmoc-azidoalanine 101 and alkyne 114 following the same procedure as described 
for the generation of Boc-triazole 116 (Scheme 2.5).
25
 Azidoalanine 101 was found to be 
poorly soluble in H2O/tBuOH and hence a 1:1 mixture of H2O/THF was used instead. After 
the reaction had reached completion, the aqueous reaction mixture was extracted with 
CH2Cl2, concentrated, and purified by column chromatography to give triazole 117 in a 
moderate yield of 35%. Without acidification of the aqueous layer, extraction of triazole 117 
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into the organics proved to be a lengthy procedure. Furthermore, LCMS analysis of the 
aqueous layer revealed presence of the monoallylated derivative of triazole 117, similar to 
the formation of the monoallylated triazole in the synthesis of Boc-triazole 116 when using 
an acidic work up. This suggests that acid-catalysed elimination of the allylic alcohol is not 
the reason for formation of mono-allylated side-products. It is possible that the mildly basic 
sodium ascorbate used to aid generation of the Cu(I) species through reduction of Cu2SO4 
may be removing allyl protection of triazoles 116 and 117. Accordingly, protected triazole 
117 was synthesised using CuI as a source of Cu(I), and, after purification using automated 
column chromatography, 117 was generated in an improved yield of 57%. With the 
optimised procedure for formation of protected triazole 117 in place, attention was turned to 
the removal of the fluorenylmethyl group. Deprotection of triazole 117 was attempted 
through addition of a fluoride anion by stirring of 117 in 0.1M TBAF at room 
temperature.
141
 Unfortunately, it was not possible to separate desired product 117 from the 
alkyl fluorenylcarbonate side-product via automated or manual chromatographic 
procedures. 
Lang et al.
87
 demonstrated the effective use of polymer-bound piperazine in the removal of 
an Fmoc group from a bicyclononyne derivative. It was anticipated that if reacted with 
triazole 117, the supported piperazine would be a weak enough base to leave the 
allyl-protecting groups of triazole 117 intact, whilst the piperazine-linked solid support 
would capture the dibenzofulvene leaving group; eliminating the need for work-up and 
purification. Thus, Fmoc-protected triazole 117 was added to a suspension of polymer-
bound piperazine in dry DMF and gravity filtered after 2.5 hours. Analysis of the filtrate 
showed a detectable amount of the monoallylated version of 117 alongside the desired 
triazole 117. Crude triazole 111 was therefore purified by mass-directed HPLC to give the 
final product in 30% yield. The analogous reaction was performed in wet DMF to generate 
the desired pTz-3 111 in a comparable yield of 31%. It should be noted that in the second 
attempt, the reaction was stopped after 2 hours and no trace of the corresponding 
monoallylated triazole was observed. Unfortunately, reduction of reaction time coincided 
with trace amounts of protected triazole 117; hence, purification by mass-directed HPLC 
was still necessary. It should be noted that in both instances, the crude yield of 111 before 
HPLC purification was significantly higher in comparison to the yield of the purified 
product. 
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Scheme 2.5: Synthesis of pTz-3 111 through Fmoc-protected triazole 117. Triazole 117 was 
generated in 57% yield through optimised cycloaddition reaction conditions utilising Cu(I) 
before Fmoc-deprotection with polymer-bound piperazine to give the desired product 111. 
Deprotection of Fmoc-pTz-3 117 to give 111 is dissapointing in terms of yield, seemingly 
due to the need for automated HPLC methodology for purification of crude 111. In general, 
removal of amino group protecting groups should involve no purification. However, in this 
case, concomitant formation of the monoallylated derivative of the desired triazole 111 has 
meant that purification of 111 was neccasary. 
2.5 Conclusions 
Third generation triazolylalanine, τ-pTz-3 111 has been generated from TIPS acetylene 96 
in 7 synthetic steps with an overall yield of 9% (Scheme 2.6). Synthesis of diallyl 
alkynylphosphate 114 has demonstrated that the synthetic strategy devised by Dr. Tom 
McAllister,
25
 can indeed be adapted to incorporation of alternative protection groups for the 
phosphonate. pTz-3 111 has the potential to be site-specifically incorporated into proteins 
using amber suppression. Scale-up of the synthetic route to pTz-3 111 devised in this 
chapter is currently on going. 
 
Scheme 2.6: Optimised synthetic route to novel τ-pTz-3 111.
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Chapter 3 Synthesis of Functionalised 1,2,4-triazines 
In addition to their use as mimics of post-translational modifications, unnatural amino acids 
can also be used in bioorthogonal chemical reporting strategies. As discussed in Section 1.2, 
there are a number of chemical reactions that have been used to label biomolecules. 
However, many of these reactions are limited in terms of biocompability or synthetic 
accessibility of reagents. The following chapters discuss progress made towards the 
generation of a novel bioorthogonal probe involving the cycloaddition of triazines to 
strained dienophiles. 
3.1 Synthesis of Functionalised 1,2,4-Triazines 
To test the utility of the 1,2,4-triazine-SPIEDAC as a novel bioorthogonal probe, a triazine 
with a functional group handle was required that could either be incorporated into an 
unnatural amino acid (to be genetically encoded into a protein), or derivatised onto a 
fluorescent reporter. Accordingly, a range of 3-amino-1,2,4-triazines were to be synthesised 
with the intention of generating target molecules through amide bond formation of the 
exocyclic amino-group handle (Figure 3.1). In order to acquire a comprehensive spectrum of 
1,2,4-triazine reactivity in SPIEDAC reactions, it was deemed necessary to generate a range 
of substituted triazine derivatives differing in size and electronic nature. Balcar et al.
107
 
measured the second order rate constant for the cycloaddition of cyclooctene to 
1,2,4-triazine, 3-phenyl-1,2,4-triazine and 3-methyl-1,2,4-triazine. Calculated rate constants 
decreased in the order H > Ph > Me. Therefore, 3-amino-1,2,4-triazine 118a, 6-phenyl-3-
amino-1,2,4-triazines 118b and 6-methyl-3-amino-1,2,4-triazine 118c would all be 
synthesised (Figure 3.1). 
 
Figure 3.1: 1,2,4-triazines with exocyclic amino handles for further derivatisation: 3-amino-1,2,4-
triazine 118a and phenyl- and methyl-3-amino-1,2,4-triazines 118b and 118c respectively. 
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3.1.1 Synthesis of Substituted 3-Amino-1,2,4-triazines 
As reported by Erickson,
142
 substituted (and non-substituted) 3-amino-1,2,4-triazines can be 
accessed through the condensation and subsequent cyclocondensation of aminoguanidine  to 
1,2-dicarbonyl compounds. A synthetic route towards aminotriazines 118a-c was devised in 
the group that involved the controlled condensation of aminoguanidine bicarbonate 119 and 
glyoxal derivatives under acidic conditions (Scheme 3.1). On formation of the 
corresponding aminoguanidine intermediate, the pH of the reaction mixture is increased to 
pH ~12 to allow for the subsequent cyclocondensation reaction to take place. Accordingly, 
aminotriazines 118a-c were synthesised through the condensation of aminoguanidine 
bicarbonate 119 and glyoxal, phenylglyoxal or methylglyoxal at pH ~3; the pH of the 
reaction mixture was increased to ~pH 12 through the addition of 50% KOH, and an 
ensuing cyclocondensation gave the corresponding products 118a-c in yields of 17%, 41% 
and 18% respectively. Methyl-aminotriazine 118c was recovered as a mixture of 
regioisomers in a 2:1 ratio, with the 6-substituted product being the major isomer as 
deduced by NMR. Efforts to improve yields of 118a-c based on more gentle 
cyclocondensation methods of stirring in either water,
142
 or phosphate buffer,
143
 resulted in 
no significant improvement. Synthetic routes to triazines 118a-c require optimisation; this 
could possibly have been achieved via the use of freshly distilled glyoxal derivatives.
144
 
However, at this time, 3-amino-1,2,4-triazine 118a became commercially available and was 
therefore used as the basis for the majority of subsequent reactions.  
 
Scheme 3.1: Synthesis of 5/6-substituted 3-amino-1,2,4-triazines 118a-c through the controlled 
condensation of aminoguanidine bicarbonate 119 and glyoxal derivatives. In the case of 
methyl-aminotriazine 118c, a mixture of regioisomers was recovered. 
3.2 Incorporation of 3-Aminotriazine into Unnatural Amino acids 
With aminotriazine 118a in hand, attention was turned to incorporation of 118a into 
unnatural amino acids. Once generated, the triazine-containing UAAs would be assessed 
against a range of amber suppression systems. The use of permissive aminoacyl tRNA-
synthetases for the genetic incorporation of UAAs that are structurally related to the UAAs 
they were evolved to incorporate is described in Section 1.3.2. 
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3.2.1 tRNA Synthetase-tRNACUA Pairs used for Genetic Code Expansion 
In general, four tRNA synthetase-tRNA pairs are used for genetic code expansion in various 
organisms. The Methanococcus jannaschi Tyrosyl-tRNA synthetase (MjTyrRS)-tRNACUA 
pair is orthogonal to natural synthetases and tRNAs in prokaryotes but not in eukaryotes and 
incorporates UAAs based on tyrosine scaffold 120 (Figure 3.2).
145
 Both E. coli Tyrosyl-
tRNA synthetase (EcTyrRS)-
146
 and E. coli Leucyl-tRNA synthetase 
(EcLeuRS)
147
- tRNACUA pairs are orthogonal in yeast and mammalian cells but not in E. 
coli. These synthetase-tRNA pairs genetically encode analogues of tyrosine 120 and leucine 
122 respectively. The pyrrolysyl-tRNAsynthetase (PylRS)-tRNACUA pair from 
Methanosarcina species has been used to genetically encode a variety of UAAs based on 
pyrrolysine scaffold 121 and is orthogonal to natural synthetases and tRNAs in E. coli,
148
 
yeast,
149
  mammalian cells
150
 and C.elegans.
151
 
The PylRS-tRNACUA pair has two advantages over the other three synthetase pairs. The first 
and most obvious advantage is that this system can be used to incorporate UAAs into more 
than one organism. Secondly, pyrrolysine  121 (the amino acid the synthetase naturally 
encodes) is not one of the 20 canonical amino acids; as such natural synthetase activity does 
not need be destroyed when creating specificity for a new amino acid.
3
 This has also made it 
possible to use the unmodified PylRS to incorporate a range of unnatural amino acids.
150
 
There have been many reports of permissive PylRS-tRNACUA pairs that have genetically 
encoded additional UAAs to the UAA they were originally evolved to incorporate.
44
 
Accordingly a triazine-containing UAA based on pyrrolysine scaffold 121 would be 
synthesised and screened as a substrate for existing pyrrolysyl-tRNA synthetases. 
 
Figure 3.2: Orthogonality of synthetases and their cognate tRNACUAs that are used for genetic code 
expansion in different organisms. 
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3.2.2 Attempted Synthesis of Triazine-containing Pyrrolysine Analogues 
Built on methodology by Du et al,
152
 triazine-containing pyrrolysine analogues 124a and 
124b were to be synthesised via the derivatisation of malonyl- (n = 1) or succinyl- (n = 2) 
lysines 123a and 123b to aminotriazine 118a (Scheme 3.2). 124a and 124b differ in the 
length of linkage between lysine and triazine by one carbon atom; it is possible that this 
difference in flexibility could result in one analogue being a substrate for a pyrrolysyl-tRNA 
synthetase. 
 
Scheme 3.2: Overview of proposed synthetic route towards triazinyl-lysine derivatives 124a and 
124b. 
In order to generate 124a and 124b, protected malonyl- and succinyl-lysines 123a and 123b 
needed to be synthesised. This was achieved as described in Scheme 3.3: Initially Boc-
Lys(Z)-OH 125 was converted to the fully protected Boc-Lys(Z)-OtBu using tBuOH in a 
yield of 68%. The Cbz group was subsequently removed through palladium catalysed 
hydrogenation to give Boc-Lys-OtBu 126 in 99% yield.
153
 Hydrogenation of the Cbz group 
of Boc-Lys(Z)-OtBu went to completion in 6 hours; leaving the hydrogenation for longer 
periods resulted in catalyst poisoning. Generation of benzyl malonate/succinate coupling 
partners 129a and 129b proceeded via the ring-opening of Meldrum’s acid 127 or succinic 
anhydride 128 by benzyl alcohol to afford benzyl malonate 129a
154
 and benzyl succinate 
129b,
155
 in yields of 14% and 61% respectively. The 14% yield obtained on formation of 
benzyl malonate 129a is attributed to the need for a base to promote the reaction. Formation 
of benzyl-protected malonyl- and succinyl-lysines 130a and 130b was achieved through 
coupling of benzyl malonate 129a or benzyl succinate 129b to Boc-Lys-OtBu 126 using a 
DCC/DMAP activation strategy. This afforded benzyl malonyl- and benzyl succinyl-lysines 
130a & 130b in yields of 53% and 56% respectively. The benzyl group of malonyl-lysine 
130a was removed by hydrogenation to yield crude malonyl-lysine 123a in 94% yield. 
Before hydrogenation of benzyl succinyl-lysine 130b to form 123b was performed, 
malonyl-lysine 123a was used in a trial coupling reaction with aminotriazine 118a in an 
attempt to form triazinyl-lysine 124a (Scheme 3.4). 
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Scheme 3.3: Synthetic route towards malonyl- succinyl-lysines 123a and 123b (123b was not 
synthesised): Benzyl malonate 129a and benzyl succinate 129b were generated through 
reaction of benzyl alcohol with meldrums acid 127 or succinic anhydride 128 respectively. 
Reaction of protected lysine 127 with 129a or 129b resulted in lysines 130a and 130b. 
Hydrogenation of 130a to remove the benzyl-protection yielded succinyl-lysine 123a. 
Attempts to couple malonyl-lysine 123a and aminotriazine 118a to generate triazinyl-lysine 
125 using an EDC/DMAP activation strategy at room temperature failed (Scheme 3.4). The 
use of higher temperatures and stronger bases may facilitate this reaction. 
 
Scheme 3.4: Failed generation of Boc-triazinyl-lysine derivative 124a (to generate triazinyl-lysine 
124a) through coupling of malonyl-lysine 123a to aminotriazine 118a. 
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At this time, independent reports of the genetic encoding of norbornyl-carboxylysine 126
85
, 
bicyclononyl-carboxylysine 128
87,156
, and trans-cyclooctenyl-carboxylysines 129
85
 and 
130
87
 into proteins using wt or evolved pyrrolysl tRNA synthetases were published.
85,87,156
 
Co-translational incorporation of cyclopropenyl-carboxylysine 127 into proteins has since 
been achieved.
86
 Due to the possibility of not finding a permissive tRNA synthesis that 
could be used for genetic incorporation of a novel triazine-containing amino acid, it seemed 
judicious to utilise amber suppression systems reported to encode strained dienophile-
containing amino acids instead. Hence, synthesis of a functionalised triazine that could be 
appended to a probe molecule was now needed. As a result, no further attempts were made 
to generate triazinyl-lysines 124a or 124b.  
 
Figure 3.3: Strained dienophile-containing lysine derivatives that have been genetically encoded into 
proteins in response to an amber codon using wt or evolved pyrrolysyl-tRNAsynthetases. 
3.3 Generation of 1,2,4-triazine Derivatives for Probe 
Functionalisation 
3.3.1 Through Amide-bond Formation 
Methods to generate functionalised triazine compounds suitable for late-stage derivatisation 
onto probe molecules initially focused on the generation of benzyl-protected 
succinylamidotriazine derivatives of the form 131a and 131b through the coupling of 
aminotriazines 118c or 118a to benzyl succinate 129b (Scheme 3.5a). Removal of the 
benzyl-protecting group of 131a or 131b by hydrogenation would generate acid 
functionalised triazines suitable for reaction with small molecule- and peptide-probes 
containing nucleophilic functionalities. 
For the synthesis of protected succinylamidotriazine 131a, an EDC/DMAP activation 
strategy was used, with stirring at room temperature for 16 h to give 131a in a poor yield of 
1%. LCMS analysis of the reaction mixture revealed presence of the N-acylurea cyclic 
displacement product, formed from rearrangement of the corresponding O-acylurea 
intermediate (generated through in situ activation of benzyl succinate 129b by EDC). To 
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promote nucleophilic attack of methyl aminotriazine 118c onto the activated O-acylisourea 
intermediate, the reaction was heated to 40 °C. This served to increase the yield of 131a to 
7% (Scheme 3.5a, top). A failed attempt to generate benzyl succinylamidotriazine 131b 
through conversion of 129b to the corresponding acid chloride, and subsequent coupling to 
aminotriazine 118a was also made (Scheme 3.5a, bottom).  
Efforts to access succinylamidotriazine 132 directly through the ring-opening of succinic 
anhydride 128 with aminotriazine 118a were also made (Scheme 3.5b). On a number of 
occasions, formation of 132 was observed by LCMS; however the reaction was too 
inefficient to yield suitable quantities of material for purification. It was also noted that at 
high temperatures aminotriazine 118a was consumed. It is possible that the high 
temperatures used in this reaction may have led to the degradation of triazine 118a and 
contribute to the insufficient quantities of crude succinylamidotriazine 132.  
 
 
Scheme 3.5: a) Syntheses of benzyl succinylamidotriazines 131a (top) and 131b (bottom) through an 
O-acylisourea or acid chloride intermediate respectively. 131a was synthesised in a poor yield 
of 7%, whilst synthesis of 131b was unsuccessful; b) attempted formation of desired acid 132 
through reaction of aminotriazine 118a and succinic anhydride 128. 
Syntheses utilising the amino-group of triazines 118a and 118c as reactive handles for 
further functionalisation have generally been unsuccessful (and when successful, as in the 
synthesis of benzyl succinylamidotriazine 131a, have generated products with inadequate 
yields to be of use). This is presumably due to the highly electron-withdrawing nature of the 
triazine core which will reduce the nucleophilicity of the exocyclic amino group of 118a and 
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118c. It was therefore necessary to alter synthetic strategy and convert the amino-group of 
triazine 118a into an alternative functional handle. 
3.3.2 Through Palladium-catalysed Cross-coupling 
Metal-mediated carbon-carbon bond forming reactions involving triazine have been 
reported using an appropriately functionalised substituted triazine and unsaturated aliphatic 
compounds.
113,157
 Carroll et al.
157
 exploited methyl iodotriazine 133 in a metal-mediated 
Sonogashira-type reaction with phenylacetylene to afford phenylethynyltriazine 134 in 80% 
yield (Scheme 3.6a). Carroll et al.
157
 generated methyl iodotriazine 133 through 
diazotization and ensuing halogenation of methyl aminotriazine 118c, using isoamyl nitrite 
and diiodomethane, in a modest yield of 20%. Jackson and co-workers
158,159
 have reported 
the synthesis of enantiomerically pure pyridylalanine amino acids through the palladium 
catalysed cross-coupling of serine-derived organozinc reagents with halopyridyl derivatives. 
It was postulated that this Negishi-type cross-coupling could be extended to include other 
N-heterocycles such as iodotriazine 136 (Scheme 3.6). Therefore a synthetic strategy was 
devised based on the metal-mediated cross-coupling of 136 and protected iodoalanine 135 
to generate (after removal of the methyl ester) Fmoc-triazinylalanine (TrzA) 137 (Scheme 
3.6b). Triazinylalanine 137 would be suitable for use in the Fmoc-strategy for SPPS and 
hence be particularly appropriate for rapid functionalisation of peptide probe molecules. 
Alternatively, it would be possible to use the acid functionality of 137 to derivatise onto 
small molecule probes. 
 
Scheme 3.6: a) Reported transformation of methyl aminotriazine 118c into methyl iodotriazine 133 
and subsequent carbonic addition to form alkynyl-triazine 134 using metal-mediated cross-
coupling;
157
 b) proposed synthetic route to Fmoc-triazinylalanine 137 via a Negishi-type cross-
coupling of iodoalanine 135 and iodotriazine 136, and subsequent methyl ester removal. 137 
could be used in an Fmoc SPPS strategy to generate a fluorescent triazine-containing 
fluorescent probe such as 138. 
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Iodotriazine 136 was formed in 30% yield through the diazotisation of aminotriazine 118a 
using isopentyl nitrite in diiodomethane at 55 °C (Scheme 3.7a). Although low, this yield is 
a 10% increase from the reported yield for formation of methyl iodotriazine 133 (Scheme 
3.6).
157
 It is possible that this difference is due to degradation of triazines 118c and 133 at 
the higher temperatures employed by Carrol et al.,
157
 as observed previously when using 
aminotriazine 118a (Scheme 3.5b, Section 3.3.1). 
Fmoc-iodoalanine methyl ester 135 was synthesised in three synthetic steps starting from 
serine methyl ester 139 (Scheme 3.7b).
158
 L-Serine methyl ester 139 was sequentially 
reacted with Fmoc-OSu and p-toluenesulfonyl chloride to give Fmoc-Ser(OTs)-OMe 140 in 
an overall yield of 55%. SN2-substitution of the tosyl group of 140 with sodium iodide in a 
Finkelstein-type reaction generated iodoalanine methyl ester 135 in 52% yield. In this 
instance, the moderate yield was attributed to incomplete conversion of tosyloxyalanine 
methyl ester 140.
160
   
For zinc insertion of iodoalanine methyl ester 135 to form the corresponding organozinc 
reagant, the procedure reported by Jackson and co-workers was initially followed.
158
 
Commercial zinc dust and I2 (0.3 eq) were weighed into an oven dried flask which was 
evacuated and purged with nitrogen three times at 0 °C. Iodoalanine methyl ester 135 was 
dissolved in anhydrous DMF (freshly opened bottle), transferred to the reaction mixture, 
and stirred at 0 °C. After 2 hours, no formation of the activated organozinc reagent was 
observed by TLC. It was reasoned that a higher temperature may be needed for formation of 
the alkyl zincate of 135, and activation of zinc dust by catalytic amounts of iodine may be 
more effective in solution. Accordingly, formation of the organozinc reagent was attempted 
a second time. After evacuation and purging of an oven-dried flask containing zinc dust, 
anhydrous DMF (freshly opened bottle) and I2 (0.15 eq) were added in quick succession and 
stirred at room temperature. After 15 minutes, iodoalanine 135 was added followed by a 
further 0.15 equivalents of I2.i Formation of the corresponding organozinc reagent was 
observed after 2 hours; at which time iodotriazine 136, Pd(II) acetate 
and  2-dicyclohexylphosphino-2′,6′-dimethoxybiphenyl (SPhos) were added in quick 
succession. The reaction was stirred at 50 °C for 5 hours and after purification by column 
chromatography, triazinylalanine methyl ester 142 was recovered in 69% yield (Scheme 
3.7b). In attempts to optimise Negishi-coupling, the palladium catalyst loading was altered 
and an alternative palladium catalyst (tris(dibenzylideneacetone)dipalladium(0)) was used; 
neither of these changes resulted in a significant change in yield. 
                                                     
i After discussions with Christian Hedberg, catalytic I2 was added once for zinc activation, and a 
second time for activation of the organozinc reagent. 
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Scheme 3.7: a) Diazotisation of aminotriazine 118a to give iodotriazine 136; b) successful synthesis 
of triazinylalanine 137 via Negishi-type cross coupling of zinc activated iodoalanine methyl 
ester 135 to 3-iodo-1,2,4-triazine 136 to generate 142 using palladium acetate and SPhos as a 
co-ligand. Methyl ester removal of 142 using trimethyltin hydroxide gave the desired product 
137. Iodoalanine methyl ester 135 was synthesised in three steps from serine methyl ester 139. 
In the optimised method for the metal-mediated cross-coupling of 135 and 136 to generate 
triazinylalanine methyl ester 142, the total 0.3 equivalents of iodine were added in two 
stages. This was to ensure consistent catalytic activation of zinc dust by iodine and 
subsequent formation of iodide. Iodide promotes in situ formation of dianionic zincate 
species RZnI3
2- 
(where R = alanine methyl ester). RZnI3
2- 
is formed from RZnI2
-
, which in 
turn is generated from the organozinc reagent (RZnI). This doubly charged zincate species 
has been shown to be the active transmetallating agent in Negishi-type cross coupling 
reactions involving alkyl halides.
161
 Hence, iodine was exploited in this reaction in two 
ways: initially for activation of zinc towards nucleophilic addition, and secondly for the 
catalytic formation of a higher order zincate species. It should also be noted that Negishi 
coupling was only successful when using a freshly opened bottle of anhydrous DMF. This is 
due to the inherent sensitivity of organozinc reagents to oxygen and water.  
Demethylation of Fmoc-TrzAla-OMe 142 to give the free acid 137 was achieved by stirring 
in DCE with trimethyltin hydroxide at 88 °C (Scheme 3.7b).
162
 Initial yields of 13% were 
reported, although alterations to the purification strategy of the crude product increased 
yields of 137 to 27%. In this case, the overall isolated yield of triazinylalanine 137 is limited 
by observable degradation of the triazinylalanines 137 and 142 at the elevated temperatures 
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required for deprotection; the methyl ester of 142 could not be removed at moderate 
temperatures of 55 °C. Base-catalysed deprotection of triazinylalanine methyl ester 142 was 
also attempted using LiOH, unfortunately, this led to concomitant Fmoc-group removal.  
3.4 Conclusions 
A novel strategy to generate an Fmoc-compatible triazine, triazinylalanine 137 has been 
developed (Scheme 3.7). The synthetic route towards 137 is robust and uses readily 
available and inexpensive starting materials. The route to 137 includes an optimised 
Negishi-type cross-coupling reaction between iodotriazine 136 and an organozinc reagent. It 
should be possible to couple iodotriazine 136 to a variety of alkyl- and aryl-organozinc 
reagents, which will ultimately increase the diversity of available (and synthetically 
accessible) triazine scaffolds. It should be possible to use triazinylalanine 137 in the 
Fmoc-strategy for SPPS to rapidly and efficiently functionalise a range of probes such as 
fluorescein isothiocyanate or carboxyfluorescein. The fully deprotected version of 
triazinylalanine 137 is similar in structure to a range of tyrosine-based scaffolds that have 
been genetically incorporated into proteins in response to an amber codon using evolved 
tyrosyl-tRNA synthetases.
145,163
 Due to the promiscuity of these synthetases it is possible 
that fully deprotected triazinylalanine could be genetically incorporated into proteins. 
Therefore, it should be possible to use triazinylalanine 137 and its derivatives as either 
counterpart of a bioorthogonal probe.  
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Chapter 4 1,2,4-Triazine Cycloaddition Reactions 
4.1 Introduction 
With triazinylalanine 137 in hand, attention was turned to investigating the reactivity of this 
N-heterocycle and its derivatives towards strained dienophiles. To assess the utility of the 
triazine cycloaddition as a bioorthogonal probe, it was ultimately envisaged that strained 
dienophiles displaying reactivity towards 137 would be genetically encoded into a model 
protein using amber suppression and subsequently reacted with a triazinylalanine-containing 
fluorescent probe. Norbornyl-carboxylysine (Norb-K) 126,
85
 cyclopropenyl-carboxylysine 
(CP-K) 127,
86
 bicyclononyl-carboxylysine (BCN-K) 128 
87,156
, trans-cyclooctenyl-
carboxylysine (TCO-K) 129
85
 and strained trans-cyclooctenyl-carboxylysine (sTCOK) 
130
87
 have all been incorporated into proteins in response to an amber codon using wt or 
engineered pyrrolysyl-tRNA synthetases (Figure 4.1a). Figure 4.1b shows calculated 
bimolecular rate constants between these strained dienophiles and disubstituted tetrazine 
derivatives.
86,87
 Their rate of reaction to tetrazine increases in the order Norb-K < CP-K < 
BCN-K < TCO-K < sTCO-K.  
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Figure 4.1: a) Strained dienophiles 126 – 130 have been genetically encoded into proteins in response 
to an amber codon and b) measured bimolecular rate constants of 126 - 130 in cycloaddition 
reactions towards tetrazine derivatives. 
4.2 Norbornene as the Dienophile  
4.2.1 Synthesis  
In order to acquire a comprehensive spectrum of triazine reactivity, norbornene, which has a 
relatively slow rate of reaction (k2 1-10 M
-1
 s
-1
)
85
 towards tetrazine (Figure 4.1b) was 
initially selected for triazine cycloaddition studies. To investigate norbornene’s reactivity 
towards triazine, generation of norbornyl-carboxylysine 126 was required. 
Norbornyl-lysine 126 was synthesised in three steps from 5-norbornene-2-ol in an overall 
yield of 29% in accordance with the procedure described by Lang et al (Scheme 4.1).
85
 A 
yield of 30% was obtained for the generation of the activated ester 144; this can be 
attributed to partial ester hydrolysis on exposure to silica during purification. Displacement 
of the succinimide ester of 144 by Boc-Lys-OH
85
 and subsequent Boc-deprotection using 
4M HCl in dioxane
164
 yielded norbornyl-lysine 126 in a near quantitative yield of 98%.  
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Scheme 4.1: Synthesis of Norbornyl-lysine 126 via NHS-ester 144. 
4.2.2 Reactivity of Norbornene to Triazinylalanine 
To investigate the reactivity of norbornyl-carboxylysine 126 to triazine, equimolar amounts 
of 126 and triazinylalanine methyl ester 142 were placed in a reaction flask at a 
concentration of 40 mM and stirred for three hours at room temperature in THF/H2O (1:1); 
after which time, no formation of pyridyl derivative 145 was observed (Scheme 4.2a). 
Incubation of the reaction mixture at 37 °C and 50 °C for three hours and overnight at 80 °C 
(below the temperature that degradation of triazines 137 and 142 had been observed to 
occur) did not lead to formation of cross-linking product 145. Triazine methyl ester 142 was 
used in this study to prevent possible interference of the free acid. However it is conceivable 
that unprotected norbornyl-carboxylysine 126 could have been interfering with the analysis. 
Accordingly, the potential conjugation of triazine methyl ester 142 to unfunctionalised 
norbornene 146 was investigated through incubating 142 and 146, at 40 mM with 
temperatures of up to 80 °C and stirring in THF/H2O (1:1) overnight (Scheme 4.2b). 
Unfortunately, no detectable formation of cycloaddition product 147 was observed. 
 
Scheme 4.2: Attempted reaction of a) triazine methyl ester 142 to norbornyl-carboxylysine 126 and 
b) 142 to unfunctionalised norbornene 146. Even at elevated temperatures of 80 °C, 
cycloaddition reactions were unsuccessful. 
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4.3 Bicyclononyne as the Dienophile 
4.3.1 Synthesis  
Due to the failure of the norbornene-triazine cycloaddition, attention was directed towards a 
coupling partner with a higher degree of ring strain. Unhindered strained 
bicyclo[6.1.0]nonynes cross-link to tetrazines more rapidly than norbornene with 
approximate rate constants of 10
2 
- 10
4
 M
-1 
s
-1 
(Figure 4.1b).
87
  
To assess the reactivity of BCN to TrzAla methyl ester 142, benzoyl-protected 
bicyclononyne (BCN-Bz) 151 was generated in five steps from 1,5-cycloctadiene (Scheme 
4.3).
165
 Rhodium catalysed cyclopropanation of cyclooctadiene 148 gave a mixture of 
bicyclononene ethyl esters 149a (anti) and 149b (syn) in an overall yield of 89%. 
anti-Bicyclononene ethyl ester 149a was converted to the corresponding alkyne by 
sequential ester reduction, dibromination and double elimination to give 150 in 34% yield. 
150 was protected using benzoyl chloride to generate cycloalkyne 151 in a yield of 57%.
166
  
The moderate yield for the three-step transformation of anti bicyclononene ethyl ester 149a 
to alkyne 150 can be attributed to formation of an unknown side-product during the 
base-catalysed elimination of the corresponding dibromo-bicyclononane species. Analysis 
of the unknown species using NMR spectroscopy suggests presence of an unsymmetrical 
diene, although it was not possible to assign the spectra.  
 
Scheme 4.3: Generation of benzoyl-protected BCN 151 through the stepwise reduction, 
dibromination and double elimination of a single diastereoisomer of bicyclononene, 149a. 
Subsequent protection with benzoyl chloride yielded BCN-Bz 151. 
4.3.2 Cross-linking of Bicyclononyne to Triazinylalanine 
To assess the reactivity of BCN-Bz 151 to TrzAla methyl ester 142, an equimolar mixture 
of 151 and 142 was incubated at 37 °C for 12 hours at high concentration (65 mM in 
dichloromethane, (Scheme 4.4)). Diasteromeric bicyclononapyridyls 152a and 152b were 
isolated together by column chromatography in 38% yield; unreacted triazine 142 was also 
isolated. In this case, the moderate yield can be attributed to the instability of bicyclononyne 
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151, which was confirmed by apparent degradation of BCN-Bz 151 over time by NMR 
spectroscopy. 
 
Scheme 4.4: Cycloaddition reaction of Fmoc-TrzAla-OMe 142 to BCN-Bz 151 at 37 °C yielded a 
mixture of diastereoisomers 152a and 152b in an overall yield of 38% yield.  
4.3.3 Rate Determination 
Encouraged by the successful cross-linking of triazinylalanine methyl ester 142 to BCN-Bz 
151, a series of experiments were conducted to determine the bimolecular rate constant for 
the reaction. This was achieved by measuring the rate of product formation by HPLC at 
37 °C, using a mixture of authentic 152a and 152b as a concentration standard.  
152a and 152b were serially diluted 3–fold and analysed by HPLC using a linear gradient 
(5% H2O in MeCN to 95% H2O). The resultant data points were plotted as a function of 
concentration to generate a concentration gradient that was used to determine the rate of 
formation of 152a and 152b in all subsequent experiments. Product formation in MeCN was 
measured by sequential injection (onto the same HPLC column and gradient as for the 
calibration) over a reaction time of approximately 18 hours at 37 °C using 1 mM Trz methyl 
ester 142 and a range of BCN-Bz 151 concentrations (1 mM, 2 mM, 4 mM and 8 mM). 
After every analysis, 2 μl of MeCN was injected onto the column and the column washed 
using the same linear gradient. The data points obtained for each concentration variant were 
then fitted against time (Figure 4.2a); the resultant calculated gradients were then plotted as 
a function of [BCN-Bz] and fitted to 2
nd
 order kinetics (Rate =
 
k2[BCN-Bz][Fmoc-TrzAla-
OMe]), under the assumption of low substrate consumption during the measured time-
course, to yield a 2
nd
 order rate constant of 3.95 ± 0.22 ×10
-4
 M
-1
 s
-1
 (Figure 4.2a inset).  
It has been suggested that the rate of the analogous tetrazine cycloaddition reaction can be 
significantly increased when in aqueous media.
167
 This phenomenon is believed to mainly 
be the result of stabilising interactions between water and the activated transition state, 
which reduces the Gibbs energy of activation. 142 and 151 are poorly water-soluble which 
prevented the analogous experiment from being carried out in water; however the reaction 
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rate measured in 10% H2O in MeCN increased slightly to 5.14 ± 0.37 × 10
-4
 M
-1
 s
-1
, 
suggesting that the rate in biological media will be slightly higher (Figure 4.2b and inset).  
 
 
Figure 4.2: Rate of reaction of Fmoc-TrzAla-OMe 142 with increasing concentrations of BCN-Bz 
151 at 37 °C determined by HPLC measurement of formation of bicyclononapyridyls 152a 
and 152b in a) pure MeCN and b) 10% H2O in MeCN. Rate data were fitted to 2
nd
 order 
kinetics (Rate = k2[BCN-Bz][Fmoc-TrzAla-OMe]) under the assumption of low substrate 
concentration to give second order rate constants of a) 3.95 ± 0.22 ×10
-4
 M
-1
 s
-1 
and b) 5.14 ± 
0.37 × 10
-4
 M
-1
 s
-1
. 
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Comparison of this rate of reaction (0.3 - 0.5 × 10
-3
 M
-1
 s
-1
) to other reactions in this class
44
 
suggests that although the cycloaddition of bicyclononyne 151 to triazine 142 is 
significantly slower than the corresponding reaction with tetrazines, it is comparable with 
other known bioorthogonal reactions such as the Staudinger ligation, which has second 
order rate constants in the low 10
-3
 M
-1
 s
-1
 range.
168
 
4.4 Application of 1,2,4-Triazine Cycloaddition Reactions in vitro 
To investigate whether the cycloaddition of triazines to bicyclononynes has utility as a 
bioorthogonal probe, the cross-linking reaction needed to be demonstrated in vitro. For this 
purpose the synthesis and subsequent genetic incorporation of bicyclononyl-carboxylysine 
128 (Figure 4.1a) into a model protein was required.  
4.4.1 Genetic Incorporation of Bicyclononyne into a Model Protein 
4.4.1.1 Bicyclononyl-lysine Synthesis 
Bicyclononynol 150 (previously synthesised in Section 4.3.1) was converted to its 
corresponding activated ester 154 using 4-nitrophenyl chloroformate 153 and reacted with 
Fmoc-Lys-OH to give Fmoc-protected BCN-lysine 155 in an overall yield of 48% (Scheme 
4.5). Fmoc-deprotection using 20% piperidine in DMF yielded the desired 
BCN-carboxylysine 128 in 88% yield.  
 
Scheme 4.5: Synthesis of BCN-Lysine 128 via 4-nitrophenylester 154. Displacement of activated 
ester 154 with Fmoc-Lys-OH  gave 155 in 66% yield. Subsequent deprotection with 20% 
piperidine in DMF yielded the desired product 128 in 88% yield. 
4.4.1.2 Aspartate α-decarboxylase (ADC) as a Model Protein 
Aspartate α-decarboxylase (ADC) is responsible for the decarboxylation of L-aspartate to 
form β-alanine as part of the pantothenate biosynthetic pathway. As shown in Figure 4.3, 
ADC exists as a tetramer and is known to bind to and be activated by PanZ in a coenzyme A 
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(CoA) dependent manner.
169
 An ADC construct, pCDF-PylT-ADC(K9X), containing a gene 
encoding ADC with Lys9 mutated to the amber codon (ADC(K9X)), together with an 
MbtRNACUA gene from Methanosarcina bakeri encoding pyrrolysyl-tRNA(PylT) was 
previously generated in the group by Michael Rugen. Once co-transformed with a cognate 
pyrrolysyl-tRNA synthetase, the resultant expression system can be used to incorporate a 
corresponding UAA into ADC in place of Lys9. The utility of this amber suppression 
system has been demonstrated by the co-translational incorporation of 
norbornyl-carboxylysine 126 using wt pyrrolysyl-tRNAsynthetase (PylRS) into this position 
in ADC (data not shown). Hence, this system will be used to incorporate bicyclononyl-
carboxylysine 128 in place of lysine 9 into ADC using a commercially available cognate 
pyrrolysyl-tRNA synthetase, BCN-PylRS, which was specifically developed to recognise 
BCN-lysine 128. 
 
Figure 4.3: Crystal structure of tetrameric ADCT57V (shown in green) with each ADC monomer 
bound to a PanZ monomer (shown in blue) to give a heterooctameric complex. PDB file: 
4CRZ. 
4.4.1.3 Genetic Incorporation of Bicyclononyl-lysine into ADC 
pCDF-pylT-ADC(K9X) and BCN-PylRS were co-transformed into E. coli ΔDZ(DE3) 
competent cells. ΔDZ(DE3) cells contain chromosomal deletions in both PanD (inactive 
ADC) and PanZ. Dual resistance agar plates (spectinomycin and ampicillin) were inoculated 
with cells that had been concentrated and resuspended and the plates were incubated 
overnight at 37 °C. Previous co-transformations utilising dilute cells had resulted in no 
colonies. 
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A mini culture of ΔDZ(DE3) pCDF-pylT-ADC(K9X) BCN-PylRS was used to inoculate 
1 L of LB media containing ampicillin and spectinomycin (100 mg/L). Protein 
overexpression was induced after 4 hours using IPTG when an OD600 between 0.4-0.6 was 
reached, at which time BCN-lysine 128 was also added (100 μM). Cells were harvested by 
centrifugation, protease inhibitor (EDTA free) was added, and 2/3 of the cells were lysed by 
sonication. The resultant lysate was cleared of cellular debris and purified using standard 
Ni-NTA column chromatography. Analysis by SDS-PAGE showed two faint bands 
corresponding to the mass of His6–ADC(K9BCN), demonstrating that BCN-lysine had been 
incorporated into the protein at the desired position (Figure 4.4). Fractions containing the 
protein were concentrated using a spin filter to ~300 μl and the concentration was 
determined to be ~1 μM by measuring absorbance at 280 nM. It was observed that some 
protein had precipitated on the filter. The lower than expected concentration obtained after 
purification of putative ADC(K9BCN) and the observation of protein precipitation both 
indicate that incorporation of BCN-lysine 128 in place of Lys9 into ADC has affected 
stability of the protein. In retrospect, this is unsurprising as Lys9 is found in the active site 
of ADC and is involved in critical hydrogen bonding with His11 and Tyr58 (Figure 4.5a). 
Clearly, disruption of this interaction has rendered the protein unstable and prone to 
precipitation.   
 
Figure 4.4: 15% SDS PAGE gel of purification of putative His6–ADCK9BCN-K by nickel column; 
lanes: 1 MW marker, 2 flow through, 3 wash with Lysis Buffer 2, 4 wash with Wash Buffer 2, 
5-9 wash with Elution Buffer 2. Protein corresponding to the correct mass is present as bands 
in lanes 7 & 8. 
Interestingly, HRMS analysis of the small amount of protein that remained in solution after 
concentration revealed a mass of 15314.5 Da (Figure 4.5b), which corresponds to the mass 
of wt ADC (the mass of ADC(K9BCN) was calculated to be 15492.3 Da). It should be 
noted that it would not have been possible for endogenous lysine to have been incorporated 
instead of BCN-lysine 128 using the amber suppression expression system described.
87
 
Therefore, presence of lysine at this position must be the result of hydrolysis of the 
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BCN-carbamate modification. It is possible that His11, which is found adjacent to the site at 
which BCN-lysine 128 has been incorporated (Figure 4.5a), could catalyse the hydrolysis of 
the BCN-carbamate to yield lysine. It appears that the small amount of protein obtained that 
had not precipitated was stable as it resembled wt ADC and lacked the BCN-carbamate 
modification. Hence, His6–ADC(K9BCN) was successfully generated but the mutant 
protein is too unstable to be of any use. Clearly, if BCN-lysine 128 is to be genetically 
incorporated into a protein and remain stable, a different amber suppression system that will 
either incorporate 128 at an alternative position away from the active site of ADC, or 
incorporate BCN-lysine 128 in place of a residue in a different protein, is needed.    
 
Figure 4.5: a) Critical hydrogen bonding interactions between Lys9 and His11/Tyr58 in the active site 
of ADC, PDB file: 4CRZ; b) Deconvoluted HRMS of putative His6–ADC(K9BCN) gives a 
mass of 15314.5 Da, which corresponds to a mass of 15315.2 Da calculated for wt His6–ADC 
(a mass of 15492.3 Da is expected for  His6–ADC(K9BCN)). This result is indicative of BCN-
carbamate hydrolysis.  
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4.4.2 Cycloaddition of 1,2,4-Triazine to trans-cyclooctene in vitro 
Due to the successful reaction of triazinylalanine methyl ester 142 with BCN-Bz 151, 
attention was turned to the cycloaddition of triazine with highly strained trans-cyclooctene 
(TCO) in vitro. This dienophile reacts with tetrazine derivatives with rate constants between 
10
3 
- 10
4
 M
-1
 s
-1
.
43,44
 TCO therefore needed to be incorporated into a model protein and a 
fluorescent triazine-containing probe needed to be generated. 
4.4.2.1 Synthesis of a Triazine-containing Fluorescent Probe 
Incorporation of triazinylalanine 137 into FITC-labelled peptide 156 was achieved on Rink 
amide resin using standard Fmoc SPPS and on-resin fluorescent labelling (Scheme 4.6). 
Following purification by mass-directed HPLC, TrzAla probe 156 was obtained in 37% 
yield. Incorporation of TrzA 137 into a peptide demonstrates the compatibility of 137 with 
the Fmoc-strategy for peptide synthesis. Moreover, the rapid and straightforward generation 
of triazine probe 156 demonstrates that triazinylalanine 137 can indeed rapidly functionalise 
probe molecules at a late stage. 
 
Scheme 4.6: Incorporation of Fmoc-compatible building block 137 into short fluorescent peptide 156 
using Fmoc SPPS and N-terminal FITC ligation. 
4.4.2.2 Incorporation of trans-cyclooctene into ADCi 
TCO-PEG3-maleimide 157 is commercially available and can be derivatised onto cysteine 
residues in proteins through conjugate addition of the maleimide functionality (Figure 4.6a). 
ADC contains two cysteine residues located at positions 26 and 78 (Figure 4.6b). Cys78 is 
exposed on the surface of the protein whilst Cys26 is buried in the active site; as a result, it 
should be possible to selectively react Cys78 with TCO-PEG3-maleimide 157. 
                                                     
i ADCS25A was generated and expressed by Diana Monteiro; the cell pellet was lysed and purified 
by Zoe Arnott 
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Figure 4.6: a) Chemical structure of TCO-PEG3-maleimide 157; b) Orientations of Cys26 and Cys78 
in ADC. PDB file: 4CRZ. 
ADC mutant, ADCS25A (200 μM), was incubated with 2.2 equivalents of 
TCO-PEG3-maleimide 157 for 1 hour at room temperature in SEC Buffer and applied 
directly to a desalting column to remove unreacted 157. Analysis by mass spectrometry 
revealed two peaks at 16294.3 Da and 16817.6 Da; which corresponded to the single 
labelled and double labelled protein respectively (Figure 4.7). Use of one equivalent of 157 
may prevent labelling of both cysteine residues in future. Nevertheless, the mixture of single 
and double-labelled ADC-TCO that had been generated was used in the following in vitro 
cycloaddition reaction, with the intention to optimise labelling of 157 to ADC in the future.  
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Figure 4.7: Labelling of ADCS25A with TCO-PEG3-maleimide 157. Deconvoluted HRMS reveals 
two peaks corresponding to single labelled (ADC-TCO) and double labelled (ADC-(TCO)2). 
Expected masses were calculated as 16293.11 Da for (ADC-TCO) and 16818.34 Da for 
(ADC-(TCO)2), which correspond to experimental masses of 16294.3 Da and 16817.6 Da 
respectively. 
4.4.2.3 Labelling of trans-cyclooctene with a Triazinylalanine-containing 
Fluorescent Probe 
A mixture of single labelled (ADC-TCO) and double labelled (ADC-(TCO)2) (combined 
concentration 30 μM) was incubated overnight at 37 °C with 10 equivalents of TrzAla probe 
156 in ITC buffer. UV Visualisation of the subsequent SDS PAGE gel revealed a 
fluorescent band at an approximate mass of 66 kDa for the unboiled reaction sample (Lane 
3, Figure 4.8a). This corresponds to the fluorescently labelled ADC tetramer, which should 
have a mass of ~69 kDa. Staining of the gel using coomassie stain revealed that the unboiled 
reaction sample had partially unfolded into both the dimeric and monomeric ADC (Lane 8). 
Unreacted TrzAla probe 156 is displayed on the gel as two bands (representing the 
interconverting quinoid and lactone forms of fluorescein) at ~6 Kda and ~20 kDa (Lanes 2 
and 3); saturating the point at which fluorescent labelling of monomeric ADC (~17 kDa) 
would be observed (Lane 3). Analysis of the reaction sample by HRMS revealed a peak at 
17430.8 Da corresponding to fluorescently labelled ADC-(TCO)2, which has a calculated 
mass of 17430.9 Da; indicating that the cross-linking of trans-cyclooctene to triazine 156 
was successful (Figure 4.8b). However, it is evident from the mass spectrometry trace that a 
significant amount of unreacted ADC-TCO and ADC-(TCO)2 is still present, suggesting that 
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the reaction procedure needs to be optimised by incubating ADC-TCO with a higher 
concentration of the fluorescent triazine probe 156. 
 
Figure 4.8: Results of incubation of a mixture of ADC-TCO and ADC-(TCO)2 with fluorescent 
triazine probe 156; a) 10% Tris-trycine SDS-PAGE gel; lanes: 1 MW marker, 2 & 3 UV 
visualisation of boiled and unboiled reaction mixture, 4 & 5 UV visualisation of boiled and 
unboiled unlabelled ADCS25A, 6 UV visualisation of TrzA probe 156 on its own. Lanes 7-11 
correspond to lanes 2-6 but coomassie stained. b) Deconvoluted ESMS of reaction mixture: 
peaks at 16294.3 Da and 16817.5 Da are unlabelled ADC-TCO and ADC-(TCO)2 respectively, 
the peak at 17430.8 Da corresponds to fluorescently labelled ADC-(TCO)2 which has a 
calculated mass of 17430.9 Da. 
Shortly after this labelling reaction was carried out, Kamber et al.
170
 reported a 
complementary study of the cycloaddition reaction between a range of 1,2,4-triazin-6-yl 
derivatives and trans-cyclooctene. This reaction was demonstrated in vitro through the 
genetic incorporation of triazinylphenylalanine into green fluorescent protein (GFP) and 
subsequent incubation with 100 equivalents of trans-cyclooctene.  
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4.5 Conclusions 
The reactivity of 1,2,4-triazine to a range of strained dienophiles, including norbornene, 
bicyclononyne and trans-cyclooctene has been investigated. Alkyl triazine 142 was found to 
react readily with bicyclononyne at 37 °C with rate constants between 0.3 - 0.5 10
-3
 M
-1
 s
-1
. 
Kamber et al. reported reaction rates between 1 and 7 × 10
-2
 M
-1
 s
-1
 for the cycloaddition of 
trans-cyclooctene to a range of triazine substrates- a rate approximately 30-fold higher than 
determined in Section 4.3.3. This ratio is similar to the approximately 15-fold difference in 
rate observed for the analogous reaction of tetrazine with bicyclononyne and 
trans-cyclooctene substrates by Lang et al.
87
 Kamber et al.’s observations are therefore fully 
consistent with observed reaction rates between triazine and bicyclononyne. A small 
triazinylalalnine containing peptide 156 was synthesised, demonstrating the applicability of 
triazinylalanine 137 to the late stage functionalization of probe molecules. Furthermore, 
probe 156 was utilised in an in vitro context where its reaction with trans-cyclooctene was 
demonstrated 
Norbornene does not react with triazine at a temperature appropriate for application in a 
biological system; this has since been confirmed in Kamber et al.’s170 complimentary study. 
Since triazines do not react with norbornene, the triazine cycloaddition to bicyclononyne or 
trans-cyclooctenes could be used in a mutually orthogonal labelling sequence alongside a 
tetrazine-norbornene cross-linking reaction. The 1,2,4-triazine cycloaddition to 
bicyclononynes and trans-cyclooctenes has potential to be used as an alternative to the 
tetrazine-cycloaddition for applications in cellular and biochemical studies. 
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Chapter 5 Conclusions and Future Work 
 
5.1 Application and Generation of Phosphohistidine Mimics 
5.1.1 Summary 
A known τ-phosphohistidine mimic, τ-phosphotriazolylalanine was used to assess the 
affinity of phosphohistidine towards two targets, Grb2-SH2 and YdiA. τ-pTz 15 was 
synthesised following an established synthetic route
25
 and incorporated into peptides that 
either mimicked the binding sequence of a canonical pY-peptide or the binding site of PPS 
(Figure 5.1a).   
Using fluorescence anisotropy and ITC, It was demonstrated that pTz peptide 91 bound to 
the SH2 domain of Grb2 with ~ 1000 fold weaker affinity than pY peptide 90.i Analogous 
peptides containing phosphohomotriazole, phosphoserine and phosphothreonine were 
generated and their affinity for Grb2-SH2 was also assessed (92, 104 and 105 respectively). 
It was determined that none of these phosphopeptides were capable of interacting with the 
protein, indicating that SH2 domains do not merely have affinity for appropriately 
positioned phosphoryl groups. The mechanism by which Grb2-SH2 links tyrosine kinases to 
the Ras signalling pathway is well established
171
 and it is therefore unlikely that histidine 
phosphorylation plays a role. However, it is possible that histidine phosphorylation plays a 
transient role in binding to one of the ~110 other phosphotyrosine binding modules; some of 
which have not been well characterised.
136
  
A fluorescence polarisation assay was also used to assess the binding affinity of pTz peptide 
probe 110 towards YdiA, it was found that 110 did not interact with the protein. Since it is 
                                                     
i ITC experiments performed by Dr. Tom McAllister 
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established that YdiA binds to PPS when a histidine residue is phosphorylated, it is unlikely 
that these results accurately reflect the binding interaction of the two proteins.
138
 It was 
decided that generating a peptide containing a phosphohistidine analogue to mimic the 
primary structure of PPS was not adequate to study this protein-protein interaction and the 
whole protein containing the post-translational modification was required. Consequently, a 
third generation τ-phosphohistidine mimic, τ-pTz-3 111 was synthesised through the 
adaptation of a synthetic route previously devised in the group to incorporate allyl 
protection for the phosphoryl group. 111 has potential to be genetically incorporated into 
proteins using amber suppression (Figure 5.1b).  
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Figure 5.1: Summary of work achieved through a) using τ-pTz 15 in peptide sequences to probe 
binding interactions involving τ-phosphohistidine and b) the generation of third generation 
τ-phosphohistidine mimic 111 suitable for genetic encoding into proteins using amber 
suppression. 
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5.1.2 Future Work 
The most obvious next-step as regards this part of the project is the scale-up of the synthesis 
to make pTz-3 111 (Figure 5.1b). This is currently on-going and when achieved 111 will be 
initially screened against a variety of established amber suppression systems. If 111 is not 
found to be a substrate for any existing tRNA synthetases, a synthetase will be evolved to 
specifically incorporate pTz-3 111. Screening of existing amber suppression systems and 
potential evolution of a novel mutant synthetase will be carried out by Jason Chin and co-
workers (MRC lab, University of Cambridge).  
5.1.2.1 Assessing the Interaction of  τ-Phosphohistidine analogues with other 
SH2 Domains 
Following the discovery that τ-phosphotriazole peptide 91 has affinity towards Grb2-SH2, it 
would be interesting to establish whether τ-phosphotriazole interacts with other SH2 
domains. Plasmids containing genes encoding over 40 different hexaHis-tagged SH2 
domains are available in the group; the majority of which have been reported to bind to 
various phosphotyrosine-containing peptide sequences with high affinity. A number of these 
phosphotyrosine binding domains could be expressed and purified simultaneously, and used 
in fluorescence anisotropy competition assays, with a cognate pY-containing fluorescent 
peptide and a competing, analogous pTz peptide (Figure 5.2). In general, the crucial 
residues involved in binding to SH2 domains tend to be small in number; it should therefore 
be possible to generate a library of pY probes and analogous pTz peptides relatively rapidly 
by tandem Fmoc SPPS. Use of fluorescence anisotropy competition assays for this purpose 
would provide a rapid means in which to assess interaction of τ-pTz to a large number of 
SH2 domains. Furthermore, fluorescence polarisation assays do not require a large amount 
of material; therefore, each SH2 domain would only need to be expressed in small quantities 
on initial screening. 
 
Figure 5.2: Proposed fluorescent anisotropy competition assay to rapidly assess binding interactions 
of pTz peptides to SH2 domains. A number of SH2 domains could be purified and their 
interaction with cognate pTz peptides could be evaluated. 
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5.1.2.2 Synthesis of π-Phosphotriazolylalanine 
As mentioned in Section 1.1.3.3, π-phosphotriazolylalanine 12 has been shown to be an 
effective mimic of the other regioisomer of phosphohistidine, π-phosphohistidine 6.26,172 To 
date, there are no reported syntheses of either a π-pHis analogue fully compatible with the 
Fmoc-strategy for SPPS or an analogue suitable for genetic incorporation into proteins. 
It should be possible to synthesise Fmoc SPPS compatible π-pTz 165 through the ruthenium 
catalysed (3 + 2) cycloaddition of azidoalanine 162 and phosphoalkyne 163 and subsequent 
hydrogenation of the benzyl group of 164 (Scheme 5.1b, left). Use of an Ru(II) catalyst in 
place of a Cu(I) catalyst has been reported to generate the desired π-isomer in high yields, 
providing the acid functionality of azidoalanine 162 is protected with a bulky protecting 
group.
22
 tBu-protected phosphoalkyne 163 can be efficiently synthesised using the same 
strategy previously used to generate both allyl- and benzyl- protected phosphoalkynes 100 
and 114 (Sections 2.2.3.2 and 2.4.1.1 respectively), but with tert-butyl alcohol rather than 
allyl alcohol or benzyl alcohol.
25
  
Allyl protected π-pTz 168, which has potential to be genetically incorporated into proteins, 
could be generated through the (3 + 2) Ru(II) catalysed cycloaddition of suitably protected 
azidoalanine 166 and allyl protected phosphoalkyne 114, and subsequent removal of both 
Boc- and tBu- protecting groups using aqueous phosphoric acid (Scheme 5.1b, middle). 
Li et al.
173
 reported the use of aqueous phosphoric acid to remove tert-butyl esters, tert-butyl 
carbamates and tert-butyl ethers in the presence of other acid sensitive functional groups. 
Although the orthogonality of aqueous phosphoric acid has not been demonstrated towards 
allyl functionalities, it is possible that this deprotection strategy is mild enough to 
effectively remove both tBu- and Boc- protection of π-pTz 167, whilst leaving the allyl 
protection for the phosphoryl groups intact. Commercially available Boc-azidoalanine-OH 
115 is purchased as the dicyclohexylammonium (DCA) salt. Low yields were reported on 
using this reagent in a Cu(I) catalysed cycloaddition with phosphoalkyne 114 to generate 
τ-pTz-3 111 (See section 2.4.1.2.1). This was due to problems with the removal of the DCA 
salt during purification of crude τ-pTz-3 111. It is, however, possible to synthesise 
Boc-azidoalanine-OH 115 from Boc-asparagine 158 in a two-step synthesis (Scheme 
5.1a).
174
 Synthesised 115 could then be used in the ensuing cycloaddition reaction to 
generate π-pTz 167 (after protection of the acid functionality of 115). If the synthetic route 
to allyl protected π-pTz 168 is particularly high-yielding, the same synthetic strategy could 
be used as an alternative route to access allyl protected τ-pTz-3 111 (Scheme 5.1b, right). 
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Scheme 5.1: a) Synthesis of Boc-azidoalanine-OH N from commercially available Boc-asparagine-
OH 158.
174
 b) Left and middle: Suggested synthetic routes towards π-pTz 165 and 168 suitable 
for either the Fmoc strategy for SPPS (left) or genetic encoding into proteins (middle); right: 
Proposed alternative synthesis of allyl protected τ-pTz-3 111. 
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5.2 The Triazine Cycloaddition to Strained Dienophiles as a Novel 
Bioorthogonal Reaction 
5.2.1 Summary 
In summary, a synthetic route to novel 1,2,4-triazin-3-yl-linked amino acids compatible 
with conventional peptide synthesis strategies has been developed using readily available 
and inexpensive starting materials (Figure 5.3a). The cycloaddition of an alkyl triazine 142 
to a range of strained dienophiles including norbornene 146, bicyclononyne 151 and trans-
cyclooctene 157 was investigated. It was found that whilst cross-linking of 142 to 
norbornene 146 at ambient physiological temperatures was not possible, triazinylalanine 
methyl ester 142 reacted readily with strained BCN-Bz 151 at 37 ºC with second order rate 
constants between 0.3 and 0.5 ×10
-3
 M
-1
 s
-1
, depending on solvent mix (Figure 5.3b, top). 
The triazine cycloaddition to strained dienophiles was also demonstrated in vitro through 
incubation of fluorescent triazine probe 156 with ADC, which had previously been 
derivatised with trans-cyclooctene (Figure 5.3b bottom).   
The synthetic strategy towards triazinylalanine 137 involves an optimised Negishi-type 
cross-coupling between iodotriazine 136 and an alkyl organozinc reagent (Figure 5.3a). 
With this optimised synthetic route in place, it should be possible to cross-link iodotriazine 
136 to a variety or alkyl- or aryl- zincate reagents which, as well as allowing for the tuning 
of cycloaddition rates, will allow easy access to a plethora of functionalised triazines. Use of 
triazinylalanine 137 in the rapid generation of triazine-containing fluorescent peptide probe 
156 demonstrates the effective use of 137 to functionalise a probe molecule at a late stage. 
Furthermore, the stability of the triazine core in the harsh conditions used for cleavage in the 
Fmoc SPPS strategy indicates that triazines may show enhanced stability over other 
bioorthogonal reagents in physiological environments. This has been confirmed by Kamber 
et al.
170
 who found that a range of monosubstitued triazines incubated with both PBS and 
cysteine at 37 °C were stable for over one week. 
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Figure 5.3: Summary of work achieved: a) Synthetic route to novel functionalised triazinylalanine 
derivative 137 and subsequent incorporation into fluorescent peptide 156 by Fmoc SPPS; b) 
Use of triazinylalanine 142 and triazine probe 156 as a reactive component in cycloaddition 
reactions with strained dienophiles in the reaction flask (top) and in vitro (bottom). 
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5.2.2 Future Work 
5.2.2.1 Demonstration of the Triazine Cycloaddition to Bicyclononynes in vitro 
Clearly, the most vital piece of future work in regards to this project is to demonstrate the 
cycloaddition of triazine to BCN on a protein. This is to be achieved by the genetic 
incorporation of BCN-lysine 128 into a model protein and subsequent incubation with 
triazinylalanine probe 156. Previous efforts to do this through the genetic encoding of BCN-
Lysine 128 into ADC in place of lysine 9 were unsuccessful (Section 4.4.1.3). This was due 
to the instability of the modified protein; therefore, an alternative model protein is required. 
PanZ is a small protein that is known to bind to PanD (the inactive form of ADC) and 
promote its activation to form ADC in a CoA dependent manner (Figure 5.4).
169
 This 
protein has been well characterised in the group, is relatively stable and consistently shows 
high levels of protein expression. It is therefore a viable choice of protein for use in the 
generation of an alternative amber suppression system.  
Codons normally encoding Ser29, Lys10 and Asp35 in PanZ will be mutated by site 
directed mutagenesis to the amber stop codon TAG, after incorporation of the wild type 
protein into a vector containing pyrrolysyl tRNACUA. Hence, 3 separate amber suppression 
systems will be generated to enable the incorporation of BCN-Lysine 128 into 3 different 
positions in PanZ; this will serve to minimise the risk of perturbing protein stability. As can 
be seen in Figure 5.4, the residues selected are part of a loop region and exposed on the 
surface of PanZ. They also do not appear to be involved in any critical interactions in the 
protein and as such, incorporation of BCN-lysine 128 in place of any of these residues 
should not affect protein stability. Work to generate the PanZ constructs is being undertaken 
by Matt Balmforth (PhD student) and is nearly complete.  
 
Figure 5.4: Crystal structure of PanZ with residues that will be mutated to TAG highlighted. PDB 
file: 4CRZ. 
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5.2.2.2 Genetic Incorporation of Triazinylalanine 
The fully deprotected version of triazinylalanine, TrzA 169 is similar in structure to a range 
of tyrosine-based scaffolds that have been genetically incorporated into proteins in response 
to an amber codon using evolved tyrosyl-tRNA synthetases (Figure 5.5a).
145,163
 It should be 
possible to screen 169 for compatibility towards one of these amber suppression systems. If 
169 is found to be a substrate for an available tyrosyl tRNA synthetase, the corresponding 
amber suppression system could be used to incorporate 169 into proteins. Triazinylalanine 
169 could easily be generated through the piperidine based Fmoc-group removal of 137. 
Kamber et al
170
 very recently demonstrated the site-specific incorporation of 
triazinylphenylalanine 170 into GFP using a mutant mjTyrRS in response to an amber codon 
(Figure 5.5b). Triazinylalanine 169 is smaller in size then 170 and therefore the capability of 
genetically encoding 169 over triazinylphenylalanine 170 into proteins will be 
advantageous. The ability to incorporate either bioorthogonal reacting partner of the 
triazine-strained dienophile cycloaddition into a protein will enable its use alongside other 
bioorthogonal reporting strategies in the same protein system. 
 
Figure 5.5: a) Deprotection of 137 using 20% piperidine in DMF should yield triazinylalanine 169, 
which could then be screened as a substrate for a library of tyrosyl tRNA synthetases. b) 
triazinylalaninephenylalanine 170 has been genetically incorporated into GFP using 
suppression and a mutant TyrRS.
170
 
5.2.2.3 Development of an Antagonistic Drug-Binding Screen 
The slower rate of the triazine-BCN cycloaddition (k2 = 0.3-0.5 × 10
-3
 M
-1
 s
-1
) in comparison 
to some of the other reported bioorthogonal cycloaddition reactions may lend itself for use 
in the development of an in vivo antagonistic drug-binding screen. A screen such as this 
could be used to demonstrate that a drug candidate has bound to its protein target in a living 
system. A prototype of this screen is illustrated in Figure 5.6. In this prototype, BCN-lysine 
128 would be genetically encoded into the required protein near to (but not obstructing) the 
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binding site that is under investigation. The modified protein would then be incubated with a 
known substrate, which would have been previously derivatised with triazinylalanine or 
another functionalised triazine. The effective concentration between the incorporated BCN 
functionality and triazine will be increased when the substrate binds to the protein binding 
site; as a result, a cycloaddition reaction between the two components will occur and the 
substrate and the protein will be covalently linked (Figure 5.6a). If the drug candidate is also 
present and does bind to its target, then the triazine-containing substrate will face 
competition for the protein binding site. This will reduce the effective concentration of 
triazine and BCN as they will no longer be in close proximity to one another. Consequently, 
cross-linking between triazine and BCN will not occur (Figure 5.6b). Hence, if the drug 
candidate does bind to its intended protein target, no cycloaddition reaction will take place 
between triazine and the incorporated BCN-functionality. Conversely, if the drug candidate 
does not bind to its protein target, a cycloaddition reaction will occur and yield a covalently 
linked substrate-protein product. The products of this assay could simply be analysed by 
mass spectrometry.  
 
Figure 5.6: Use of the triazine cycloaddition to BCN as an antagonistic drug-binding screen: a) drug 
candidate does not bind to target binding site; b) drug candidate binds to target binding site. 
The triazine-BCN cycloaddition is a perfect choice for application in this technology as its 
intrinsically slow reaction rate indicates that the reaction is not under diffusional control. 
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Hence if triazine-containing substrate is not in close proximity with the incorporated BCN-
functionality, a cross-linking reaction should not occur. In addition, the enhanced stability of 
triazine over other bioorthogonal reagents makes it suitable for application in living 
systems. Work to establish whether this will be possible is needed. 
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Chapter 6 Experimental 
 
6.1 Preparation of Small Molecules 
All reagents were purchased from Sigma Aldrich, Alfa Aesar, Merck or Fisher Scientific 
and were used without further purification unless otherwise stated. All solvents used were 
HPLC grade and mixtures are v/v. NMR data were collected using a Bruker DPX300 and 
analysed using MestReNova software. The following abbreviations are used to describe the 
multiplicity of signals: s = singlet, d = doublet, dd = doublet of doublets, qn = quintet, m = 
multiplet. J-values are given in Hz. IR spectra were recorded using a PerkinElmer spectrum 
one FTIR spectrometer, vibrational frequencies are reported in wavenumbers (cm
-1
). Optical 
rotations were measured using a Schmidt+Haensch polartronic H532, [α]D values are given 
in 10
-1
 deg cm
2
 g
-1
. High resolution mass spectrometry (HRMS) was carried out on a Bruker 
Daltonics micrOTOF using electrospray ionisation (ES), a Bruker maXis impact using ES or 
on a Micromass GCT Premier, using electron impact ionisation (EI). Column 
chromatography was carried out using silica gel or on an automated Biotage Isolera 1.3.3 
using SNAP prepacked flash column silica cartridges from RediSep
®
Rf. TLC was 
performed on silica gel 60-F254
 
(Merck) with detection by fluorescence upon irradiation with 
UV light or staining by immersion in a solution of potassium permanganate, bromocresol 
green or ninhydrin and heating. Melting points were determined on a Stuart SMP3 melting 
point apparatus. Melting points obtained were uncorrected. Dropwise additions were 
performed manually or using a KD scientific syringe pump (KDS-100-CE). HPLC analyses 
were carried out on a Dionex HPLC system using an Ace UltraCore 2.5 Super C18, (50 x 
2.1mm) and diode array as a detector; either on gradient A: mobile phase (H2O/MeCN, 
0.1% TFA), gradient (5-95% MeCN) or B: mobile phase (H2O/MeCN), gradient (5-95% 
MeCN), at a flow rate of 0.5 ml/min. mass-directed HPLC purification was performed on an 
Agilent Techonologies 1260 infinity system. Lyophilisation was performed using a Virtis 
Benchtop K freezedryer or a BenchTop Pro with Omnitronics
TM
 from VirTis SP Scientific. 
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Dibenzyl (triisopropylsilyl)ethnylphosphonate 99
25
 
 
Isopropylmagnesium chloride (2.0 M in diethyl ether, 10 mL, 20 mmol, 1.1 eq.) was added 
dropwise to a solution of TIPS-acetylene (4.4 mL, 19.4 mmol, 1.02 eq.) in anhydrous THF 
(150 mL) at 0 °C. The reaction mixture was stirred over ice for 5 min, allowed to warm to 
room temperature and stirred for a further 30 min. The mixture was cooled once more to 
0 °C, bis(diethylamino)chlorophosphine (4 mL, 19.0 mmol, 1 eq.) was added dropwise, the 
reaction mixture was warmed to room temperature and stirred for a further 3 hours; at which 
time complete consumption of bis(diethylamino)chlorophosphine was observed by TLC. 
The volatiles were concentrated in vacuo to leave an amorphous white solid, the apparatus 
back-filled with N2, the flask quickly removed and purged with N2. Anhydrous acetonitrile 
(150  mL) was added to the flask followed by anhydrous benzyl alcohol (4.5 mL, 44 mmol, 
2.3 eq.). The stirred reaction mixture was cooled to 0 °C and tetrazole (0.45 M in MeCN, 93 
mL, 42 mmol, 2.2 eq.) was added dropwise. The reaction was stirred at 0 °C for 15 min, 
allowed to warm to room temperature and then stirred at 30 °C for 20 min. The reaction 
mixture was concentrated to ca. 30 mL in vacuo, quenched with sat. NH4Cl aq (100 mL) and 
extracted with EtOAc (3 × 200 mL). The organics were combined and washed with H2O2 
(10% (v/v) in H2O, 2 × 30 mL), H2O (2 × 30 mL), Na2S2O3 (aq) (10% (w/v) H2O, 2 × 100 mL) 
and brine (2 × 100 mL). The organics were dried (MgSO4), concentrated in vacuo and the 
crude material was purified by column chromatography on silica gel, eluting the sample  
with 0.25% MeOH in CH2Cl2. dibenzyl (triisopropylsilyl)ethnylphosphonate 99
25
 (3.67 g, 
8.3 mmol, 44%) was recovered as a colourless oil. RF (0.25% MeOH in CH2Cl2) 0.41; δH 
(300 MHz, CDCl3): 7.42 – 7.33 (10 H, m, 2 × Ph-H), 5.14 (4 H, d, 
3
JH-P 8.5, 2 × OCH2Ph), 
1.14 ‒ 1.07 (21H, m, Si(CH(CH3)2)3 & Si(CH(CH3)2)3); δC (75 MHz, d6-DMSO): 130.3 (d, 
2
JC-P 7.6, Ph-C1), 123.3 (s), 123.2 (s) & 122.2 (s) (2 × Ph-C2-5) 102.6 (d, 
2
JC-P 38.2, PCCSi), 
90.6 (d, 
1
JC-P 274.8, PCCSi), 63.2 (d, 
2
JC-P 5.2, 2 × OCH2Ph), 13.2 (s) & 5.6 (s) 
(Si(CH(CH3)2)3 & Si(CH(CH3)2)3); δ P (121 MHz, CDCl3): -8.01 (qn, 
3
JP-H 8.6); m/z (ES): 
Found: M(+Na) 465.1992 C25H35O3PSiNa requires 465.1985; HPLC (5-95% A): retention 
time 4.92 min, 100%. 
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Dibenzyl ethnylphosphonate 100
25
 
 
To a stirred solution of dibenzyl (triisopropylsilyl)ethnylphosphonate 99 (1.53 g, 3.23 
mmol, 1 eq.) in THF, freshly opened TBAF (1.0 M in THF, 3.6 mL, 3.6 mmol, 1.1 eq.) was 
added  with stirring at -78 °C and the reaction was stirred for 1.5 h; after which time 
complete consumption of 99 was observed by TLC. The reaction was warmed to 0 °C and 
quenched with sat. NH4Cl aq ((w/v) 70 mL), generating a thick white suspension. H2O (50 
mL) was added and the resultant homogenous mixture was extracted with diethyl ether (4 × 
150 mL). The combined ethereal layers were washed with brine (1 × 150 mL), dried 
(MgSO4) and the volatiles were removed to leave a brown oil. The crude product was 
purified by column chromatography on silica gel eluting the sample with 2:1 
hexanes:EtOAc to yield dibenzyl ethnylphosphonate 100
25
 (764 mg, 2.67 mmol, 83%) as a 
colourless oil. RF (2:1 hexanes:EtOAc) 0.28; δ H (300 MHz, CDCl3): 7.41 – 7.30 (10 H, m, 
2 × Ph-H), 5.11 (4 H, d,
 3
JH-P 8.6, 2 × OCH2Ph), 2.91 (1 H, d 
3
JH-P 13.5, PCCH); δ C (75 
MHz, CDCl3): 135.2 (d, 
3
JC-P 7.5, 2 × Ph-C1), 128.7 (s), 128.6 (s) & 128.0 (s)  (2 × Ph-C2-5), 
88.4 (d, 
2
JC-P 51.8, PCCH), 74.0 (d, 
1
JC-P 294.9, PCCH), 68.8 (d, 
2
JH-P 5.3, 2 × OCH2Ph); δ P 
(121 MHz, CDCl3): -7.87 (dqn, 
3
JP-H 13.5, 
3
JP-H 8.6); m/z (ES): Found: M(+H) 287.0834 
C16H16O3P requires 287.0832; HPLC (5-95% A): retention time 3.04 min, 100%. 
(2S)-3-(4-Dibenzylphosphonyl-[1,2,3]-triazol-1-yl)-2-(9H-fluoren-9-
ylmethoxycarbonyl)-amino-propionate 15
25
 (Fmoc-pTz(OBn)2-OH) 
 
A freshly prepared solution of copper (II) sulphate (84 mg, 0.52 mmol, 0.1 eq.) and sodium 
ascorbate (623 mg, 3.2 mmol, 0.6 eq.) in H2O (10 mL) was added to a solution of dibenzyl 
ethnylphosphonate 100 (1.50 g, 5.2 mmol, 1 eq.) in anhydrous THF (10 mL). After 1 min, a 
solution of Fmoc-AzaAla-OH (1.67 g, 4.7 mmol, 0.9 eq.) dissolved in 1:1 THF:H2O (40 
mL) was added in one portion and the reaction mixture was stirred for 1.5 h at room 
temperature, until complete consumption of the azide was observed by TLC. The reaction 
mixture was diluted with Na2CO3 aq (10% w/v in H2O, 100 mL) and extracted with diethyl 
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ether (2 × 130 mL). The aqueous phase was acidified to pH 1 by dropwise addition of conc. 
HCl aq and extracted with EtOAc (5 × 130 mL). The organic extracts were combined, dried 
(MgSO4) and the volatiles were removed in vacuo to leave an off-white foam, which was 
purified by column chromatography on silica (90:8:2 CH2Cl2:MeOH:AcOH). The resultant 
amorphous solid was dissolved in H2O/MeCN and lyophilised to yield Fmoc-pTz(OBn)2-OH 
15
25
 (1.68 g, 2.63 mmol, 84%) as an amorphous white solid. RF (90:8:2 
CH2Cl2:MeOH:AcOH) 0.28; δ H (500 MHz, d6-DMSO): 8.53 (1 H, s, Tz-H5 ), 7.84 (2 H, d, 
3
JH-H 7.5, Fmoc-H4), 7.59 & 7.54 (2 H,  2 × d, 
3
JH-H 7.5 & 7.6, 2 × Fmoc-H1), 7.40 – 7.33 (2 
H, m, 2 × Fmoc-H3), 7.33 – 7.24 (12 H, m, 2 × Ph-H2-6 & 2 × Fmoc-H2), 6.88 (1 H, s, NH), 
5.10 – 4.91 (5 H, m, 2 × OCH2Ph & Hβ), 4.73 – 4.58 (1 H, m, Hβ’), 4.23 – 3.99 (4 H, m, 
Fmoc-CH, Fmoc-CH2 & Hα). δ C (125 MHz, d6-DMSO): 143.8 (s, Ph-C1), 140.6 (s, 2 × 
Fmoc-C1a), 136.1 – 135.9 (m, Tz-C4), 132.3 (d, 
2
JH-H 32.6 Tz-C5) 128.4, 128.2, 127.8, 127.6, 
127.1, 125.1 & 120.0 (s, 2 × Ph-C2-5 & 2 × Fmoc-C1-4a), 67.29 (s, POCH2Ph), 66.33 (s, 
Fmoc-CH2), 65.6 (s, Cβ), 52.02 – 51.66 (m, Cα & Fmoc-CH); δ P (121 MHz, d6-DMSO): 
8.45 (qn, 
3
JP-H 7.3); m/z (ES): Found: M(+H) 639.2003 C34H32N4O7P requires 639.1925; 
HPLC (5-95% A): retention time 3.58 min, 81% 
Diallyl (triisopropylsilyl)ethnylphosphonate 113 
 
The reaction procedure was the same as was used to generate dibenzyl 
(triisopropylsilyl)ethnylphosphonate 99 apart from allyl alcohol (3.9 mL, 28.0 mmol, 2.3 
eq.) was used instead of benzyl alcohol. Allyl alcohol was dried by stirring in CaSO4 under 
anhydrous conditions for 16 h and distilled before use. Phosphine 112 was found to be 
volatile and therefore concentration of 112 in vacuo was performed at 50 mbar and 40 °C. 
The crude product was purified by column chromatography on silica gel, eluting the sample 
with 4:1 hexanes:EtOAc to give  diallyl (triisopropylsilyl)ethnylphosphonate 113 (5.68 g, 
16.5 mmol, 59%) as a colourless oil. RF (4:1 hexanes:EtOAc) 0.31; δ H (500 MHz, CDCl3): 
5.94 – 5.85 (2 H, m, 2 × allyl-H2), 5.36 – 5.30 (2 H, m, 2 × allyl-H3a), 5.20 (2 H, dd 
3
JH-H 
10.4, 
2
JH-H 0.7, 2 × allyl-H3b), 4.54 (4 H, dd, 
3
JH-P 7.7 & 
4
JH-H 3.5, 2 × allyl-H1), 1.06 – 1.00 
(21 H, m, Si(CH(CH3)2)3 & Si(CH(CH3)2)3); δ C (125 MHz, CDCl3): 132.2 (d, 
3
JC-P 7.21, 2 × 
allyl-C2), 118.4 (s, 2 × allyl-C3), 107.5 (d, 
2
JC-P 38.3, PCCSi), 74.0 (d, 
1
JC-P 274.4, PCCSi),  
67.4 (d, 
2
JC-P 5.2, 2 × allyl-C1), 18.4 (s) & 10.9 (s) (Si(CH(CH3)2)3 & Si(CH(CH3)2)3); δ P 
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(121 MHz, CDCl3): -8.11 (qn, 
3
JP-H 9.01); νmax (solid)/cm
-1
: 2131 (disubstituted alkyne), 
1268 (PO); m/z (ES): Found: M(+H) 343.1858 C17H32O3PSi requires 343.1853;  
Diallyl ethnylphosphonate 114 
 
Diallyl ethnylphosphonate 114 was synthesised in the same manner as dibenzyl 
ethnylphosphonate 100, however  diallyl (triisopropylsilyl)ethnylphosphonate 113 (4.96 g, 
14.5 mmol, 1 eq.) was used instead of dibenzyl (triisopropylsilyl)ethnylphosphonate 99. The 
crude product was purified by column chromatography (2:1 hexanes:EtOAc) to yield diallyl 
ethnylphosphonate 114 (2.40 g, 12.8 mmol, 89%) as a colourless oil. RF (2:1 
hexanes:EtOAc) 0.20; δ H (500 MHz, CDCl3): 5.96 (2 H, dd, 
3
JH-H 10.8 &
 3
JH-H 5.6, 2 × 
allyl-H2), 5.44 – 5.36 (2 H, m, 2 × allyl-H3a), 5.31 – 5.26 (2 H, m, 2 × allyl-H3b), 4.71 – 4.49 
(4 H, m, 2 × allyl-H1) 2.94 (1 H, d, 
3
JH-P 13.4, PCCH); δ C (75 MHz, CDCl3): 135.2 (d, 
3
JC-P 
7.5, 2 × allyl-C2), 118.8 (s, 2 × allyl-C3), 88.4 (d, 
2
JC-P 51.8, PCCH), 74.0 (d, 
1
JC-P 294.9, 
PCCH), 68.8 (d, 
2
JC-P 5.3, 2 × allyl-C1); δ P (121 MHz, CDCl3): -7.96 (dqn, 
3
JP-H13.5, 
3
JP-H 
8.9); νmax (solid)/cm
-1
: 3176 (C-H alkyne), 1255 (PO); m/z (ES): Found: M(+Na) 209.0338 
C8H11O3PNa requires 209.0346. 
(2S)-3-(4-Diallylphosphonyl-[1,2,3]-triazol-1-yl)-2-(tertbutoxycarbonyl)amino-
propionate 116 (Boc-pTz(OAllyl)2-OH) 
 
The reaction procedure to generate 116 was similar to that use to generate Fmoc-pTz(OBn)2-
OH 15, however diallyl ethnylphosphonate 114 (299 mg, 1.6 mmol, 1.2 eq.) was used 
instead of dibenzyl ethnylphosphonate 100 and Boc-AzaAla-OH 115 (purchased as a 
dicyclohexylammonium salt, 535 mg, 1.3 mmol, 1.0 eq.) was used instead of Fmoc-AzaAla-
OH 101. The reaction was stirred for 24 h and concentrated as far as possible. Dioxane was 
added to dissolve the precipitate and the solution was lyophilised. The crude product was 
purified by mass-directed HPLC (50 – 95% MeCN) and lyophilised to yield 
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Boc-pTz(OAllyl)2-OH 116 (68 mg, 0.16 mmol, 12%) as a pale yellow solid. RF (10% MeOH 
in CH2Cl2) 0.06; δ H (500 MHz, MeOD): 8.46 (1 H, s, Tz-H5), 6.06 – 5.93 (2 H, m, 2 × 
allyl-H2), 5.46 – 5.36 (2 H, m, 2 × allyl-H3a), 5.32 – 5.24 (2 H, m, 2 × allyl-H3b), 5.08 – 4.99 
(1 H, m, Hβ), 4.82 (2 H, dd, 
2
JH-H 13.9,
 3
JH-H 8.4, Hβ’), 4.74 –  4.59 (5 H, m, 2 × allyl-H1 & 
Hα), 1.47 – 1.38 (9 H, m, CO2(CH3)2); δ C (75 MHz, MeOD): 171.9 (s, COOH), 157.4 (s, 
NHC(O)O), 136.9 (d, 
1
JC-P 243.7, Tz-C4), 133.7 – 133.2 (m, Tz-C5 & 2 × allyl-C2), 118.8 (s, 
allyl-C3), 80.9 (s, OC(CH3)2), 68.7 (d, 
2
JC-P 5.5, 2 × allyl-C1), 54.8 (s, Cα), 51.9 (s, Cβ), 28.6 
(s, OC(CH3)2); δ P (121 MHz, MeOD): 8.18 (qn, 
3
JP-H 8.5); νmax (solid)/cm
-1
: 3337 (OH), 
1711 (CO) 1237 (PO); m/z (ES): Found: M(+2Na-H) 461.1174 C16H24N4O7PNa2 requires 
461.1173. 
(2S)-3-(4-Diallylphosphonyl-[1,2,3]-triazol-1-yl)-2-(9H-fluoren-9-ylmethoxycarbonyl)-
amino-propionate 117 (Fmoc-pTz(OAllyl)2-OH) 
 
Fmoc-AzaAla-OH (235 mg, 0.61 mmol, 1 eq.) was dissolved in H2O (10 mL) and added to 
a stirred solution of diallyl ethnylphosphonate 114 (150 mg, 0.80 mmol, 1.2 eq.) in THF (10 
mL). Copper(I) iodide (29 mg, 0.15 mmol, 0.25 eq.) was dissolved in 1:1 THF/H2O (5 mL), 
added to the reaction mixture and the white suspension was stirred for 48 h. The reaction 
was filtered at the pump, washed with 1:1 MeOH/DCM (2 × 30 mL), and the filtrate was 
concentrated in vacuo. The recovered solid was dissolved in H2O:dioxane and lyophilised to 
leave a pale green flocculent solid which was purified by automated column 
chromatography (0 – 4% MeOH in CH2Cl2 (v/v)). Fmoc-pTz(OAllyl)2-OH 117 (188 mg, 
0.35 mmol, 57%) was recovered as an amorphous white solid. RF (10% MeOH in CH2Cl2 
(v/v)) 0.08; δ H (500 MHz, d6-DMSO): 8.51 (1 H, s, Tz-H5), 7.89 (2 H, d, 
3
JH-H 7.5 2 × 
Fmoc-H4), 7.66 & 7.63 (2 H, 2 × d, 
3
JH-H 7.6 & 7.5, 2 × Fmoc-H1), 7.41 (2 H, t, 
3
JH-H 7.4, 2 
× Fmoc-H3), 7.33 (2 H, t, 
3
JH-H 7.3, 2 × Fmoc-H2), 6.95 (1 H, s, NH), 5.94 – 5.81 (2 H, m, 2 
× allyl-H2), 5.31 – 5.24 (2 H, m, 2 × allyl-H3a), 5.17 (2 H, d,
 3
JH-H 10.5, 2 × allyl-H3b), 4.98 
(1 H, d, 
2
JH-H 11.7, Hβ), 4.67 (1 H, dd, 
2
JH-H 12.0, 
3
JH-H 7.9, Hβ’), 4.58 – 4.42 (4 H, m, 2 × 
allyl-H1), 4.28 – 4.07 (4 H, m, Fmoc-CH, Fmoc-CH2 & Hα); δ C (125 MHz, d6-DMSO): 
170.4 (s, COOH), 155.52 (s, NHC(O)O), 143.8 (s, 2 × Fmoc-C1a), 140.6 (s, 2 × Fmoc-C4a), 
135.3 (d, 
1
JC-P 238.8, Tz-C4) 133.0 (d, 
3
JC-P 6.7, 2 × allyl-C2), 131.9 (d,
 2
JC-P 35, Tz-C5), 
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127.6 (s, 2 × Fmoc-C3), 127.1 (s, 2 × Fmoc-C2), 125.1 (s, 2 × Fmoc-C1), 120.0 (s, 2 × Fmoc-
C4), 117.7 (s, 2 × allyl-C3), 91.4 (s, 2 × Fmoc-C4a), 66.4 (d, 
2
JC-P 5.1, 2 × allyl-C1), 65.7 (s, 
Fmoc-CH2), 56.2 (s, Cα), 51.7 (s, Cβ), 46.6 (s, Fmoc-CH); δ P (121 MHz, d6-DMSO): 8.26 
(qn, 
3
JP-H 8.5); νmax (solid)/cm
-1
: 3334 (OH), 1702 (CO), 1232 (PO); m/z (ES): Found: 
M(+H) 539.1697 C26H28N4O7P requires 539.1690; HPLC (5-95% A): retention time 3.07 
min, 75% 
 (2S)-3-(4-Diallylphosphonyl-[1,2,3]-triazol-1-yl)-2-amino-propionate 111 
(pTz(OAllyl)2-OH) 
 
Boc-pTz(OAllyl)2-OH 116 (24 mg, 0.06 mmol) was stirred in 2M HCl in dioxane (2 mL) for 
16 h under N2, the volatiles were removed in vacuo and the resultant white solid was 
purified by mass-directed HPLC (5 – 95% MeCN in H2O) to yield pTz(OAllyl)2-OH 111 
(6.1 mg, 0.02 mmol, 34%) as a viscous orange oil.  
 
pTz(OAllyl)2-OH 111 was also synthesised from Fmoc-pTz(OAllyl)2-OH 117: 
Fmoc-pTz(OAllyl)2-OH 117 (160 mg, 0.30 mmol, 1 eq.) was added to a solution of 
piperazine (polymer bound, 200-400 mesh, extent of labelling 1.0  –  2.0 mmol/g 2% cross-
linked with divinylbenzene, 1.18 g, 1.18 mmol, 4 eq.) in DMF (10 mL) and the reaction was 
stirred for 2 h. The reaction was vacuum filtered, the solid support washed with 1:1 
MeOH:CH2Cl2 (4 × 10 mL) and the filtrate concentrated in vacuo. The resultant white solid 
was dissolved in CH2Cl2, extracted with H2O (3 × 15 mL) and the combined aqueous layers 
were lyophilised. The crude product was purified by mass directed HPLC (5 – 95% MeCN 
in H2O) to yield pTz(OAllyl)2-OH 111 (29 mg, 0.09 mmol, 31%) as a brittle white solid; δ H 
(500 MHz, d6-DMSO) 8.58 (1H, s, Tz-H5), 5.94 (2 H, ddtd, 
3
JH-H 18.2, 
3
JH-H 7.8, 
3
JH-H 5.3, 
4
JH-P 2.5, 2 × allyl-H2), 5.38 – 5.31 (2 H, m, 2 × allyl-H3a), 5.25 – 5.19 (2 H, m, 2 × allyl-
H3b), 4.92 – 4.83 (1 H, m, Hβ) 4.73 – 4.60 (1 H, m, Hβ), 4.60 – 4.48 (5 H, m, 2 × allyl-H1 & 
Hβ). 3.74 (1 H, s, COOH); δ C (125 MHz, CDCl3): 175.0 (s, COOH), 135.6 (d, 
1
JC-P 240.0, 
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Tz-C4), 133.1 (d, 
3
JC-P 6.5, 2 × allyl-C2), 132.4 (d, 
2
JC-P 34.1, Tz-C5), 117.7 (s, 2 × allyl-C3), 
66.4 (d, 
2
JC-P 5.4, 2 × allyl-C1), 54.1 (s, Cα), 52.7 (s, Cβ); δ P (121 MHz, d6-DMSO): 8.11 
(qn, 
3
JH-P 8.3); νmax (solid)/cm
-1
: 3100 & 2982 (NH2), 2740 (OH) 1593 (CO), 1225 (PO); m/z 
(ES): Found: M(+H) 317.1015 C11H18N4O5P requires 317.1009. 
1,2,4-Triazin-3-amine 118a
142
 
 
Aminoguanidine bicarbonate (3.00 g, 22 mmol, 1 eq.) was stirred in H2O (40 ml), the pH 
was dropped to 3-4 on addition of small portions of 18% HCl (~5 ml) until CO2 gas 
evolution seized and the solution became clear. Glyoxal (40% in H2O) (2.5 ml, 22 mmol, 1 
eq.) was added and the pH increased to 12 with addition of 50% KOH aq ((w/v) 5 mL). The 
mixture was stirred for 2 hours and lyophilised. The resultant brown powder was triturated 
in 1:3 hexanes/EtOAc and hot filtered. The solution was concentrated and the crude product 
was recrystallised from 1:3 hexanes:EtOAc to give 1,2,4-triazin-3-amine 118a
142
 (365 mg, 
3.91 mmol, 17%) as pale orange needles. m.p. 179.2-179.9 ºC; RF  (5% MeOH in CH2Cl2) 
0.17; δ H (300 MHz, CDCl3) 8.50 (1H, d, 
3
JH-H 2.4, H6), 8.20 (1H, d, 
3
JH-H 2.4, H5), 7.17 
(2H, s, NH2); δ C (125 MHz, CDCl3) 163.3 (C3), 149.88 (C5), 140.63 (C6); νmax (solid)/cm
-1
:
 
3016 & 2970 (NH stretch); m/z (EI) Found:
 
M(+H) 
 
93.0 C3H5N4 requires 93.0436; HPLC 
(5-95% A): retention time 0.43 min, 100%. 
6-Phenyl-3-amino-1,2,4-triazine 118b
144
 
 
The reaction procedure was similar used to synthesise 1,2,4-triazin-3-amine 118a however 
phenylglyoxal monohydrate (8.5 g, 56 mmol, 1 eq.) was used instead of glyoxal. The crude 
product was recrystallized twice from boiling isoproponal to give 6-phenyl-1,2,4-triazin-3-
amine 118b
144
 (3.96 g, 23 mmol, 41%) as a flocculent orange solid; RF (5% MeOH in 
CH2Cl2) 0.10; δ H (500 MHz, CDCl3): 9.34 (1H, s, H5), 8.19 (2H, dd, 
3
JH-H 8.2, 
4
JH-H 1.4, Ph-
H2+6), 7.63 – 7.56 (3H, m, Ph-H3-5), 7.25 (2H, s, NH2); δ C (125 MHz, CDCl3): 163.8 (C3), 
150.4 (C5), 135.7 (C6), 130.3 (Ph-C1),  126.7 (Ph-C2-6); νmax (solid)/cm
-1
:
 
3301 (NH stretch); 
m/z (ES) Found: M(+H) 173.0822 C9H9N4 requires 173.1866; HPLC: retention time 1.20 
min, 90%. 
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6-Methyl-1,2,4-triazin-3-amine & 5-methyl-1,2,4-triazin-3-amine 118c
144
 
 
The reaction procedure was the same as used to synthesise 3-amino-1,2,4-triazine 118a, 
however methyl glyoxal (40% in H2O, 10 mL, 65 mmol, 1 eq.) was used instead of glyoxal. 
The crude product was recrystallized twice from boiling isopropanol to give a mixture of 6-
methyl-1,2,4-triazin-3-amine & 5-methyl-1,2,4-triazin-3-amine (2:1) 118c
144
 (1.28 g, 12 
mmol, 18%) as a yellow solid; δ H (300 MHz, MeOD): 8.46 (1H, s, 5-methyl-H6), 8.23 (1H, 
s, 6-methyl-H5), 5.46 (2H, s, NH2), 2.48 (3H, s, 6-methyl-CH3), 2.38 (3H, s, 5-methyl-CH3). 
Nε-(Carboxybenzyl)-Nα-(1,1-dimethylethoxy-carbonyl)-L-lysine-tert-butyl ester
153
 
(Boc-Lys(Z)-OtBu) 
 
Boc-Lys(Z)-OH (1.86 g, 4.88 mmol, 1 eq.), 4-dimethylaminopyridine (358 mg, 2.93 mmol, 
0.6 eq.) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (1.87 g, 9.76 mmol, 2 eq.) 
were dissolved in anhydrous CH2Cl2 (10 mL) before addition of anhydrous tert-butanol (4.8 
mL, 48.8 mmol, 10 eq.) and the mixture was stirred for 16 h. The reaction mixture was 
diluted with CH2Cl2 (~30 mL), washed with H2O (2 × 30 mL) and brine (2 × 20 mL); dried 
(MgSO4) and concentrated in vacuo. The crude product was purified by column 
chromatography (2:1 hexanes:EtOAc) to give Boc-Lys(Z)-OtBu
153
 (1.44 g, 3.19 mmol, 68%) 
as a colourless oil; RF 0.27 (2:1 hexanes:EtOAc); [α]D
21
 -0.1 (c 2.2, (CHCl3); δ H (300 MHz, 
CDCl3); 7.40 – 7.33 (5H, m, Bn-H2-6); 5.15 (2H, s, Bn-CH2); 4.81 (1H, br s, 
NHC(O)OCH(CH3)3); 4.21 – 4.06 (1H, m, Hα); 3.21 (2H, dd, 
3
JH-H 12.6 & 
3
JH-H 6.4, Hε); 
1.60 – 1.51 (4H, m, Hβ & Hδ); 1.47 (10H, s, NHC(O)OCH(CH3)3 & NHC(O)OCH(CH3)3); 
1.45 (10H, s, C(O)OCH(CH3)3 & C(O)OCH(CH3)3); 1.41 – 1.33 (2H, m, Hγ); δ C (125 MHz, 
CDCl3); 171.9 (Bn-OC(O)); 156.4 & 155.5 (C(O)OCH(CH3)3 & NHC(O)OCH(CH3)3); 
136.6 (Bn-C1); 128.5, 128.1 & 128.1 (Bn-C2-6); 81.9 & 79.7 (NHC(O)OCH(CH3)3 & 
C(O)OCH(CH3)3); 66.6 (Bn-CH2); 53.7 (Cα); 40.8 (Cε); 32.7 (Cβ); 29.4 (Cδ); 28.3, 28.3 & 
28.0 (NHC(O)OCH(CH3)3 & C(O)OCH(CH3)3); 22.3 (Cγ); νmax (solid)/cm
-1
:
 
3334 (NH); 
1695 (CO); m/z (ES) Found: M(+Na), 459.2468 C23H36N2O6 requires 459.2466. HPLC (5-
95% A): retention time 3.86 min, 87%. 
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Nα-(1,1-Dimethylethoxy-carbonyl)-L-lysine-tert-butyl ester 126
153
 
(Boc-Lys-OtBu) 
 
Boc-Lys(Z)-O
t
Bu (1.44 g, 3.3 mmol) and palladium on activated carbon (10%, 144 mg) were 
suspended in MeOH:CH2Cl2 (1:1) (10 mL) and stirred under H2 for 6 h. The catalyst was 
removed by vacuum filtration through celite and the filtrate concentrated to give the Boc-
Lys-OH 126
153
 (985 mg, 3.26 mmol, 99%) as a yellow oil. RF 0.04 (10% MeOH in CH2Cl2); 
[α]D
21 
+1.0 (c 3.4, CHCl3); δ H (300 MHz, CDCl3); 7.38 (2H, br s, NH2); 5.16 (1H, d, 
3
JH-H 
8.8, NH); 4.20 – 4.09 (1H, m, Hα); 3.03 (2H, ap s, HƐ); 1.90 – 1.74 (2H, m, Hβ); 1.67 – 1.56 
(2H, m, Hδ); 1.48 (10H, s, NHC(O)OCH(CH3)3 & NHC(O)OCH(CH3)3); 1.46 (10H, s, 
C(O)OCH(CH3)3 & C(O)OCH(CH3)3); 1.27 (2H, dd, 
3
JH-H 9.9 & 
3
JH-H 4.6, Hγ); δ C (125 
MHz, DMSO-d6); 156.0 (C(O)OCH(CH3)3); 141.8 (NHC(O)OCH(CH3)3); 81.9 & 79.7 
(NHC(O)OCH(CH3)3 & C(O)OCH(CH3)3); 53.8 (Cα); 40.1 (Cε); 32.4 (Cβ & Cδ); 28.3 & 28.0 
(NHC(O)OCH(CH3)3 & C(O)OCH(CH3)3); 22.4 (Cγ); νmax (solid)/cm
-1
:
 
3354 (NH); 2977 
(NH2); 1700 (CO); m/z (ES) Found: M(+H) 303.2278 C15H31N2O4 requires 302.2274; 
HPLC (5-95% A): retention time 4.07 min, 91%.  
3-(Benzyloxy)-3-oxopropanoic acid 129a
154
 
 
A mixture of benzyl alcohol (3.00 g, 20.8 mmol, 1 eq.) and 
2,2-dimethyl-1,3-dioxane-4,6-dione (Meldrum’s acid) (2.15 ml, 20.8 mmol, 1 eq.) was 
heated to 120 ºC and stirred for 16 h. The reaction was quenched with a solution of Na2CO3 
(5% (w/v) 5 mL), acidified with to pH 3-4 with 1M HCl aq, extracted with EtOAc (3 × 10 
mL), washed with brine (2 × 10 mL), dried (MgSO4) and concentrated. The crude product 
was purified by column chromatography (2:1 hexanes:EtOAc) to give the 3-(Benzyloxy)-3-
oxopropanoic acid 129a
154
 (566 mg, 2.9 mmol, 14%) as an amorphous white solid; RF  0.16 
(2:1 hexanes:EtOAc); ; δ H (500 MHz, CDCl3); 7.43 – 7.36 (5H, m, Bn-H2-6); 5.25 (2H, s, 
Bn-CH2); 3.52 (2H, s, C(O)CH2C(O)); δ C (125 MHz, CDCl3); 170.0 (COOH 167.1 
(OC(O)CH2); 134.8 (Bz-C1); 128.7, 128.7 & 128.5 (Bn-C2-6); νmax (solid)/cm
-1
:
 
2980 (OH); 
1700 (CO); m/z (ES) Found: M(+Na) 217.0475. C10H10O4Na requires 217.0471. HPLC (5-
95% A): retention time 3.00 min, 100%. 
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3-((Benzyloxy)carbonyl)propanoic acid 129b
155
 
 
A mixture of succinic anhydride (2.00 g, 20 mmol, 1 eq.), benzyl alcohol (2.1 mL, 20 mmol, 
1 eq.), 4-dimethylaminopyridine (2.48 g, 20 mmol, 1 eq.) and triethylamine (3 mL, 1.1 eq., 
22 mmol) in CH2Cl2 (30 mL) was stirred at room temperature for 16 h.
154
 The reaction was 
quenched with Na2CO3 ((5% w/v) 30 mL) and the aqueous layer was acidified to pH 3-4 
with 1M HCl aq, extracted with EtOAc (3 × 30 mL). The combined organics were washed 
with brine (2 × 20 ml), dried (MgSO4) and the volatiles evaporated in vacuo to give 3-
((Benzyloxy)carbonyl)propanoic acid 129b
155
 (2.52 g, 12.1 mmol, 61%) as an amorphous 
white solid; RF (2:1 hexanes:EtOAc) 0.21; δ H (500 MHz, CDCl3): 7.39 – 7.26 (5H, m, Bn-
H2-6), 5.16 (2H, s, Bn-CH2), 2.84 – 2.56 (4H, m, C(O)CH2CH2C(O)NH);  δ C (125 MHz, 
CDCl3): 178.0 (COOH), 172.0 (OC(O)CH2), 135.7 (Ar-C1), 128.6, 128.3 & 128.2 (Bn-C2-6), 
66.7 (Bn-CH2), 28.9 (OCH2CH2O); νmax (solid)/cm
-1
: 3181 (OH); 1736 (CO); m/z (ES): 
Found M(+Na) 231.0628. C11H12O4Na requires 231.0555); elemental analysis (Found: C, 
62.5; H, 5.8; O, 30.7; C11H12O4 requires C, 63.4; H, 5.8; O, 30.7); HPLC (5-95% A): 
retention time 2.14 min, 100%. 
Nε-(Carbamoylacetylbenzyl)-Nα-(1,1-dimethylethoxy-carbonyl)-L-lysine-tert-butyl ester 
130a  
 
3-(Benzyloxy)-3-oxopropanoic acid N (269 mg, 1.37 mmol, 1 eq.), Boc-Lys-OtBu N (414 
mg, 1.37 mmol, 1 eq.), N,N'-Dicyclohexylcarbodiimide (0.2 mL, 1.37 mmol, 1 eq.) and 4-
dimethylaminopyridine (167 mg, 1.37 mmol, 1 eq.) were suspended in dry CH2Cl2 (5 mL) 
and stirred for 16 h. The resultant mixture was washed with sat. NH4HCl aq (2 × 25 mL) and 
sat. NaHCO3 aq (2 × 20 mL); and the combined organics were dried (MgSO4) and 
concentrated. The crude product was purified by column chromatography (5% MeOH in 
CH2Cl2) to give Nε-(carbamoylacetylbenzyl)-Nα-(1,1-dimethylethoxy-carbonyl)-L-lysine-tert-
butyl ester 130a (350 mg, 0.73 mmol, 53%) as a yellow oil; RF 0.45 (5% MeOH in DCM); δ 
H (500 MHz, CDCl3); 7.40 – 7.33 (5H, m, Bn-H2-6); 7.06 (1H, d, 
3
JH-H 5.4, malonyl-NH);  
5.18 (2H, s, Bn-CH2); 5.04 (1H, d, 
3
JH-H 6.3, Boc-NH); 4.18 – 4.13 (1H, m, Hα); 3.35 (2H, s, 
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C(O)CH2C(O)); 3.27 (2H, dd, 
3
JH-H 13.0 & 
3
JH-H 7.0, HƐ); 1.87 – 1.72 (2H, m, Hβ); 1.66 – 
1.50 (2H, m, Hδ); 1.47 (10H, s, NHC(O)OCH(CH3)3 & NHC(O)OCH(CH3)3); 1.45 (10H, s, 
C(O)OCH(CH3)3 & C(O)OCH(CH3)3); 1.42 – 1.31 (2-H, m, Hγ); δC (125 MHz, CDCl3); 
171.9 (C(O)CH2OC(O) & C(O)CH2OC(O)); 169.4 (C(O)OCH(CH3)3); 155.4 
(NHC(O)OCH(CH3)3); 135.0 (Bn-C1); 128.7, 128.6 & 128.4 (Bn-C2-6); 81.9 & 79.7 
(NHC(O)OCH(CH3)3 & C(O)OCH(CH3)3); 67.3 (Bn-CH2); 53.7 (Cα); 41.1 (C(O)CH2C(O)); 
39.4 (Cε); 32.7 (Cβ); 28.9 (Cδ); 28.3 & 28.0 (NHC(O)OCH(CH3)3 & C(O)OCH(CH3)3); 22.6 
(Cγ); νmax (solid)/cm
-1
:
 
3322, 2977 & 2866 (NH); 1660 (CO); m/z (ES) Found: M(+Na) 
501.2591, C25H38N2O7Na requires 501.2571; HPLC (5-95% A): retention time 3.51 min, 
85%. 
Nε-(Benzylcarbamoylpropanoyl)-Nα-(1,1-dimethylethoxy-carbonyl)-L-lysine-tert-butyl 
ester 130b 
 
The reaction procedure was similar to that used to synthesise Nε-(carbamoylacetylbenzyl)-
Nα-(1,1-dimethylethoxy-carbonyl)-L-lysine-tert-butyl ester 130a apart from  3-
((Benzyloxy)carbonyl)propanoic acid 129b (354 mg, 1.7 mmol, 1 eq.) was used instead of 
3-(Benzyloxy)-3-oxopropanoic acid 129a. The resultant mixture was washed with sat. 
NH4HCl aq (2 × 25 mL), sat. NaHCO3 aq (2 × 20 mL), and the combined organics were dried 
(MgSO4) and concentrated to leave the title compound 130b (471 mg, 0.96 mmol, 56%) as a 
viscous orange oil which did not require further purification; RF 0.56 (5% MeOH in 
CH2Cl2); [α]D
21
 +1.8 (c 2.2 (CHCl3); δ H (500 MHz, CDCl3); 7.39 – 7.31 (5H, m, Bn-H2-6); 
5.74 (1H, br s, succinyl-NH); 5.13 (2H, s, Bn-CH2); 5.12 (1H, s, Boc-NH); 4.18 – 4.11 (1H, 
m, Hα); 3.26 – 3.19 (2H, m, HƐ); 2.73 (2H, t,
 3
JH-H 6.9, C(O)CH2CH2C(O)NH); 2.47 (2H, t, 
3
JH-H 6.9, OCH2CH2ONH); 1.66 – 1.48 (4H, m, Hβ & Hδ); 1.46 (10H, s, NHC(O)OCH(CH3)3 
& NHC(O)OCH(CH3)3); 1.44 (10H, s, C(O)OCH(CH3)3 & C(O)OCH(CH3)3); 1.36 (2H, dd, 
3
JH-H 14.4 
3
JH-H 8.4, Hγ); δ C (125 MHz, CDCl3); 172.8 & 171.3 (C(O)CH2CH2OC(O) & 
C(O)CH2CH2OC(O)); 160.1 (C(O)OCH(CH3)3; 150.5 NHC(O)OCH(CH3)3); 135.8 (Bz-C1); 
128.6, 128.3 & 128.2 (Bz-C2-6); 81.9 (NHC(O)OCH(CH3)3 & C(O)OCH(CH3)3); 66.5 (Bn-
CH2); 53.7 (Cα); 39.3 (Cε); 32.7 (Cβ); 31.1 (C(O)CH2CH2OC(O) & C(O)CH2CH2OC(O)); 
29.7 (Cβ); 29.0 (Cδ); 28.4 & 28.0 (NHC(O)OCH(CH3)3 & C(O)OCH(CH3)3); 22.5 (Cγ); νmax 
(solid)/cm
-1
: 3332, 2977 & 2851 (NH); 1713 & 1660 (CO); m/z (ES) Found: M(+Na) 
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515.2739, C26H40N2O7Na requires 5145.2728; HPLC (5-95% A): retention time 3.56 min, 
81%. 
Nε-(Carbamoylacetate)-Nα-(1,1-dimethylethoxy-carbonyl)-L-lysine-tert-butyl ester 123a  
 
Nε-(carbamoylacetylbenzyl)-Nα-(1,1-dimethylethoxy-carbonyl)-L-lysine-tert-butyl ester 130a 
(282 mg, 0.59 mmol) was dissolved in 1:1 MeOH:CH2Cl2; palladium on activated carbon 
(10%, 28 mg) was added and the reaction was stirred at room temperature under a nitrogen 
atmosphere for 48 h. The reaction mixture was filtered through a celite pad and the filtrate 
was concentrated in vacuo to leave Nε-(carbamoylacetate)-Nα-(1,1-dimethylethoxy-
carbonyl)-L-lysine-tert-butyl ester 123a (215 mg, 0.55 mmol, 94%) as a crude brittle white 
foam. δ H (500 MHz, CDCl3); 6.86 (1 H, br s, succinyl-NH), 5.18 (1 H, d, 
3
JH-H 5.0, Boc-NH), 
4.14 (1 H, app. S, Hα), 3.50 – 3.21 (4 H, m, HƐ & C(O)CH2C(O)), 1.84 – 1.67 (2 H, m, Hβ), 1.62 (2 
H, s, Hδ), 1.47 (10 H, s, NHC(O)OCH(CH3)3 & NHC(O)OCH(CH3)3), 1.45 (10 H, s, 
C(O)OCH(CH3)3 & C(O)OCH(CH3)3), 1.27 (2 H, d, 
3
JH-H 10.0, Hγ); m/z (ES) Found: M(+Na) 
411.2109, C18H32N2O7Na requires 411.2102; HPLC (5-95% A): retention time 3.05 min, 
82%. 
Benzyl 3-(6-methyl-1,2,4-triazin-3-ylcarbamoyl)propanoate and benzyl 3-(5-methyl-
1,2,4-triazin-3-ylcarbamoyl)propanoate 131a 
 
3-((benzyloxy)carbonyl)propanoic acid 129b (297 mg, 2.7 mmol, 1 eq.), 6-methyl-1,2,4-
triazin-3-amine & 5-methyl-1,2,4-triazin-3-amine (2:1 mixture) 118c (561 mg, 2.7 mmol, 1 
eq.), 4-dimethylaminopyridine (660 mg, 5.4 mmol, 2 eq.) and 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide (1.03 g, 5.4 mmol, 2 eq.) were stirred at 40 °C under a 
nitrogen atmosphere in DMF (10 mL) for 32 hours. The reaction was quenched with H2O 
(20 mL) and the aqueous layer extracted with EtOAc (4 × 30 mL). The combined organics 
were washed with H2O (1 × 30 mL) and brine (2 × 40 mL), dried (MgSO4) and concentrated 
in vacuo. The crude yellow oil was purified by column chromatography on silica gel (2:1 
hexanes:EtOAc) to give a mixture of benzyl 3-(6-methyl-1,2,4-triazin-3-
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ylcarbamoyl)propanoate and benzyl 3-(5-methyl-1,2,4-triazin-3-ylcarbamoyl)propanoate 
(1:1) 131a (45 mg, 0.15 mmol, 7%) as an orange solid. RF (2:1 hexanes:EtOAc) 0.27; δ H 
(500 MHz, CDCl3): 8.87 (1 H, s, 5-methyl- H6), 8.36 (1 H, s, 6-methyl-H5), 7.38 – 7.35 (5 
H, m, Bn-H2-6), 3.22 – 3.18 (2 H, m, 5-methyl-C(O)CH2CH2OH), 3.12 (2 H, t, 
3
JH-H 6.5, 6-
methyl- C(O)CH2CH2OH), 2.86 – 2.81 (2 H, m, C(O)CH2CH2OH), 2.68 (3H, s, 6-methyl-
CH3), 2.54 (3 H, s, 5-methyl-CH3); νmax (solid)/cm
-1
: 3430 (NH stretch), 1709 (CO); m/z 
(ES): Found M(+H) 301.1294, C15H17N4O3 requires 301.1295; HPLC (5-95% A): retention 
time 1.88 min, 84%. 
3-Iodo-1,2,4-triazine 136 
 
Isoamyl nitrite (42 ml, 300 mmol, 14 eq.) was added to a stirred solution of 3-amino-1,2,4-
triazine (2 g, 20 mmol, 1 eq.) in diiodomethane (~40 mL). The turbid orange mixture was 
stirred at 55 °C for 4 h, allowed to cool, filtered at the pump and concentrated as far as 
possible in vacuo. The remaining filtrate was applied to a silica column and purified by 
column chromatography eluting with 3:1 hexanes/EtOAc. The resultant orange solid was 
dissolved in 1,4-dioxane and lyophilised to yield 3-Iodo-1,2,4-triazine 136 (1.25g, 6.04 
mmol, 30%) as a flocculent orange solid. RF (3:1 hexanes/EtOAc) 0.29; δ H (500 MHz, 
CDCl3): 9.26 (1H, d, 
3
JH-H 2.1 Hz, H6), 8.38 (1H, d, 
3
JH-H 2.2 Hz, H5); δ C (125 MHz, 
CDCl3); 149.2 (C5), 148.4 (C6); νmax (solid)/cm
-1
: 3450 & 3417 (NH2 stretch) m/z (ES): 
Found: M(+H) 207.9366, C3H3IN3 requires 207.9293; HPLC (5-95% A): retention time 
1.41 min, 100%. 
(9H-Fluoren-9-yl)methyl (S)-1-(methoxycarbonyl)-2-hydroxyethylcarbamate 140 
(Fmoc-Ser-OMe) 
 
Sodium bicarbonate (6.7 g, 60 mmol, 2.5 eq.) was added to a vigorously stirred solution of 
L-serine methyl ester hydrochloride (5.0 g, 32 mmol, 1 eq.) in H2O (60 ml) at 0 °C; the 
turbid solution immediately became clear. Fmoc N-hydroxysuccinimide ester (10.8 g, 32 
mmol, 1 eq.), dissolved in H2O (60 mL) was added dropwise and a colourless precipitate 
formed. The solution was allowed to warm to room temperature and stirred for 4 h, at which 
time TLC showed complete consumption of both reagents. The reaction was quenched with 
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H2O (1 × 50 mL) and extracted with EtOAc (3 × 60 mL). The combined organics were 
washed with H2O (2 × 50 mL) and brine (2 × 50 mL); dried (MgSO4) and concentrated on 
the cold finger. The crude colourless solid was recrystalised from EtOAc:hexanes, cooled to 
-20 °C, and the resultant crystals collected by vacuum filtration, before being washed with 
ice-cold hexanes (2 × 50 mL) to yield Fmoc-Ser-OMe 140 (9.66 g, 28 mmol, 88%) as large, 
colourless crystals. m.p. 128.2 – 130.6 °C; [α]D
27 
+4.35 (c = 0.12, CHCl3); RF (3:1 
hexanes:EtOAc) 0.17; δ H (500 MHz, CDCl3): 7.70 (2H, d, 
3
JH-H 7.5, 2 × Fmoc-H4), 7.57 – 
7.50 (2H, m, 2 × Fmoc-H1), 7.34 (2H, t, 
3
JH-H 7.5, 2 × Fmoc-H3), 7.25 (2H, t, 
3
JH-H 7.5, 2 × 
Fmoc-H2), 5.62 (1H, br s, NH), 4.45 – 4.27 (3H, m, 2 × Fmoc-CH2 & Hα), 4.16 (1 H, t, 
3
JH-H 
6.8, 2 × Fmoc-CH), 3.94 (1 H, d, 
2
JH-H 8.9, Hβ), 3.86 (1 H, d, 
2
JH-H 9.1, Hβ), 3.73 (3 H, s, 
OCH3); δ C (125 MHz, CDCl3): 171.1 (C(O)OCH3), 156.2 (OC(O)NH), 143.7, 141.4 & 
141.3 (2 × Fmoc-C4a/1a), 127.77 (2 × Fmoc-C3), 127.1 (2 × Fmoc-C2), 125.1 (2 × Fmoc-C1), 
120.0 (2 × Fmoc-C4), 67.2 (2 × Fmoc-CH2), 63.3 (Cβ), 56.03 (Cα), 52.8 (OCH3), 47.2 
(Fmoc-CH); νmax (solid)/cm
-1
: 3470 & 2431 (NH stretch), 3314 (OH) 1749 (CO); m/z (ES): 
Found: M(+H) 342.1339, C19H20NO5 requires 342.1336; HPLC (5-95% B): retention time 
2.94 min, 100%.  
(9H-Fluoren-9-yl)methyl (S)-1-(methoxycarbonyl)-2-(p-toluenesulfonate)ester 140 
(Fmoc-Ser(OTs)-OMe) 
 
p-toluenesulfonyl chloride (16.4 g, 86 mmol, 2 eq.) was added to a solution of Fmoc-Ser-
OMe 140 (14.7 g, 43 mmol, 1 eq.) in pyridine (40 mL) at 0 °C and the colourless solution 
immediately turned pale orange. The reaction mixture was allowed to warm to room 
temperature and stirred for 16 h. The resultant clear ruby solution was quenched with H2O 
(1 × 40 mL) and extracted with EtOAc (3 × 60 mL). The combined organics were washed 
with 1M citric acid solution (3 × 50 mL), saturated NaHCO3 (2 × 50 mL), brine (1 × 40 
mL), 1M HCl solution (3 × 50 mL), sat. NaHCO3 (2 × 50 mL) and brine (2 × 40 ml). The 
organic layer was dried (MgSO4) and concentrated on the cold finger. The colourless solid 
was recrystallised from 1:1 EtOH:Petroleum ether and the crystals collected by vacuum 
filtration. The resultant pale yellow crystals were triturated in ice-cold petroleum ether for 
30 minutes and collected to yield Fmoc-Ser(OTs)-OMe 141 (13.38 g, 27 mmol, 63%) as 
- 108 - 
colourless crystals. m.p. 119.7 – 120.2 °C; [α]D
27 
+3.25 (c = 0.14, CH2Cl2); RF (3:1 
hexanes/EtOAc) 0.29; δ H (500 MHz, CDCl3): 7.74 – 7.64 (4 H, m, 2 × Fmoc-H4 & OTs-
H2), 7.56 – 7.49 (2 H, m, 2 × Fmoc-H1), 7.34 (2 H, t, 
3
JH-H 7.3, 2 × Fmoc-H3), 7.29 – 7.23 (2 
H, m, 2 × Fmoc-H2), 7.21 (2 H, d, 
3
JH-H 8.2, OTs-H3), 5.55 (1 H, d, 
3
JH-H 7.9, NH), 4.53 – 
4.48 (1 H, m, Hα), 4.39 (1 H, d, 
2
JH-H 7.0, Hβ), 4.35 (1H, d, 
2
JH-H 7.5, Hβ’), 4.32 – 4.15 (2 H, 
m, Fmoc-CH2), 4.12 (1 H, t, 
3
JH-H 7.2, Fmoc-CH), 3.67 (3 H, s, OCH3), 2.29 (3 H, s, 
OTsCH3). δC (125 MHz, CDCl3): 168.7 (C(O)OCH3) 155.6 (OC(O)NH), 145.2 (OTs-C4) 
143.6 (2 × Fmoc-C4a) 141.3 (2 × Fmoc-C1a) 132.3 (OTs-C2), 130.0 (OTs-C3), 128.0 & 127.8 
(2 × Fmoc-C3), 127.2 (2 × Fmoc-C2), 125.2, & 125.1 (2 × Fmoc-C1), 120.0 (2 × Fmoc-C4), 
69.0 (Cβ), 67.5 (Fmoc-CH2), 53.4 (Cα), 53.1 (OCH3), 47.02 (Fmoc-CH), 21.58 (OTs-CH3); 
νmax (solid)/cm
-1
: 3428 & 3338 (NH stretch), 1749 (CO); m/z (ES): Found: M(+H) 
496.1428, C26H26NO7S requires 496.1424; HPLC (5-95% B): retention time 4.10 min, 61%.  
(9H-Fluoren-9-yl)methyl (R)-1-(methoxycarbonyl)-2-iodoethylcarbamate 135 
(Fmoc-IodoAla-OMe) 
 
Sodium iodide (7.20 g, 48 mmol, 3 eq.) in acetone (80 ml) was added to a stirred solution of 
Fmoc-Ser(OTs)-OMe 141 (8.00 g, 16 mmol, 1 eq.) in acetone (160 mL). The colourless 
solution turned yellow. After stirring for 16 h at room temperature the mixture was filtered 
at the pump and concentrated in vacuo to obtain a yellow oil. The oil was dissolved in 
CH2Cl2 (40 mL) and washed with H2O (3 × 50 mL), sat. sodium thiosulfate solution (2 × 50 
mL) and brine (2 × 40 mL). The organic layer was dried (MgSO4), concentrated and 
purified by column chromatography on silica gel (2:1 CH2Cl2/hexanes) to leave a colourless 
viscous oil. The oil was triturated in an ice-cold solution of 1:1 hexanes:EtOH and collected 
at the pump to yield Fmoc-IodoAla-OMe 135 (3.74 g, 8.2 mmol, 52%) as a flocculent, 
colourless solid. m.p. 148.8 – 149.4°C; [α]D
27 
+ 4.85 (c = 0.11, CH2Cl2); RF (2:1 
CH2Cl2:hexanes) 0.21; δ H (500 MHz, CDCl3): 7.78 (2 H, d, 
3
JH-H 7.5, 2 × Fmoc-H4), 7.63 (2 
H, d, 
3
JH-H 7.4, 2 × Fmoc-H1), 7.42 (2 H, t, 
3
JH-H 7.5, 2 × Fmoc-H3), 7.34 (2 H, td, 
3
JH-H 7.5, 
4
JH-H 3.0, 2 × Fmoc-H2), 5.69 (1 H, d, 
3
JH-H 7.3, NH), 4.60 (1 H, dt, 
3
JH-H 7.6, 
3
JH-H 3.8, Hα), 
4.48 – 4.36 (2 H, m, Fmoc-CH2), 4.26 (1 H, t, 
3
JH-H 7.2, Fmoc-CH), 4.00 (1 H, dd, 
3
JH-H 
11.4, 
3
JH-H 3.8, Hβ); 3.91 (1 H, dd, 
3
JH-H 11.4, 
3
JH-H 3.8, Hβ’); 3.84 (3 H, s, OCH3); δ C (125 
MHz, CDCl3); 169.7 (C(O)OCH3), 155.4 (OC(O)NH), 143.8 & 143.7 (2 × Fmoc-C4a), 141.3 
(2 × Fmoc-C1a), 127.8 (2 × Fmoc-C3), 127.1 (2 × Fmoc-C2), 125.2 & 125.1 (2 × Fmoc-C1), 
120.0 (2 × Fmoc-C4), 67.4 (Fmoc-CH2), 54.1 (Cα) 53.1 (OCH3), 45.2 (Fmoc-CH), 7.4 (Cβ); 
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νmax (solid)/cm
-1
: 3743 & 3338 (NH stretch), 1749 (CO); m/z (ES) Found: M(+H), 452.0349, 
C19H19INO4 requires 452.0353; HPLC (5-95% B): retention time 3.91 min, 72%. 
(9H-Fluoren-9-yl)methyl (S)-1-(methoxycarbonyl)-2-(1,2,4-triazin-3-yl)ethylcarbamate 
142 
(Fmoc-TrzAla-OMe) 
 
To an oven dried two-neck flask, zinc dust (1.16 g, 18 mmol, 3 eq.) was added; the flask 
was evacuated, dried with a flame and purged with nitrogen three times. The flask was 
allowed to cool to room temperature and freshly opened, dry DMF (18 mL) and I2 (225 mg, 
0.89 mmol, 0.15 eq.) were added in quick succession. The solution became orange, and after 
two min returned to grey. After 15 min, Fmoc-IodoAla-OMe 135 (2.67 g, 5.9 mmol, 1 eq.) 
was added, followed immediately by I2 (225 mg, 0.89 mmol, 0.15 eq.) and the reaction 
mixture was stirred at room temperature. After two h, formation of the organozincate was 
shown to be complete by TLC (2:1 hexanes:EtOAc) and 3-iodo-1,2,4-triazine 136 (1.59 g, 
7.68 mmol, 1.3 eq.), palladium (II) acetate (33 mg, 0.15 mmol, 0.025 eq.) and 2-
Dicyclohexylphosphino-2′,6′-dimethoxybiphenyl (SPhos, 121 mg, 0.30 mmol, 0.05 eq.) 
were added to the flask in quick succession. The flask was heated to 50 °C and stirred for 
five h, the reaction was allowed to cool and filtered through a celite pad, which was washed 
several times with CH2Cl2. The resultant solution was concentrated in vacuo and the pale 
orange solid was purified by column chromatography on silica gel, eluting initially with 4:1 
hexanes:EtOAc and then EtOAc. The combined fractions were concentrated in vacuo and 
lyophilised to give Fmoc-TrzAla-OMe 142 (1.66 g, 4.12 mmol, 69%) as a flocculent, pale 
orange solid. [α]D
27 
+4.12 (c = 0.19, CH2Cl2); RF (EtOAc) 0.72; δ H (500 MHz, CDCl3): 
9.36 (1 H, app s, Tz-H6), 8.81 (1 H, d, 
3
JH-H 2.4, Tz-H5), 7.79 – 7.73 (2 H, m, 2 × Fmoc-H4), 
7.58 (2 H, t, 
3
JH-H 7.4, 2 × Fmoc-H1), 7.43 – 7.37 (2 H, m, 2 × Fmoc-H3), 7.31 (2 H, t, 
3
JH-H 
7.3, 2 × Fmoc-H2), 5.98 (1 H, d, 
3
JH-H 8.5, NH), 5.07 – 4.96 (1 H, m, Hα), 4.45 – 4.35 (2 H, 
m, Fmoc-CH2), 4.21 (1 H, t, 
3
JH-H 7.0, Fmoc-CH), 3.79 – 3.72 (5 H, m, Hβ & OCH3); δ C 
(125 MHz, CDCl3): 171.4 (C(O)OCH3), 166.8 (Trz-C3), 155.9 (OC(O)NH), 148.7 (Trz-C6), 
148.1 (Trz-C5), 143.8, (2 × Fmoc-C4a), 141.3, (2 × Fmoc-C1a), 127.7 & 127.1 (2 × Fmoc-
C3/2), 125.1 (2 × Fmoc C1), 120.0 (2 × Fmoc C4), 67.2 (Cβ), 67.1 (Fmoc-CH2), 53.1 (Cα), 
51.9 (OCH3), 47.0 (Fmoc-CH); νmax (solid)/cm
-1
: 3049 & 2950 (NH stretch), 1715 (CO); m/z 
(ES) Found: M(+H) 405.1560 C22H21N4O4 requires 405.1557; HPLC (5-95% B): retention 
time 2.93 min, 100%. 
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(9H-Fluoren-9-yl)methyl (S)-1-(carboxy)-2-(1,2,4-triazin-3-yl)ethylcarbamate 137 
(Fmoc-TrzAla-OH) 
 
Fmoc-TrzAla-OMe 142 (300 mg, 0.74 mmol, 1 eq.) and trimethyltin hydroxide (402 mg, 2.2 
mmol, 3 eq.) were dissolved in anhydrous DCE (9 mL) and heated to reflux temperature for 
2.5 h, when methyl deprotection was shown to be complete by TLC (EtOAc). The reaction 
was allowed to cool to room temperature and quenched with H2O (15 mL). The organic 
layer was extracted with CH2Cl2 (3 × 20 mL) and the combined organics were washed with 
H2O (1 × 20 mL) and brine (2 × 20 mL), dried (MgSO4) and concentrated in vacuo. The 
orange oil was purified by column chromatography on silica gel (95:4:1 
CH2Cl2:MeOH:AcOH) and lyophilised to yield Fmoc-TrzAla-OH 137 (78 mg, 0.19 mmol, 
27%) as a pale yellow, flocculent solid. [α]D
27 
+4.90 (c = 0.10, CH2Cl2); RF (95:4:1 
CH2Cl2:MeOH:AcOH) 0.26; δ H (500 MHz, CDCl3): 9.18 (1 H, app s, Tz-H6), 8.63 (1 H, 
app s, Tz-H5), 7.75 (2 H, d, 
3
JH-H 7.5, 2 × Fmoc-H4), 7.57 (2 H, dd, 
3
JH-H 7.4, 
4
JH-H 3.1, 2 × 
Fmoc-H1), 7.39 (2 H, t, 
3
JH-H 7.3, 2 × Fmoc-H3), 7.30 (2 H, t, 
3
JH-H 7.4, 2 × Fmoc-H2), 6.05 
(1 H, d, 
3
JH-H 8.3. NH), 5.04 – 4.97 (1 H, m, Hα), 4.44 – 4.35 (2 H, m, Fmoc-CH2), 4.22 (1 
H, t, 
3
JH-H 7.1, Fmoc-CH), 3.79 (1 H, d, 
3
JH-H 5.5, Hβ), 3.76 (1 H, d, 
3
JH-H 5.0, Hβ); δ C (125 
MHz, CDCl3); 174.3 (COOH), 167.0 (Trz-C3), 156.2 (OC(O)NH), 149.2 (C6), 148.0 (C5), 
143.7 (2 × Fmoc-C4a), 141.3 (2 × Fmoc-C1a), 127.7 (2 × Fmoc C3), 127.1 (2 × Fmoc C2), 
125.1 (2 × Fmoc C1), 120.0 (2 × Fmoc C4), 67.3 (Cβ), 67.1 (Fmoc-CH2), 52.2 (Cα), 39.0 
(Fmoc-CH); νmax (solid)/cm
-1
: 3379 (OH stretch), 1714 (CO); m/z (ES) Found: M(+H) 
391.1401 C21H19N4O4 requires 391.1401; HPLC (5-95% A): retention time 2.87 min, 100%. 
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(1R, 2R*)-(norborn-5-ene-2-yloxy-carbonyl)-succinimide (endo/exo (2:1)) 144 
 
Disuccinimide carbonate (17.6 g, 68.8 mmol, 1.7 eq.) was added to a stirred solution of (1R, 
2R*)-5-norbornene-2-ol (endo/exo mixture, 4.46 g, 40.5 mmol, 1 eq.) and triethylamine 
(dried over 4Å MS and freshly distilled before use, 16.9 ml, 121.5 mmol, 3 eq.) in 
anhydrous MeCN (50 mL) at room temperature. After 16 h, the volatiles were evaporated 
and the crude product was purified by column chromatography (1% diethyl ether in CH2Cl2) 
to leave the title compound (1R, 2R*)-(5-norbornene-2-yloxy-carbonyl)-succinimide 144 
(3.05g, 12.1 mmol 30%, 7:3 endo/exo) as a pale yellow solid; RF (1% diethyl ether in 
CH2Cl2) 0.50; δ H (500 MHz, CDCl3): 6.40 & 6.31 (1 H, dd, 
3
JH-H 5.7, 
3
JH-H 3.1, H5 endo & dd, 
3
JH-H 5.7, 
3
JH-H 2.9, H5 exo), 6.04 & 5.96 (1 H, dd, 
3
JH-H 5.7,
 3
JH-H 2.9, H6 endo & dd, 
3
JH-H 5.7, 
3
JH-H 3.3, H6 exo), 5.36 & 4.77 – 4.73 (1 H, ddd, 
3
JH-H 8.1, 
3
JH-H 3.9, 
3
JH-H 2.6, H2 endo & m, H2 
exo), 3.27 & 3.08 (1 H, d, 
3
JH-H 2.0, H1 endo & d, 
3
JH-H 1.5, H1 exo), 2.91 (1 H, dd, 
3
JH-H 2.5, 
3
JH-H 
1.8, H4), 2.82 (4 H, s, 2 × succinimide-CH2), 2.19 & 1.80 (1 H, ddd, 
2
JH-H 12.9, 
3
JH-H 8.1,
 3
JH-
H 3.7, H3a endo & ddd, 
2
JH-H 13.0, 
3
JH-H 6.9,
 3
JH-H 2.7 H3a exo), 1.73 (0.3 H, d, 
2
JH-H 8.9, H7a exo), 
1.69 – 1.65 (0.3 H, m, H7b exo), 1.62 (0.3 H, ddd, 
2
JH-H 13.0, 
3
JH-H 3.5,
 3
JH-H 2.2, H3b exo), 1.55 
– 1.51 (0.7 H, m, H7a endo), 1.34 (0.7 H, dd, 
2
JH-H 9.1, 
3
JH-H 0.4, H7b endo), 1.15 (0.7 H, ddd, 
3
JH-
H 13.0,
 3
JH-H 3.9,
 3
JH-H 2.6, H3b endo). δ C (125 MHz, CDCl3): 168.69 (2 × succinimide-CO), 
151.32 (OC(O)O), 142.13 (C5 exo), 139.14 (C5 endo), 131.74 (C6 exo), 130.95 (C6 endo), 83.30 (C2 
exo), 82.84 (C2 endo), 47.61 (C7 endo), 47.29 (C1 exo), 46.28 (C7 exo), 45.78 (C1 endo), 42.21 (C4), 
34.47 (C3 exo), 34.35 (C3 endo), 25.48 (2 × succinimide-CH2); m/z (ES): Found: 274.0697 
M(+Na) C12H13NO5Na requires 274.0686; HPLC (5-95% A): retention times 3.12 min 
(endo), 3.19 min (exo), 99%.  
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(1R, 2R*)-NƐ-(norborn-5-ene-2-yloxy-carbonyl)-Nα-(tertbutoxycarbonyl)-L-lysine 
(endo/exo 2:1) 
 
Boc-Lys-OH (1.16 g, 4.71 mmol, 1.3 eq.) and (1R, 2R*)-(norborn-5-ene-2-yloxy-carbonyl)-
succinimide (endo/exo (2:1)) 144 (914 mg, 3.64 mmol, 1 eq.) were stirred in anhydrous 
DMF (30 mL). After 16 h the reaction mixture was quenched with H2O (30 mL) and 
extracted with EtOAc (3 × 30 mL). The combined organic layers were washed with brine (2 
x 20 mL), dried (MgSO4) and concentrated to give the title compound (1.37g, 3.58 mmol, 
98%, 7:3 endo/exo) as a brittle, off-white foam; δH (500 MHz, CDCl3); 6.39 & 6.34 – 6.29 
(1H, dd, 
3
JH-H 6.4, 
3
JH-H 3.1, H5’ exo & m, H5’ endo); 6.03 & 5.96 (1H, dd, 
3
JH-H 5.8, 
3
JH-H 2.9, 
H6’ exo & dd, 
3
JH-H 5.6, 
3
JH-H 3.0, H6’ endo); 5.36 & 5.27 – 5.22 (1H, ddd, 
3
JH-H 8.1, 
3
JH-H 3.9, 
3
JH-H 2.6, H2’ exo & m, H2’ endo); 4.69 – 4.59 (1H, m, Hα); 4.44 – 4.24 (1H, br, NH); 3.31 – 
3.24 & 3.20 – 3.04  (3H, m, H1’ exo & m, HƐ & H1’ endo); 2.84 – 2.83 & 2.82 – 2.81 (1H, m, 
H4’ exo & m, H4’ endo); 2.19 & 2.15 – 2.08 (1H, ddd, 
2
JH-H 12.9, 
3
JH-H 8.1 & 
3
JH-H 3.7, H3a’ exo & 
m, H3a’ endo); 1.93 – 1.74 (2H, m, Hβ); 1.74 –1.56 (2H, m, Hδ); 1.53 – 1.36 (11H, m, 7’-H & 
OC(CH3)2); 1.35 – 1.29 (2H, m, Hγ); 1.14 & 0.97 – 0.92 (1H, ddd, 
2
JH-H 13.0, 
3
JH-H 4.0, 
3
JH-H 
2.6, H3b’ exo & m, H3b’ endo); m/z (ES): Found: 405.2001 M(+Na) C19H30N2O6Na requires 
405.1996. 
(1R, 2R*)-NƐ-(norborn-5-ene-2-yloxy-carbonyl)-L-lysine (endo/exo) 126 
 
4M HCl in dioxane (anhydrous, 10 mL) was added to (1R, 2R*)-NƐ-(norborn-5-ene-2-yloxy-
carbonyl)-Nα-(tertbutoxycarbonyl)-L-lysine (endo/exo 2:1) (1.68 g, 4.39 mmol, 1 eq.) and 
the mixture was stirred at rt under nitrogen for 30 min. The volatiles were evaporated and 
the resultant cream powder was triturated in ice cold ether for 30 min. A pale yellow solid 
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was collected by gravity filtration and lyophilised (H2O) to give (1R, 2R*)-NƐ-(norborn-5-
ene-2-yloxy-carbonyl)-L-lysine 126 (1.24 g, 4.39 mmol, 100%, 7:3 endo/exo) as an off-
white flocculent solid; δ H (500 MHz, MeOD); 6.35 & 6.31 (1H, dd, 
3
JH-H 5.2, 
3
JH-H 2.9, H5’ 
endo & dd, 
3
JH-H 5.7, 
3
JH-H 2.6, H5’ exo); 6.04 & 6.02 – 5.99 (1H, dd, 
3
JH-H 5.7, 
3
JH-H 3.2, H6’ exo 
& m, H6’ endo); 5.25 – 5.19 & 4.60 – 4.55 (1H, m, H2’ endo & m, H2’ exo); 4.02 – 3.97 (1H, m, 
Hα); 3.20 – 3.11 & 2.93 – 2.82 (4H, m, HƐ + H1’ endo & m, H1’ exo, H4’ exo & H4’ endo); 2.15 
(0.7H, ddd, 
2
JH-H 12.0,
 3
JH-H 8.2, 
3
JH-H 3.6, H3a’ endo); 2.07 – 1.88 (2H, m, Hβ); 1.76 – 1.67 
(0.6H, m, H3’ exo); 1.56 – 1.42 (5.3H, m, Hδ, Hγ, H7a’ endo & H7’ exo); 1.42 – 1.37 (0.7H, m, H7b’ 
endo); 0.99 – 0.93 (0.7H, m, H3b’ endo); δ C (125 MHz, CDCl3); 172.0 (COOH); 159.4 
(NHC(O)O); 140.3 (C5’exo); 139.3 (C5’ endo); 133.7 (C6’ exo); 132.7 (C6’ endo); 76.6 (C-2’); 54.1 
(Cα); 47.3 (C1’ & C7’); 42.0 (C4’); 41.3 (CƐ); 35.6 (C3’); 31.3 (Cβ); 30.5 (Cγ); 23.3 (Cδ); m/z 
(ES) (Found: MNa
+
, 305.1473. C14H22N2O4 requires 305.1472); HPLC (5-95% A): 
retention times 2.07 min (endo), 2.16 min (exo), 100%.  
(Z,1R,8S,9r)-9-(Ethoxymethyl)bicyclo[6.1.0]non-4-ene 149a
165
 
 
1,5-cyclooctadiene (35 mL, 283 mmol, 8 eq.) and rhodium (II) acetate (94 mg, 0.22 mmol, 
0.01 eq.) were added to a flask which was evacuated and charged with nitrogen three 
times.
165
 The reactants were vigorously stirred in dry CH2Cl2 (20 mL) and ethyl diazoacetate 
(85% in CH2Cl2, 4.4 mL, 35 mmol, 1 eq.) was added dropwise via a syringe pump over 12 
h. The resultant orange solution was concentrated in vacuo, and purified using flash 
chromatography on silica eluting with hexanes, and after collection of excess 1,5-
cyclooctadiene, 1% Et2O in hexanes, to leave (Z,1R,8S,9r)-9-
(Ethoxymethyl)bicyclo[6.1.0]non-4-ene 149a
165
 (3.17 g, 46%, 18 mmol) (combined isomers: 
6.11 g, 34 mmol, 89%) as a colourless oil. [α]D
27 
+1.0 (c = 0.07, CH2Cl2); RF (1 % Et2O in 
hexanes) 0.24; δ H (500 MHz, CDCl3): 5.68 – 5.60 (2 H, m, H4), 4.14 – 4.07 (2 H, m, 
CH2CH3), 2.34 – 2.27 (2 H, m, H3), 2.23 – 2.16 (2 H, m, H2), 2.13 – 2.05 (2 H, m, H3’), 1.59 
– 1.54 (2 H, m, H2a), 1.48 (2 H, dddd, 
2
JH-H 11.0, 
3
JH-H 8.7, 
3
JH-H 5.4, 
3
JH-H 2.9, H2’), 1.25 (2 
H, 2, 
3
JH-H 7.2, CH2CH3), 1.19 (1 H, t, 
3
JH-H 4.6, H1); δ C (125 MHz, CDCl3): 174.4 
(COOEt), 129.9 (C4), 60.2 (CH2CH3), 28.3 (C2), 27.9 (C2a), 27.7 (C1), 26.6 (C3), 14.20 
(CH2CH3); νmax (solid)/cm
-1
: 2934 (alkyne), 1095 (ether); m/z (EI) (Found: MH
+
, 195.1388. 
C12H19O2 requires 195.1380; HPLC (5-95% B): retention time 3.77 min, 99%. 
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(Z,1R,8S,9s)-9-(Ethoxymethyl)bicyclo[6.1.0]non-4-ene 149b
165
 
 
(Z,1R,8S,9s)-9-(ethoxymethyl)bicyclo[6.1.0]non-4-ene 149b was synthesised alongside 
(Z,1R,8S,9r)-9-(ethoxymethyl)bicyclo[6.1.0]non-4-ene 149a and gave the title compound 
149b
165
 (2.94 g, 16 mmol, 43%) as a colourless oil. [α]D
27 
+3.2 (c = 0.03, CH2Cl2); RF (1 % 
Et2O in hexanes) 0.33; δ H (500 MHz, CDCl3): 5.65 – 5.58 (2 H, m, H4), 4.12 (2 H, q, 
3
JH-H 
7.1, CH2CH3), 2.55 – 2.46 (2 H, m, H3), 2.25 – 2.17 (2 H, m, H2), 2.10 – 2.02 (2 H, m, H3’), 
1.88 – 1.79 (2 H, m, H2a), 1.71 (1 H, t, 
3
JH-H 8.8, H1), 1.44 – 1.35 (2 H, m, H2’), 1.26 (2 H, t, 
3
JH-H 7.1, CH2CH3). δ C (125 MHz, CDCl3): 172.31 (CH2OEt), 129.47 (C4), 59.72 
(CH2CH3), 27.09 (C3), 24.18 (C2a), 22.68 (C2), 21.27 (C1), 14.41 (CH2CH3); νmax (solid)/cm
-
1
: 2937 (alkyne), 1010 (ether); m/z (EI) (Found: MH
+
, 195.1383. C12H19O2 requires 
195.1380); HPLC (5-95% B): retention time 4.00 min, 100%. 
(Z,1R,8S,9r)-Bicyclo[6.1.0]non-4-ene-9-ylmethanol 150
165
 
 
Under a nitrogen atmosphere, a solution of (Z,1S,8S,9r)-9-(ethoxymethyl)bicyclo[6.1.0]non-
4-ene 149a (4.58 g, 23.6 mmol, 1 eq.) in CH2Cl2 (100 mL) was added dropwise to a stirred 
suspension of lithium aluminium hydride (2.7 g, 71 mmol, 3 eq.) in CH2Cl2 (100 mL) at 0 
°C. The suspension was allowed to warm to room temperature and stirred for 2 h until TLC 
showed complete reduction of the ester (3:1 hexanes:EtOAc). The mixture was cooled to 0 
°C and quenched with sodium sulphate decahydrate (~20 g), filtered through a celite pad, 
concentrated and azeotroped with toluene to leave a colourless oil. Under a nitrogen 
atmosphere the reduction product was dissolved in CH2Cl2 (100 mL) and stirred at 0 °C 
before a solution of bromine (1.6 mL, 30.7 mmol, 1.3 eq.) in DCM (18 mL) was added 
dropwise until a persistent red colour was observed. The reaction was quenched with 10% 
sodium thiosulphate solution (100 mL), the organics were combined and washed with H2O 
(2 × 80 mL), brine (1 × 70 mL), concentrated and azeotroped with toluene. The resultant 
yellow oil was dissolved in THF (100 mL) under a nitrogen atmosphere and cooled to 0 °C 
before potassium tert-butoxide (1M in THF, 71 mL, 71 mmol, 3 eq.) was added dropwise. 
The solution was heated to reflux and stirred for 16 h before being cooled to room 
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temperature, quenched with sat. NH4Cl aq solution (100 mL), extracted with DCM (3 × 100 
mL), brine (1 × 100 mL), dried (MgSO4) and concentrated to leave an orange oil. The crude 
residue was purified by column chromatography on silica gel eluting with 1% Et2O in 
CH2Cl2 to leave (Z,1R,8R,9r)-bicyclo[6.1.0]non-4-ene-9-ylmethanol 150
165
 (1.2 g, 8.0 
mmol, 34 %) as a viscous yellow oil. [α]D
27 
+2.9 (c = 0.12, CH2Cl2); RF (1 % Et2O in 
hexanes) 0.17; δ H (500 MHz, CDCl3): 3.56 (2 H, d, 
3
JH-H 6.3, CH2OH), 2.42 (2 H, dd, 
2
JH-H 
13.3, 
3
JH-H 2.7, H2), 2.33 – 2.25 (2 H, m, H3), 2.20 – 2.13 (2 H, m, H3’), 1.45 – 1.35 (2 H, m, 
H2’), 0.74 – 0.64 (3 H, m. H2a+1). δ C (125 MHz, CDCl3): 98.8 (C4), 67.2 (CH2OH), 33.4 
(C2), 27.3 (C1), 22.6 (C2a), 21.4 (C3); νmax (solid)/cm
-1
: 3350 (OH stretch), 2923 (alkyne); 
HPLC (5-95% B): retention time 1.85 min, 86%. 
(1R,8S,9r)-9-((Benzoyloxy)methyl)bicyclo[6.1.0]non-4-yne 151
166
 
 
(Z,1R,8S,9r)-bicyclo[6.1.0]non-4-ene-9-ylmethanol 150 (159 mg, 1.1 mmol, 1 eq.) and 4-
dimethylaminopyridine (8 mg, 0.06 mmol, 0.06 eq.) were stirred in CH2Cl2 (10 mL) under a 
nitrogen atmosphere and freshly distilled triethylamine (dried with 4Å MS, 0.45 mL, 1.32 
mmol, 3 eq.) was added.
166
 The solution was cooled to 0 °C and benzoyl chloride (0.24 ml, 
2.11 mmol, 2 eq.) was added dropwise, the colourless solution became amber. The reaction 
mixture was allowed to warm to room temperature and stirred for 4 h until TLC showed 
complete consumption of starting material (4:1 hexanes:EtOAc). The reaction was quenched 
with sat. NH4Cl aq (10 mL) and extracted with CH2Cl2 (3 × 20 mL), the combined organics 
were washed with brine (2 × 15 mL), dried (MgSO4) and concentrated to leave a brown oil, 
which was purified by column chromatography on silica (25:1 hexanes:EtOAc) to leave 
(Z,1R,8S,9r)-Bicyclo[6.1.0]non-4-ene-9-ylmethanol 151
166
 (144 mg, 0.59 mmol, 57 %) as a 
white solid. [α]D
27 
+1.2 (c = 0.07, CH2Cl2); RF (25:1 hexanes:EtOAc) 0.09; δ H (500 MHz, 
CDCl3): 8.08 – 8.04 (2 H, m, Bz-H2), 7.59 – 7.55 (1 H, m, Bz-H4), 7.45 (2 H, t, 
3
JH-H 7.8, 
Bz-H3), 4.27 (2 H, d, 
3
JH-H 6.4, OCOCH2), 2.48 – 2.41 (2 H, m, H2), 2.36 – 2.27 (2 H, m, 
H3), 2.18 (2 H, dd, 
2
JH-H 9.4, 
3
JH-H 5.6, H3’), 1.42 (2 H, d, 
2
JH-H 11.5, H2’), 0.90 – 0.80 (3 H, 
m, H2a+1); δ C (125 MHz, CDCl3): 132.83 (Bz-C4), 130.5 (Bz-C1), 129.6 (Bz-C2), 128.3 (Bz-
C3), 98.8 (C4), 69.1 (CH2OH), 33.3 (C2), 23.6 (C1), 23.1 (C2a), 21.4 (C3); νmax (solid)/cm
-1
: 
2227 (alkyne), 1263 (ether); HPLC (5-95% B): retention time 3.93 min, 100%. 
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Methyl (2S)-3-[2-((1S,8R,9r)-9-benzoyloxymethylbicyclo[6.1.0]nona[4,5-c]pyridyl)-2-
((1S)N-(9-fluorenylmethoxycarbonyl)amino)propionate & Methyl (2S)-3-[2-
((1R,8S,9s)-9-benzoyloxymethylbicyclo[6.1.0]nona[4,5-c]pyridyl)-2-((1S)N-(9-
fluorenylmethoxycarbonyl)amino)propionate 152a & 152b 
 
To a solution of (Z,1R,8S,9r)-Bicyclo[6.1.0]non-4-ene-9-ylmethanol 151b (66 mg, 0.26 
mmol, 1 eq.) in CH2Cl2 (2 mL), Fmoc-TrzAla-OMe N (105 mg, 0.26 mmol, 1 eq.) in CH2Cl2 
(2 mL) was added and the reaction was stirred at 37 °C for 16 h, at which time, complete 
consumption of (Z,1S,8R,9r)-Bicyclo[6.1.0]non-4-ene-9-ylmethanol 151 was observed (4:1 
hexanes:EtOAc). The orange solution was concentrated in vacuo and purified by column 
chromatography on silica gel (5% MeOH in CH2Cl2). The resultant pale yellow solid was 
dissolved in dioxane and lyophilised to leave Methyl (2S)-3-[2-((1S*,8R*,9r*)-9-
Benzoyloxymethylbicyclo[6.1.0]nona[4,5-c]pyridyl)-2-(1S)N-(9-
fluorenylmethoxycarbonyl)amino)propionate (1:1)  152a and 152b (62 mg, 0.09 mmol, 
38%) as a pale yellow, flocculent solid. [α]D
27 
+4.7 (c = 0.11, CH2Cl2); RF (25:1 
hexanes:EtOAc) 0.09; δ H (CD2Cl2, 500 MHz); 8.26 – 8.18 (1H, m, H9), 8.08 – 7.96 (2H, m, 
Bz-H2), 7.79 (2H, dd, 
3
JH-H 7.6, 
4
JH-H 4.0 Hz, 2 × Fmoc-H4), 7.67 – 7.55 (3H, m, Bz-H4 & 2 
× Fmoc-H1), 7.53 – 7.43 (2H, m, Bz-H3), 7.43 – 7.38 (2H, m, 2 × Fmoc-H3), 7.37 – 7.28 
(2H, m, 2 × Fmoc-H2), 7.03 – 6.93 (1H, m, H8), 6.64 – 6.55 (1H, m, NH), 4.83 – 4.73 (1H, 
m, Hα), 4.43 – 4.29 (2H, m, Fmoc-CH2), 4.25 (1H, t, 
3
JH-H 7.1 Hz, Fmoc-CH), 4.12 – 3.98 
(2H, m, Bz-C(O)OCH2), 3.67 (3H, s, OCH3), 3.54 (1H, ddd, 
2
JH-H 17.0, 
4
JH-H 12.1,
 3
JH-H 5.6 
Hz, H), 3.31 (1H, ddd, 
2
JH-H 16.0, 
4
JH-H 11.4, 
3
JH-H 4.3 Hz, H’), 3.05 – 2.92 (2H, m, H3+7), 
2.87 – 2.72 (2H, m, H3’+7’), 2.64 – 2.44 (2H, m, H4+6), 1.48 – 1.33 (2H, m, H4’+6’), 0.95 – 
0.88 (1H, m, H5), 0.85 – 0.70 (2H, m, H4a). δ C (125 MHz, CD2Cl2): 172.8 (COOCH3), 
166.8 (Bz-C(O)OCH2), 156.5 (Fmoc-C(O)ONH), 155.0 (C2), 152.3 (C2a), 146.1 (C9), 144.4 
(2 × Fmoc-C4a), 141.6 (2 × Fmoc-C1a), 136.6 (C7a), 133.1 (2 × Fmoc-C1), 131.0 (Bz-C1), 
129.8 (Bz-C2), 128.7 (Bz-C3), 128.0 (2 × Fmoc-C3), 127.4 (2 × Fmoc-C2), 125.5 (Bz-C4), 
124.5 (C8), 120.3 (2 × Fmoc-C4), 68.8 (C5’), 67.2 (Fmoc-CH2), 53.1 (COOCH3), 52.5 (Cα), 
47.6 (Fmoc-CH), 35.9 (Cβ), 33.9 (C3), 29.0 (C4), 26.7 (C5), 22.4 (C4a); νmax (solid)/cm
-1
m/z: 
3335 (NH stretch), 1714 (CO); m/z (ES): found M(+H) 631.2814, C39H39N2O6 requires 
631.2803, HPLC (5-95% B): retention time 4.75 min, 100%. 
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(Z,1R,8S,9r)-Bicyclo[6.1.0]non-4-ene-9-ylmethanol (4-nitrophenyl)carbonate 154
165
 
(BCN-ONP) 
 
(1R,8S,9r)-9-((Benzoyloxy)methyl)bicyclo[6.1.0]non-4-yne 150 (1.09 g, 7.3 mmol, 1 eq.) 
and p-nitrophenylchloroformate (1.76 g, 8.7 mmol, 1.2 eq.) were dissolved in anhydrous 
CH2Cl2 (200 mL) and pyridine (wet, 1.5 mL, 18 mmol, 2.5 eq.) was added. The reaction 
mixture was stirred for 20 minutes, until consumption of 150 was observed by TLC (6:1 
hexanes:EtOAc), quenched with NH4Cl aq (200 mL), extracted with CH2Cl2 (3 × 150 mL), 
dried (MgSO4) and concentrated in vacuo. The crude product was purified by column 
chromatography on silica gel, (8:1 hexanes:EtOAc) to give BCN-ONP 154
165
 (1.66 g, 5.26 
mmol, 73%) as an amorphous white solid. RF (8:1 hexanes:EtOAc) 0.24; δ H (500 MHz, 
CDCl3): 8.30 – 8.26 (2 H, m, Ph-H3), 7.41 – 7.37 (2 H, m, Ph-H2), 4.22 (2 H, d, 
3
JH-H 6.9, 
CH2OC(O)Ph), 2.45 (2 H, dd, 
2
JH-H 13.3, 
3
JH-H 2.5, H2), 2.36 – 2.26 (2 H, m, H3), 2.22 – 2.15 
(2 H, m, H3’), 1.48 – 1.36 (2 H, m, H2’), 0.91 – 0.78 (3 H, m, H2a+1); δC (125 MHz, CDCl3): 
155.61 (OC(O)Ph), 152.6 (Ph-C4), 145.4 (Ph-C1), 125.3 (Ph-C3), 121.8 (Ph-C2), 98.7 (C4), 
74.0 (CH2O(C)OPh), 33.1 (C2), 23.3 & 23.0 (C1 & C2a), 21.3 (C3); m/z (ES): Found: 
631.2294 2M(+H) C34H35N2O10 requires 631.2286; HPLC (5-95% A): retention time 3.79 
min, 100%. 
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(2S)-2-(9H-fluoren-9-ylmethoxycarbonylamino)-6-[((Z,1R,8S,9r)-Bicyclo[6.1.0]non-4-
ene)oxycarbonylamino]hexanoic acid 155
87
  
(Fmoc-BCN-K) 
 
BCN-ONP 154 (158 mg, 0.50 mmol, 1 eq.) and Fmoc-Lys-OH (243 mg, 0.60 mmol, 1.2 eq.) 
were dissolved in anhydrous DMF (12 mL) and triethylamine (dried with 4Å MS and 
freshly distilled before use, 121 µL, 0.87 mmol, 1.7 eq.) was added. The reaction was stirred 
at rt for 45 minutes (at which time consumption of BCN-ONP 154 was observed by TLC 
(3:1 hexanes:EtOAc)), quenched with sat. Na2CO3 aq (10 mL) and extracted with CH2Cl2 (3 
× 15 mL). The combined organics were dried (MgSO4) and concentrated to leave a white 
foam which was purified by column chromatography on silica, eluting the sample with 10% 
MeOH in CH2Cl2 to leave Fmoc-BCN-K 155
87
 (158 mg, 0.33 mmol, 66%) as a brittle white 
foam. RF (10% MeOH in CH2Cl2) 0.26; δ H (500 MHz, CDCl3): 7.90 (2 H, d, 
3
JH-H 7.5, 
Fmoc-H4), 7.70 (2 H, d, 
3
JH-H 7.5, Fmoc-H1), 7.43 (2 H, t, 
3
JH-H 7.3, Fmoc-H3), 7.34 (2 H, 
dd, 
3
JH-H 7.1, 
4
JH-H 4.9, Fmoc-H2), 7.06 (1 H, br s, BCN-NH), 6.71 (1 H, br s, Fmoc-NH), 
4.30 (1 H, d, 
4
JH-H 10.5, Fmoc-CH), 4.23 (2 H, d, 
3
JH-H 7.0, Fmoc-CH2), 3.84 (2 H, d, 
3
JH-H 
6.9, BCN-CH2), 3.70 (1 H, br s, Hα), 2.94 (2 H, d, 
3
JH-H 6.4, HƐ), 2.33 – 2.16 (4 H, m, H2 & 
H3), 2.07 (2 H, d, 
2
JH-H 15.1, H3’), 1.69 (1 H, br s, Hβ), 1.55 (1 H, br s, Hβ), 1.43 – 1.20 (5 H, 
m, Hγ, Hδ & H2’), 0.71 – 0.58 (3 H, m, H2a+1). 
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(2S)-2-amino-6-[((Z,1R,8S,9r)-Bicyclo[6.1.0]non-4-ene)oxycarbonylamino]hexanoic 
acid
87
 
 
Fmoc-BCN-K 155 (374 mg, 0.69 mmol) was stirred in 20% piperidine in DMF (40 mL) for 
30 min at room temperature, the volatiles were removed as far as possible in vacuo and the 
resultant solid azeotroped with toluene three times. The off-white solid was triturated in ice-
cold diethyl ether for 1 h and gravity filtered. The precipitate was dissolved in H2O and 
lyophilised to leave BCN-lysine 128
87
 (181 mg, 0.56 mmol, 81%) as a flocculent white 
solid. δ H (500 MHz, d6-DMSO): 3.86 (2 H, d, 
3
JH-H 6.2, CH2OC(O)NH), 3.12 – 3.06 (1 H, 
s, Hα), 2.95 (2 H, d, 
3
JH-H 6.0, HƐ), 2.35 – 2.19 (4 H, m, H2 & H3), 2.09 (2 H, d, 
2
JH-H 16.4, 
H3’), 1.76 – 1.66 (1 H, m, Hβ), 1.59 – 1.48 (1 H, m, Hβ), 1.41 – 1.26 (5 H, m, Hγ, Hδ & H2’), 
0.72 – 0.60 (3 H, m, H2a+1); m/z (ES): Found: 323.1973 M(+H) C17H26N2O4 requires 
323.1965; HPLC (5-95% A): retention time 0.26 min, 100%. 
6.2 Peptide Synthesis 
Resins and amino acids were purchased from Novabiochem: Fmoc-Asn(Trt)-OH, Fmoc-
Gaba-OHi, Fmoc-His(Trt)-OH, Fmoc-Gln(Trt)-OH, Fmoc-Ser(tBu)-OH, Fmoc-Val-OH, 
Fmoc-Asn(Trt)-OH, Fmoc-Tyr(tBu)-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Gly-OH, Fmoc-Ala-
OH, Fmoc-Thr(tBu)-OH, Fmoc-Ser(PO(OH)(OBn))-OH, Fmoc-Thr(PO(OH)(OBn))-OH, 
Fmoc-Tyr(PO(OH)(OBn))-OH and Fmoc-Tyr(PO(NMe2)2)-OH. Q-Sepharose FF resin was 
purchased from GE Healthcare. Other reagents were purchased from Sigma Aldrich, Alfa 
Aesar, Merck or Fisher Scientific and were used without further purification.  
Peptides were generated manually using a standard solid phase peptide synthesis protocol: 
Resin (amount specified in each reaction) was swollen in DMF (2-5 mL per 100 mg of resin 
– the same volume was used for the wash steps) for 30-90 min with agitation (Stuart Rotator 
SB2). After removal of DMF by vacuum filtration and the first coupling mixture added. 
                                                     
i Gaba = -aminobutyric acid 
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Coupling reactions using commercially available amino acids were performed using with 
respect to resin 5 eq. Fmoc-amino acid, 5 eq. HCTU and 10 eq. DIPEA in DMF (minimal 
volume) for 60 min with agitation – unless otherwise stated. After each coupling reaction 
the resin was drained by vacuum filtration and washed with DMF (3 × 2 min), 20% 
piperidine in DMF (5 × 2 min) and DMF (5 × 2 min). Subsequent couplings were carried 
out in the same manner. 
Peptide N-termini were acetylated by mixing the drained resin with a solution containing 
acetic anhydride (5 eq.) and DIPEA (5 eq.) in DMF (2-5 mL per 100 mg of resin) for 30 min 
with agitation, the solution was removed from the resin by vacuum filtration and washed 
with DMF (3 × 2 min). 
To prepare the resin for cleavage it was washed with CH2Cl2 (3 × 2 min) and MeOH (3 × 2 
min) then dried for a minimum of 2 h in vacuo. The peptide was cleaved from the resin by 
mixing with a cleavage cocktail (2-5 mL per 100 mg of resin) consisting of TFA (95%), 
H2O (2.5%) and triisopropylsilane (2.5%). The cleavage cocktail was applied to the resin 
and mixed for 2 h, then then precipitated into ice-cold diethyl ether (10 × volume of 
cleavage cocktail – same volume used in later ethereal washes) and the precipitate collected 
by centrifugation (4,000 × g, 10 minutes). The ethereal supernatant was decanted, the 
peptide pellet resuspended in ice-cold diethyl ether and centrifuged again. This was repeated 
2 more times before residual ether was removed under a stream of nitrogen. The resultant 
amorphous solid was dissolved in the minimum volume H2O (with the addition of small 
portions of dioxane), frozen and lyophilized before further purirfication.  
If stated, peptides were purified by ion exchange chromatography: the lyophilised peptide 
was dissolved in H2O, loaded onto a bed of Q-Sepharose FF resin or SP-Sepharose FF resin 
(1 mL), washed with with H2O (10 mL), then eluted with a stepwise gradient of 
NH4HCO3(aq) (10, 20, 50, 100, 200 and 500 mM, 10 mL per elution) under gravity. Fractions 
containing the peptide were identified by LCMS, combined (as appropriate) and lyophilised. 
Q-Sepharose FF resin was cleaned by washing with 1 M NH4HCO3 aq (10 mL) then H2O (10 
mL) and stored in 20% EtOH at 4 °C. 
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FITC-Gaba-Ser-pTyr-Val-Asn-Val-Gln-NH2 95 
 
FITC-Gaba-Ser-pTyr-Val-Asn-Val-Gln-NH2 95 was synthesised using Rink Amide 
Novagel™ resin (0.64 mmol/g loading; 100 mg, 0.064 mmol). Coupling of Fmoc-
Tyr(PO(NMe2)2)-OH was carried out using 5 eq. amino acid, 5 eq. HCTU and 10 eq. 
DIPEA in DMF for 1 hour. Coupling of Fmoc-GA-OH was carried out using 3 eq. amino 
acid, 3 eq. HCTU and 6 eq. Coupling of FITC was carried out using 6 eq. amino acid, 6 eq. 
DIPEA with agitation in the dark for 16 h. Everything subsequent to coupling of FITC was 
carried out in the dark. For cleavage, a standard cleavage cocktail was applied to the resin 
and mixed for 2 h, 10% H2O (v/v) was added and the resin was swelled overnight. The 
peptide was then precipitated according to standard procedure and lyophilised. The crude 
peptide was dissolved in H2O and purified by anion-exchange chromatography (Q-
Sepharose). After lyophilisation of relevant fractions FITC-Gaba-Ser-pTyr-Val-Asn-Val-
Gln-NH2 95 was obtained as a flocculent orange solid (46 mg, 0.036 mmol, 57%). m/z (ES): 
Found M(-2H)
2+
 629.6998, C56H66N11O19PS requires 629.7003; HPLC (5-95% A): retention 
time 2.16 min, 100%. 
AcHN-Ser-pTzAla-Val-Asn-Val-Gln-NH2 91 
 
AcHN-Ser-pTzAla-Val-Asn-Val-Gln-NH2 91 was synthesised using Rink Amide Novagel™ 
resin (0.64 mmol/g loading; 100 mg, 0.064 mmol). Coupling of Fmoc-pTz(OBn)2-OH 15 
was carried out using 3 eq. amino acid (123 mg, 0.192 mmol), 2.9 eq. HCTU and 6 eq. 
DIPEA in DMF for 1 h. After cleavage and lyophilisation, the crude peptide was dissolved 
in H2O and purified by anion-exchange chromatography (Q-Sepharose). After lyophilisation 
of relevant fractions, AcHN-Ser-pTzAla-Val-Asn-Val-Gln-NH2 91 was obtained as a 
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flocculent white solid (6.81 mg, 0.0085 mmol, 13%). δ Hii  (500 MHz, CD3OD): 8.02 (1H, s, 
pTzAla-H5), 5.01 – 4.91 (1H, m, Asn4-Hα), 4.41 (1H, t, 
3
JH-H 5.6, Ser1-Hα), 4.34 (1H, dd, 
3
JH-H 9.5, 
3
JH-H 5.1, Gln6-Hα), 4.19 – 4.11 (2H, m, Val3-Hα & Val5-Hα), 3.77 (2H, d, 
3
JH-H 
5.9, Ser1-Hβ), 2.94 – 2.78 (2H, m, Asn4-Hβ), 2.45 – 2.39 (2H, m, Gln6-Hγ), 2.33 – 2.11 (2H, 
m, Val3-Hβ & Val5-Hβ), 1.01 – 0.91 (12H, m, Val3-Hγ & Val5-Hγ), 2.10 (3H, s, Acetyl-
CH3), 2.09 – 2.09 (2H, m, Gln6-Hβ). m/z Found M(-H) 803.3241, C29H48N12O13P requires 
803.3207; HPLC (5-95% A): retention time 1.12 min, 92%. 
AcHN-Ser-phTzAla-Val-Asn-Val-Gln-NH2 92 
 
AcHN-Ser-phTzAla-Val-Asn-Val-Gln-NH2 92 was prepared by Dr Tom McAllister.
175
 
AcHN-Ser-pSer-Val-Asn-Val-Gln-NH2 104 
 
AcHN-Ser-pSer-Val-Asn-Val-Gln-NH2 104 was prepared by Dr Tom McAllister.
175
 
AcHN-Ser-pThr-Val-Asn-Val-Gln-NH2 105 
 
AcHN-Ser-pThr-Val-Asn-Val-Gln-NH2 105 was prepared by Dr Tom McAllister.
175
 
 
 
                                                     
ii Signals for pTzAla-Hα & Hβ are coincident with the suppressed residual water peak. 
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AcHN-Ser-pTyr-Val-Asn-Val-Gln-NH2 90 
 
AcHN-Ser-pTyr-Val-Asn-Val-Gln-NH2 90 was synthesised using Rink Amide Novagel™ 
resin (0.64 mmol/g loading; 100 mg, 0.064 mmol). Coupling of 
Fmoc-Tyr(PO(OH)(OBn))-OH was carried out using 5 eq. amino acid, 5 eq. HCTU and 10 
eq. DIPEA in DMF for 1 hour. After cleavage and lyophilisation, the crude peptide was 
dissolved in H2O and purified by anion-exchange chromatography (Q-Sepharose). After 
lyophilisation of relevant fractions, AcHN-Ser-pTyr-Val-Asn-Val-Gln-NH2 90 was obtained 
as a flocculent white solid (26 mg, 0.031 mmol, 49%). m/z Found M(-2H)
2+
 828.3291, 
C32H51N9O14P requires 828.3299; HPLC (5-95% A): retention time 1.26 min, 79%. 
AcHN-Ser-His-Val-Asn-Val-Gln-NH2 106 
 
 
AcHN-Ser-His-Val-Asn-Val-Gln-NH2 106 was prepared by Dr Tom McAllister.
175
 
AcHN-Ser-Tyr-Val-Asn-Val-Gln-NH2 107 
 
 
AcHN-Ser-Tyr-Val-Asn-Val-Gln-NH2 107 was prepared by Dr Tom McAllister.
175
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FITC-HN-Arg-Gly-Gly-Arg-Thr-Ser-His-pTzAla-Ala-NH2 110 
 
 
FITC-HN-Arg-Gly-Gly-Arg-Thr-Ser-His-pTzAla-Ala-NH2 N was synthesised using Rink 
Amide Novagel™ resin (0.64 mmol/g loading; 100 mg, 0.064 mmol). Coupling of FITC 
was carried out using 5 eq. amino acid, 5 eq. DIPEA with agitation in the dark for 16 h. 
Everything subsequent to coupling of FITC was carried out in the dark. For cleavage, a 
standard cleavage cocktail was applied to the resin and mixed for 2 h, 10% H2O (v/v) was 
added and the resin was swelled overnight. The peptide was then precipitated according to 
standard procedure and lyophilised. The crude peptide was dissolved in H2O and purified by 
cation-exchange chromatography (SP-Sepharose) and further purified by UV-directed 
(HPLC 50-95% MeCN + 0.1% formic acid) After lyophilisation of relevant fractions FITC-
Gaba-Ser-pTyr-Val-Asn-Val-Gln-NH2 110 was obtained as a flocculent orange solid (31 mg, 
0.021 mmol, 33%). m/z (ES): Found 733.7753, C59H82N21O20PS requires 733.7746; HPLC 
(5-95% A): retention time 1.64 min, 100%. 
FITC-Gaba-TrzAla-CONH2 156 
 
FITC-Gaba-TrzA-CONH2 156 was synthesised using Rink Amide Novagel™ (0.64 mmol/g 
loading, 50 mg, 0.032 mmol). Coupling of Fmoc-TrzAla-OH 156 was carried out using 3 eq. 
amino acid, 3 eq. HCTU and 3 eq. DIPEA in DMF for 1 hour. Coupling of Fmoc-GA-OH 
was carried out using 5 eq. amino acid, 5 eq. HCTU and 10 eq. Coupling of FITC was 
carried out using 5 eq. amino acid, 5 eq. DIPEA with agitation in the dark for 16 h. 
Everything subsequent to coupling of FITC was carried out in the dark. After cleavage and 
lyophilisation the crude peptide was purified by mass-directed HPLC (5-95% MeCN + 0.1% 
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formic acid). After lyophilisation of relevant fractions FITC-Gaba-TrzA-CONH2 156 was 
obtained as a flocculent orange solid compound (7.52 mg, 0.12 mmol, 37%). m/z (ES): 
Found M(+H) 642.1759 C31H28N7O7S requires 642.1765; HPLC (5-95% A): retention time 
1.11 min, 100%. 
6.3 Assays 
Fluorescence Polarisation Assays 
Fluorescence polarization assays were carried out in triplicate at rt in black 96 well plates 
(160 μL per well). All experiments were performed in 50 mM Tris.HCl, 100 mM NaCl pH 
7.4 (SEC buffer). A 2.5–fold or 3–fold dilution series of each peptide or protein were 
routinely prepared before mixing in the plate well. Data was acquired using a Perkin Elmer 
EnVision™ 2103 MultiLabel plate reader (fluorescein FP mirror, fluorescein FP 480 
excitation filter and P-pol 535 and S-pol 535 emission filters). 
Rate Determination Experiments 
Fmoc-TrzAla-OMe 142 (0.73 mg, 1.80 μmol, 1 eq) was dissolved in 900 μL of the required 
solvent mix (either 100% MeCN or 10% H2O). BCN-Bz 151 was dissolved in 900 μL of the 
required solvent mix ((0.46 mg, 1.8 μmol), (0.92 mg, 3.6 μmol), (1.83 mg, 7.20 μmol) or 
(3.66 mg (14.3 μmol) with respect to a final concentration (in 1.8 mL) of 1 mM, 2 mM, 4 
mM or 8 mM respectively. The two solutions were combined, mixed thoroughly and capped 
before being immediately incubated at 37 °C in the auto loader of an Agilent technologies 
1290 HPLC, fitted with an ACE Ultracore 2.5 Super C18 column (50 × 2.1 mm).  
Each 2 µL sample was injected and analysed using a linear gradient (B, 5% H2O, in MeCN 
to 95% H2O) over 5 min. Typically 4 reactions of varying concentration in respect to BCN-
Bz were assayed in parallel. After every analysis, 2 μL of MeCN was injected onto the 
column and the column washed using the same linear gradient over 9 min. HPLC analysis 
was carried out over a 20 hour period. Concentration of the cycloaddition product was 
measured against a previously measured concentration dilution series of the product. A 
typical calibration graph (Figure 6.2) and HPLC trace (Figure 6.1) are shown below. 
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Figure 6.1: Calibration curve for determination of cycloaddition product formation by HPLC 
. 
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Figure 6.2: Representative chromatogram from cycloaddition rate determination. 1. Fmoc-TrzAla-
OMe 142, 3. BCN-Bz 151 and 4/5 cycloaddition products 152a and 152b 
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6.4 Procedures for Protein Production, Purification and 
Characterisation 
6.4.1 Materials 
Instrumentation 
Media, buffer and other equipment were sterilised using either a Prestige Medical bench top 
autoclave or an LTE Touchclave-R autoclave. All contaminated glassware, plastic-ware and 
media containing genetically modified bacteria was disposed of by bleaching, using either 
Virkon or Presept for 24 h or autoclaved (120 °C for 20 min) before disposal as aqueous 
waster for incineration. When a sterile environment was req.uired, work was undertook in a 
Thermo electron corporation Microbiological safety cabinet SAFE 2010 Class II or on the 
benchtop under a blue flame. Bacterial cultures were incubated in a Kuhner ShakerX ISF1-
X or a Stuart orbital incubator. LB Agar plates and small scale assays were incubated in a 
Binder BD23 incubator at 37°C. Centrifugation was carried out in a Beckman Coulter
TM
 
Avanti
TM
 J-301 centrifuge and in bench-top centrifuges Pico
TM
 and Fresco
TM
 17/21 from 
Thermo electron corporation. Cells were disrupted using a Bandelm Sonopuls HD2070 
sonicator or a Constant Systems Cell Disrupter (T2/40/AA/AA). Size exclusion 
chromatography was performed using an Äkta Purifier FPLC from GE Healthcare with a 
20/60 Superdex 75 column. Spectrophotometric readings were measured using a Thermo 
Scientific Nanodrop 2000. SDS-PAGE electrophoresis was carried out using a Bio-Rad 
mini-protean 3 apparatus and the polyacrylamide gels were imaged with both UV and white 
light using a Bio-Rad molecular imager
R 
Gel Doc
TM
 XR. Water was purified before use to 
15 Mq using an ELGA PURLAB
®
 Classic purification system. Protein mass spectrometry 
was performed in original buffers on a Bruker MaXis impact spectrometer and the raw mass 
spectrum were deconvoluted using a maximum entropy algorithm part of Bruker data 
analysis. Results are quoted as mass-charge ratios (m/z). 
Materials 
Analytical grade reagents were purchased from Sigma Aldrich, VWR International, Fisher 
Scientific and Alfa Aesar unless otherwise stated. Ni-NTA agarose was purchased from 
Qiagen. Enzymes, buffers and molecular weight markers were supplied by New England 
Biolabs. DNase I recombinant and Protease inhibitor cocktail (cOmplete
TM
) were purchased 
from Roche Diagnostics. Instant blue was purchased from PAGEgel inc.  
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Media 
Lysogeny Broth (LB): LB pre-mix freeze dried powder (consisting of tryptone (10 g/L), 
yeast extract (5 g/L), NaCl 10 (g/L)) was made up with purified water to a quantity of 25 
g/L, autoclaved at 121 °C for 20 minutes as required and allowed to cool before use. 
Agar 
Agar plates were made with agar (15 g/L) and LB (25 g/L) before being autoclaved at 121 
°C for 20 minutes and stored at 60 °C. Agar was allowed to cool for 15 minutes before 
being inoculated with the desired antibiotic(s), poured onto Petri dishes in 20 ml portions 
and left to set in a sterile environment. Plates were stored at 4 °C prior to use.  
Antibiotics 
All antibiotic stock solutions were made to 1000× working concentration. Kanamycin stock 
was made to 50 mg/mL (using kanamycin sulfate from BioChemica). Both ampicillin and 
spectinomycin stock were purchased from Melford and made up to 100 mg/mL (using the 
sodium salt of ampicillin and the hydrochloride salt of spectinomycin respectively). 
Cell strains 
Chemically competent cell lines of E. coli MG1655 ΔDZ DE3 (double deletion of PanD 
(ADC) and PanZ (yhhk)), C41(DE3) and BL21 (DE3) were available in house. E. coli 
MG1655 ΔDZ DE3 cells were used for all ADC work. E .coli C41(DE3) and BL21 (DE3) 
cells were used for all Grb2SH2 and YdiA work respectively.  
Plasmids 
Name Resistance Gene encoded 
pET28a-Grb2SH2 Kanamycin His6–Grb2SH2 
pCDF-PylT-ADC(K9X) Spectinomycin tRNACUA and His6–ADCK9X 
BCN-PylRS Ampicillin Pyrrolysyl tRNA synthetase (Y271M, L274G, 
C313A) 
pRSETA-ADC(S25A)  Ampicillin His6–ADCS25A 
pMALc2x-YdiA Ampicillin MBP–YdiA 
pET28a-Grb2SH2 was generated by Dr Tom McAllister;
175
 pET-28a was purchased from 
Novagen. pMALc2x-YdiA was generated by Dr Jeff Hollins.
140
 pCDF-PylT-ADC(K9X) 
was generated by Michael Rugen (MSc student); pCDF-PylT was previously obtained from 
Jason Chin (MRC lab, University of Cambridge). BCN-PylRS was purchased from 
GenScript. pRSETA-ADC(S25A) was generated by Diana Monteiro (PhD student).
169
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Buffers and Stains 
Recipes where quantities are given in the parenthesis are for 1 L of buffer. Where no 
quantities are listed, buffers were available in house as stock solutions. Buffers for Ni-NTA 
chromatography were used without further sterilisation or filtration. Buffers for size 
exclusion were vacuum filtered through a 0.22 μM membrane. 
Phosphate buffer 1: 50 mM sodium phosphate (NaH2PO4 1.4 g, Na2HPO4 5.42 g), 300 mM 
NaCl (17.5 g), pH 7.4 at 4 °C 
Lysis Buffer 1: Phosphate Buffer 1 with 10 mM imidazole (681 mg)  
Wash Buffer 1: Phosphate Buffer 1 with 20 mM imidazole (1.36 g) 
Wash Buffer 1a: Phosphate Buffer 1 with 50 mM imidazole (3.40 g) 
Elution Buffer 1: Phosphate Buffer 1 with 250 mM imidazole (17.02 g) 
Phosphate Buffer 2: 50 mM potassium phosphate (KH2PO4 1.5 g, K2HPO4 6.78 g) 
300 mM NaCl (17.5 g), pH 7.4 at 4 °C 
Lysis Buffer 2:  Phosphate Buffer 2 with 10 mM imidazole (681 mg) 
Wash Buffer 2: Phosphate Buffer 2 with 20 mM imidazole (1.36 g) 
Elution Buffer 2: Phosphate Buffer 2 with 250 mM imidazole (17.02 g) 
Inclusion Body Buffer 1: 20 mM Tris (Tris 970 mg, Tris.HCl 1.86 g), 200 mM NaCl 
(11.7 g), 2 mM EDTA (1.49 g of EDTA di-sodium salt), 1.5% (v/v) Triton X-100, (15 mL) 
pH 8.0 at 25 °C 
Inclusion Body Buffer 2: 10 mM Tris (Tris 490 mg, Tris.HCl 930 mg), 1 M NaCl (58.5 g), 
1 mM EDTA (750 mg of EDTA di-sodium salt), 1.5% (v/v) Triton X-100, (15 mL) pH 8.0 
at 25 °C 
SEC Buffer: 50 mM Tris (4.93 g Tris, 2.92 g Tris-HCl), 100 mM NaCl (5.84 g), pH 7.4 at 
25°C. 
2 × Loading Buffer (5 mL): 100 mM Tris HCl (0.6 g) pH 6.8, SDS (0.3 g), DTT (0.2 g), 
bromophenol blue (2 mg), 10% (v/v) glycerol (0.5 mL) 
5 × SDS-PAGE Tris-glycine running Buffer: 125 mM Tris (15.15 g), 960 mM glycine (72 
g), 0.5% (w/v) SDS (5 g) 
SDS-PAGE Tris-tricine gel Buffer (100 mL): 3 M Tris (36 g), 0.3% (w/v) SDS (300 mg), 
pH 8.45 (the pH was adjusted by addition of 1 M HCl) 
SDS-PAGE Tris-tricine cathode buffer: 0.1 M Tris (12.1 g), 0.1 M tricine (17.9 g), 0.1% 
(w/v) SDS (100 mg), pH 8.25 (the pH was adjusted by addition of 1 M HCl) 
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SDS-PAGE Tris-tricine anode buffer: 0.2 M Tris (24.2 g), pH 8.90 (the pH was adjusted 
by addition of 1 M HCl) 
Coomassie Stain: Coomassie blue R-250 (1.0 g), 40% (v/v) methanol (400 mL), 10% (v/v) 
acetic acid (100 mL) 
Coomassie Destain: 40% (v/v) methanol (400 mL), 10% (v/v) acetic acid (100 mL) 
6.4.2 Methods 
Transformations 
Under sterile conditions chemically competent cells (stored in -80 °C freezer) were thawed 
on ice. Aliquots (50 μL) were dispensed into sterilised Eppendorf tubes that had been 
chilled on ice and 1 μL of the req.uired plasmid was mixed with the cells (for double 
transformations 1 μL of each plasmid was added). The Eppendorf tubes were incubated on 
ice for 10 minutes, at 42 °C for 30-45 seconds and returned to ice for 10 minutes, LB (900 
μL) was added and the culture was incubated at 37 °C for 90 minutes and 100 μL of the 
aliquot was spread onto LB-agar plates containing the appropriate antibiotic(s). The 
remaining culture was centrifuged at 13,000g for 30 seconds, the Eppendorf tube inverted to 
remove the majority of the media and the remaining cells were resuspended and spread onto 
LB-agar plates, again, containing the appropriate antibiotic(s). The LB-agar plates were 
incubated overnight at 37 °C.  
Starter Cultures 
Under aseptic conditions, 5 mL of sterile LB media was inoculated with a single colony 
picked from an LB-agar plate or a scraping from a frozen glycerol stock in a 30 mL sterilin 
tube. The appropriate antibiotic(s) were added and culture was incubated overnight at 37 °C 
with shaking at 230 rpm. 
Glycerol Cell Stocks 
500 μL of starter culture was removed and mixed with 500 μL of sterile 80% glycerol (v/v) 
in a sterile Eppendorf and stored at -80 °C. Cell stocks were used to initiate subsequent 
starter cultures as described in 0. 
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Protein Overexpressioniii 
N-terminal hexaHis-tagged Grb2-SH2 was overexpressed in E .coli C41(DE3) cells 
harbouring a pET28a-GrbSH2 plasmid as described by McAllister et al.
175
 N-terminal 
MBP–tagged YdiA was overexpressed in E. coli BL21 (DE3) harbouring a pMALc2x-YdiA 
plasmid.
140
 N-terminal His6–ADC(S25A) was overexpressed in E. coli MG1655 ΔDZ DE3 
cells containing a pRSETA-ADC(S25A) plasmid as described by Monteiro et al.
169
 N-
terminal hexaHis-tagged ADC(K9BCN) was overexpressed in E. coli MG1655 ΔDZ DE3 
cells harbouring pCDF-PylT-ADCK9X and BCN-PylRS plasmids. 
Protein Overexpression of His6–ADC(K9BCN) in LB Media  
1 L of LB media was inoculated with 1 mL of each antibiotic stock (spectinomycin and 
ampicillin) followed by 3 mL of starter culture. The culture was incubated at 37 °C with 
shaking at 200 rpm and monitored by taking aliquots and measuring the optical density 
(OD600). When an OD600 between 0.4-0.6 was reached (OD600 = 0.586 after ca. 4 h), 
expression was induced with IPTG (1 M, 1 mL) and BCN-lysine 128 (100 μM, 32 mg) was 
added. The culture was then incubated at 37 °C with shaking (200 rpm) for 16 h and the 
cells harvested by centrifugation at 6000 rpm at 4 °C for 10 minutes and, after decanting the 
supernatant, stored at -80 °C prior to lysis for protein purification or used immediately. 
Cell Lysis  
Pelleted cells were resuspended in Lysis Buffer 1 or 2 for His6–Grb2SH2 and His6–
ADC(K9BCN) respectively (50 – 100 mL per litre of cells) over ice and lysed using either a 
constant cell disrupter (20 psi, 5 mL injections), or by sonication, keeping the sample on ice 
(3 × 5 min at 40% power, 40% cycle). Before lysis of His6–ADC(K9BCN), protease 
inhibitor cocktail was added. DNase was added to the cell lysate, which was clarified by 
centrifugation at 30,000g for 45 min (or 48,000g for 20 min) to collect the cellular debris. 
The supernatant was decanted and stored over ice for no more than 4 h before purification.  
Inclusion Body Lysis of His6–Grb2SH2  
The cellular debris obtained from cell lysis was resuspended in Inclusion Body Buffer 1 (50 
mL) and stirred for 30 minutes at rt. The mixture was centrifuged (17,000g, 20 min) and the 
supernatant decanted. The insoluble fraction was resuspended in Inclusion Body Buffer 2 
(50 mL), stirred at room temperature for 20 min, centrifuged (17,000g, 20 min) and the 
supernatant again decanted. This was repeated a further 2 times using Inclusion Body Buffer 
                                                     
iii His6-Grb2-SH2, MBP-YdiA and His6-ADC(S25A) were overexpressed by Dr Tom McAllister, 
Ieva Drulyte and Diana Monteiro respectively. MBP-YdiA and His6-ADC(S25A) cell pellets 
were lysed and purified by Ieva Drulyte and Zoe Arnott respectively. 
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2 and the insoluble fraction was solubilised into Stock Buffer 1 + 8M urea (50-80 mL) by 
stirring at room temperature overnight. 
Purification of hexaHis-tagged Proteins by Ni-NTA chromatography 
Ni-NTA agarose resin (10 mL, stored in 20% EtOH at 4 °C) was washed under gravity (in 
this instance 1 CV is 10 mL) with: 
 10 CV of H2O 
 10 CV of Lysis Buffer 1 or 2. 
 The supernatant while collecting the flow through 
 5 CV of Lysis Buffer 1 or 2 
 5 CV of Wash Buffer 1 or 2 while collecting the flow through 
 5 CV of Wash Buffer 1a (for His6-Grb2SH2) while collecting the flow through 
 3 CV of His Elution Buffer 1 or 2 while collecting 6 × 5 mL fractions 
 10 CV of Lysis Buffer 1 or 2 
The presence of protein in the fractions was determined by SDS-PAGE and the elution 
fractions containing the protein combined and concentrated using a spin concentrator, to ca. 
1 mL. 
Colum Regeneration 
After every 4 uses of the column and each time a different protein was purified the column 
was stripped and regenerated using the following procedure: 
 5 CV 0.1% SDS 
 5 CV 0.1M NaOH 
 5 CV 10 mM EDTA 
 20 CV H2O 
 2 CV 500 mM NiSO4 
 20 CV H2O 
Size Exclusion Chromatography 
Following affinity purification, the concentrated protein was further purified by size 
exclusion chromatography using an Äkta Purifier FPLC from GE Healthcare with a 20/60 
Superdex 75. The column was pre-eq.uilibrated with 1 CV SEC buffer before loading the 
protein sample and eluting with 1 CV of SEC buffer while collecting 5-10 mL fractions. 
Fractions containing protein were identified by their UV absorbance at 280 nm and analysed 
by SDS-PAGE. 
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Protein Concentration 
Protein concentration was determined by loading 1.5 μL of protein sample onto the Nandrop 
and measuring the absorbance at 280 nm in triplicate. Protein concentration (μM) was then 
calculated by application of the Beer-Lambert equation: A = ε × C × l, where ε = molar 
extinction coefficient (M
-1
, cm
-1
) calculated from the amino acid seq.uences of each protein 
using the ProtParam online platform; C = concentration (M) and l = path length (cm). 
SDS-PAGE analysis 
Sample Preparation 
Protein samples were mixed in a 1:1 ratio with 2 × Loading Buffer (typically 15 μM of each) 
and heated at 95 °C (100 °C for ADC) for 5 min (10 min for ADC) and allowed to cool 
before being loaded onto the gel – 10, 15, 20 μL for 0.75, 1.0 and 1.5 mm gels respectively. 
A molecular weight marker (10 μL) was also used in one lane. Unboiled protein samples 
were prepared immediately before loading onto the gel in order to minimize protein 
denaturation. 
Tris-glycine SDS-PAGE 
12% or 15% resolving gels were prepared according to Table 1; recipes shown produces 
enough to case two gels of any thickness. All components (except APS and TEMED) were 
mixed thoroughly by inversion. Prior to casting, APS was added followed by TEMED and 
the solution was mixed carefully between additions. The resultant mixture was poured so as 
to fill ca. 80% of each mould and isopropanol was added to fill the remaining space. The 
separating gel was prepared in the same manner as the resolving gel (with APS and TEMED 
added last). Once the resolving gel had set (ca. 20 min), isopropanol was blotted off and the 
stacking gel carefully poured on top of the resolving gel. Immediately after this, a comb of 
the desired amount of lanes was place in the mould and the gel was left to set (ca. 20 min). 
The comb was then removed and the gel used immediately or wrapped in a damp paper 
towel and stored at 4 °C. 
The set gel was incorporated into a running vat and the inner vessel filled with 1 ×  SDS 
Running Buffer (made by 1 in 5 dilution of the 5 × concentrated stock). The gel was loaded 
with the desired protein samples and the outer vat filled up to the relevant mark on the side 
with 1 × SDS Running Buffer and the gel was ran at 180 V (120 V for 15% gels). 
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 Stacking Gel Resolving 
Gel - 12% 
Resolving 
Gel - 15% 
H2O (mL) 3.112 4.885 3.385 
0.5 M Tris pH 6.8 (mL) 0.945 - - 
1.5 M Tris pH 8.8 (mL) - 3.8 3.8 
30% Acrylamide (mL) 0.833 6 7.5 
10% SDS (mL) 0.05 0.15 0.15 
15% APS (mL) 0.05 0.15 0.15 
TEMED (mL) 0.01 0.015 0.015 
Total (mL) 5 15 15 
Table 1: Component quantities necessary to make two Tris-glycine SDS-PAGE gels 
Tris-tricine SDS-PAGE 
The 10% resolving and stacking gels were prepared according to Table 2. All components 
except for APS and TEMED were mixed thoroughly by vortexing and the solution was 
allowed to set for 20 minutes prior to casting. The stacking and resolving solutions were 
loaded onto the mould, and protein samples loaded in the same manner as described in for 
loading a Tris-glycine SDS-PAGE gel. SDS-PAGE Tris-tricine Cathode Buffer and 
SDS-PAGE Tris-tricine Anode Buffer were added to the outer and inner vessels respectively 
and the gel was ran at a constant current of 35 mA. 
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 Stacking Gel Resolving Gel - 10% 
H2O (mL) 8.04 4.14 
Glycerol (mL) - 2 
Tris-tricine gel buffer (mL) 3.10 5.00 
40% Acrylamide (mL) 1.25 3.75 
20% APS (mL) 0.1 0.1 
TEMED (mL) 0.01 0.01 
Total (mL) 12.6 15 
Table 2: Component quantities necessary to make two Tris-tricine SDS-PAGE gels 
Visualisation of SDS-PAGE gels 
Gels were stained with enough of either Coomassie stain or Instant Blue to cover the gel. 
Gels stained with Instant Blue were incubated at rt with rocking for 1-12 h, then in H2O for 
an hour before being photographed. Gels stained with Coomassie blue stain were warmed in 
the microwave (15 s, full 750 W), incubated for 1.5 h, then in Coomassie destain for 3 h 
(both at rt with rocking), and washed with H2O before being photographed. Gels containing 
fluorescent probes were visualised by UV light and photographed prior to staining. 
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